PHREESIA, INC., 10-K filed on 3/31/2026
Annual Report
v3.26.1
Cover - USD ($)
 12 Months Ended
Jan. 31, 2026
Mar. 25, 2026
Jul. 31, 2025
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Jan. 31, 2026    
Current Fiscal Year End Date --01-31    
Document Transition Report false    
Entity File Number 001-38977    
Entity Registrant Name PHREESIA, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 20-2275479    
Entity Address, Address Line One 1521 Concord Pike    
Entity Address, Address Line Two Suite 301 PMB 221    
Entity Address, City or Town Wilmington    
Entity Address, State or Province DE    
Entity Address, Postal Zip Code 19803    
City Area Code 888    
Local Phone Number 654-7473    
Title of 12(b) Security Common stock, $0.01 par value per share    
Trading Symbol PHR    
Security Exchange Name NYSE    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction false    
Entity Shell Company false    
Entity Public Float     $ 1,541,348,304
Entity Common Stock, Shares Outstanding   60,763,065  
Documents Incorporated by Reference
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s Definitive Proxy Statement relating to its 2026 Annual Meeting of Stockholders to be filed hereafter are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.
    
Amendment Flag false    
Entity Central Index Key 0001412408    
Document Fiscal Year Focus 2026    
Document Fiscal Period Focus FY    
v3.26.1
Audit Information
 12 Months Ended
Jan. 31, 2026
Audit Information [Abstract]  
Auditor Name KPMG LLP
Auditor Location Pittsburgh, PA
Auditor Firm ID 185
v3.26.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jan. 31, 2026
Jan. 31, 2025
Current:    
Cash, cash equivalents, and restricted cash (including restricted cash of $1,691) $ 73,830 $ 84,220
Settlement assets 32,999 29,176
Accounts receivable, net of allowance for doubtful accounts of $1,523 and $1,468 as of January 31, 2026 and 2025, respectively 97,453 73,617
Cardholder receivables 38,330 0
Deferred purchase price receivables 18,003 0
Accrued interest and fees receivables 840 0
Deferred contract acquisition costs 410 401
Prepaid expenses and other current assets 17,978 15,871
Total current assets 279,843 203,285
Property and equipment, net of accumulated depreciation and amortization of $94,193 and $84,505 as of January 31, 2026 and 2025, respectively 20,332 23,651
Capitalized internal-use software, net of accumulated amortization of $69,390 and $55,991 as of January 31, 2026 and 2025, respectively 54,270 52,763
Operating lease right-of-use assets 2,002 1,477
Deferred contract acquisition costs 338 583
Intangible assets, net of accumulated amortization of $13,489 and $8,407 as of January 31, 2026 and 2025, respectively 79,761 28,143
Goodwill 170,064 75,845
Deferred tax assets 1,593 0
Other assets 2,442 2,668
Long-term cardholder receivables 47,723 0
Long-term deferred purchase price receivables 5,422 0
Total Assets 663,790 388,415
Current:    
Settlement obligations 32,999 29,176
Current portion of debt and finance lease liabilities 7,971 8,043
Current portion of operating lease liabilities 1,254 964
Accounts payable 11,477 5,622
Accrued expenses 41,257 37,460
Due to healthcare providers 38,056 0
Deferred revenue 49,522 32,758
Other current liabilities 705 0
Total current liabilities 183,241 114,023
Long-term debt and finance lease liabilities 92,117 8,150
Operating lease liabilities, non-current 1,107 646
Long-term due to healthcare providers 45,329 0
Long-term deferred revenue 244 119
Long-term deferred tax liabilities 4,498 484
Other long-term liabilities 47 185
Total Liabilities 326,583 123,607
Commitments and contingencies (Note 11)
Stockholders’ Equity:    
Preferred stock, undesignated, $0.01 par value—$20,000,000 shares authorized as of both January 31, 2026 and 2025; no shares issued or outstanding as of January 31, 2026 and 2025, respectively 0 0
Common stock, $0.01 par value—500,000,000 shares authorized as of both January 31, 2026 and 2025; 62,020,186 and 60,083,444 shares issued as of January 31, 2026 and 2025, respectively 620 601
Additional paid-in capital 1,181,679 1,111,274
Accumulated deficit (799,190) (801,496)
Accumulated other comprehensive loss (382) (51)
Treasury stock, at cost, 1,355,169 shares as of both January 31, 2026 and 2025 (45,520) (45,520)
Total Stockholders’ Equity 337,207 264,808
Total Liabilities and Stockholders’ Equity $ 663,790 $ 388,415
v3.26.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Jan. 31, 2026
Jan. 31, 2025
Statement of Financial Position [Abstract]    
Accounts receivable, allowance for doubtful accounts $ 1,523 $ 1,468
Accumulated depreciation and amortization, net 94,193 84,505
Accumulated amortization of capitalized internal-use software 69,390 55,991
Accumulated amortization of intangible assets $ 13,489 $ 8,407
Preferred stock par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock authorized (in shares) 20,000,000 20,000,000
Preferred stock issued (in shares) 0 0
Preferred stock outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 500,000,000 500,000,000
Common stock, shares issued (in shares) 62,020,186 60,083,444
Treasury stock (in shares) 1,355,169 1,355,169
v3.26.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Revenue:      
Total revenues $ 480,591 $ 419,813 $ 356,299
Expenses:      
Cost of revenue (excluding depreciation and amortization) 71,365 66,227 61,025
Payment solutions expense [1] 82,758 68,707 62,986
Sales and marketing 100,243 121,129 147,008
Research and development 121,481 117,364 112,346
General and administrative 79,903 76,597 79,926
Depreciation 12,972 14,183 17,584
Amortization 18,481 13,703 11,903
Total expenses 487,203 477,910 492,778
Operating loss (6,612) (58,097) (136,479)
Other income, net 2,953 1,956 44
Loss on extinguishment of debt (501) 0 (1,118)
Interest expense (6,953) (2,347) (1,854)
Interest income 2,173 2,677 4,065
Total other (expense) income, net (2,328) 2,286 1,137
Loss before income tax expense (8,940) (55,811) (135,342)
Income tax benefit (expense) 11,246 (2,716) (1,543)
Net income (loss) $ 2,306 $ (58,527) $ (136,885)
Net income (loss) per share attributable to common stockholders - basic (in dollars per share) $ 0.04 $ (1.02) $ (2.51)
Net income (loss) per share attributable to common stockholders - diluted (in dollars per share) $ 0.04 $ (1.02) $ (2.51)
Weighted-average common shares outstanding - basic (in shares) 59,737,915 57,589,687 54,561,449
Weighted-average common shares outstanding - diluted (in shares) 61,494,878 57,589,687 54,561,449
Subscription and related services      
Revenue:      
Total revenues $ 219,461 $ 196,510 $ 165,436
Payment solutions      
Revenue:      
Total revenues [1] 121,459 101,740 94,610
Network solutions      
Revenue:      
Total revenues $ 139,671 $ 121,563 $ 96,253
[1]
(1) The revenue line previously labeled “Payment processing fees” has been relabeled “Payment solutions” to reflect the expanded scope of our payments offerings following the AccessOne Acquisition, which closed on November 12, 2025. Additionally, “Payment processing expense” has been relabeled “Payment solutions expense.” Prior period amounts have not been reclassified, as the Company did not own the acquired operations in prior periods and the change in presentation did not affect any previously reported amounts. See Note 2 - Basis of presentation.
v3.26.1
Consolidated Statements of Comprehensive Income (Loss) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Statement of Comprehensive Income [Abstract]      
Net income (loss) $ 2,306 $ (58,527) $ (136,885)
Other comprehensive loss:      
Net change in unrealized losses on cash flow hedges (133) 0 0
Change in foreign currency translation adjustments (198) (51) 0
Other comprehensive loss (331) (51) 0
Comprehensive income (loss) $ 1,975 $ (58,578) $ (136,885)
v3.26.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common stock
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive loss
Treasury stock
Beginning balance (in shares) at Jan. 31, 2023   54,187,172        
Beginning balance at Jan. 31, 2023 $ 287,819 $ 542 $ 926,957 $ (606,084) $ 0 $ (33,596)
Stockholders’ Equity            
Net income (loss) (136,885)     (136,885)    
Stock-based compensation expense $ 63,981   63,981      
Exercise of stock options and vesting of restricted stock units and performance stock units (in shares) 249,247 1,779,430        
Exercise of stock options and vesting of restricted stock units and performance stock units $ 862 $ 18 844      
Issuance of common stock for employee stock purchase plan (in shares)   141,121        
Issuance of common stock for employee stock purchase plan 3,235 $ 1 3,234      
Issuance of stock for share-settled bonus awards (in shares)   354,817        
Issuance of stock for share-settled bonus awards 9,041 $ 4 9,037      
Issuance of common stock as consideration in business combinations (in shares)   1,247,222        
Issuance of common stock as consideration in business combinations 35,320 $ 12 35,308      
Treasury stock from vesting of restricted stock units - satisfaction of tax withholdings (11,924)         (11,924)
Ending balance (in shares) at Jan. 31, 2024   57,709,762        
Ending balance at Jan. 31, 2024 251,449 $ 577 1,039,361 (742,969) 0 (45,520)
Stockholders’ Equity            
Net income (loss) (58,527)     (58,527)    
Other comprehensive loss (51)       (51)  
Stock-based compensation expense $ 59,021   59,021      
Exercise of stock options and vesting of restricted stock units and performance stock units (in shares) 220,523 1,808,993        
Exercise of stock options and vesting of restricted stock units and performance stock units $ 1,024 $ 18 1,006      
Issuance of common stock for employee stock purchase plan (in shares)   158,262        
Issuance of common stock for employee stock purchase plan 2,821 $ 2 2,819      
Issuance of stock for share-settled bonus awards (in shares)   406,427        
Issuance of stock for share-settled bonus awards $ 9,071 $ 4 9,067      
Ending balance (in shares) at Jan. 31, 2025 60,083,444 60,083,444        
Ending balance at Jan. 31, 2025 $ 264,808 $ 601 1,111,274 (801,496) (51) (45,520)
Stockholders’ Equity            
Net income (loss) 2,306     2,306    
Other comprehensive loss (331)       (331)  
Stock-based compensation expense $ 56,255   56,255      
Exercise of stock options and vesting of restricted stock units and performance stock units (in shares) 237,516 1,386,691        
Exercise of stock options and vesting of restricted stock units and performance stock units $ 1,445 $ 14 1,431      
Issuance of common stock for employee stock purchase plan (in shares)   124,869        
Issuance of common stock for employee stock purchase plan 2,225 $ 1 2,224      
Issuance of stock for share-settled bonus awards (in shares)   425,182        
Issuance of stock for share-settled bonus awards $ 10,499 $ 4 10,495      
Ending balance (in shares) at Jan. 31, 2026 62,020,186 62,020,186        
Ending balance at Jan. 31, 2026 $ 337,207 $ 620 $ 1,181,679 $ (799,190) $ (382) $ (45,520)
v3.26.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Operating activities:      
Net income (loss) $ 2,306 $ (58,527) $ (136,885)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:      
Depreciation and amortization 31,453 27,886 29,487
Stock-based compensation expense 67,452 66,975 71,613
Amortization of deferred financing costs and debt discount 2,977 236 321
Loss on extinguishment of debt 501 0 1,118
Non-cash gain on settlement 0 (2,345) 0
Cost of Phreesia hardware purchased by customers 1,022 1,873 1,619
Deferred contract acquisition costs amortization 570 1,815 1,056
Non-cash operating lease expense 914 747 702
Deferred taxes (13,271) 214 228
Gains and losses for fair value option (1,020) 0 0
Changes in operating assets and liabilities:      
Accounts receivable (23,397) (8,812) (11,205)
Collections of principal on receivables originally held for sale to securitization 13,691 0 0
Accrued Interest Receivable (446) 0 0
Prepaid expenses and other assets (1,393) (1,427) (2,209)
Deferred contract acquisition costs (334) (1,045) 0
Accounts payable 5,261 (3,234) (1,993)
Accrued expenses and other liabilities 2,894 182 14,195
Payment of due to provider for receivables originally held for sale to securitization (17,588) 0 0
Lease liabilities (1,107) (824) (1,156)
Deferred revenue 8,329 8,667 731
Net cash provided by (used in) operating activities 78,814 32,381 (32,378)
Investing activities:      
Collections of cardholder receivables held for investment and deferred purchase price 15,709 0 0
Acquisitions, net of cash acquired (153,191) 0 (14,573)
Capitalized internal-use software (13,296) (15,380) (19,291)
Purchases of property and equipment (11,101) (8,709) (5,806)
Net cash used in investing activities (161,879) (24,089) (39,670)
Financing activities:      
Proceeds from issuance of common stock upon exercise of stock options 1,454 1,012 955
Treasury stock to satisfy tax withholdings on stock compensation awards 0 0 (12,176)
Proceeds from employee stock purchase plan 2,371 2,918 3,209
Finance lease payments (6,825) (7,811) (6,779)
Constructive financing 0 0 1,688
Principal payments on financing agreements (1,330) (1,199) (600)
Debt issuance costs and loan facility fee payments (3,190) (152) (1,321)
Financing payments of acquisition-related liabilities 0 (6,254) (1,333)
Debt extinguishment costs 0 0 (758)
Proceeds from debt instruments 110,000 0 0
Principal payments on debt instruments (20,000) 0 0
Payments due to provider for unfunded receivables (9,629) 0 0
Net cash provided by (used in) financing activities 72,851 (11,486) (17,115)
Effect of exchange rate changes on cash, cash equivalents and restricted cash (176) (106) 0
Net decrease in cash, cash equivalents and restricted cash (10,390) (3,300) (89,163)
Cash and cash equivalents—beginning of year 84,220 87,520 176,683
Cash, cash equivalents and restricted cash—end of year 73,830 84,220 87,520
Supplemental information of non-cash investing and financing activities:      
Non-cash activity related to credit card receivables and deferred purchase price 17,585 0 0
Right of use assets acquired in exchange for operating lease liabilities 0 1,958 398
Property and equipment acquisitions through finance leases 0 13,709 7,438
Purchase of property and equipment and capitalized software included in accounts payable and accrued liabilities 1,975 1,787 1,299
Capitalized stock-based compensation 1,286 1,362 1,415
Issuance of stock to settle liabilities for stock-based compensation 12,724 11,892 12,276
Deferred consideration liabilities payable in business combinations 0 0 8,732
Issuance of stock as consideration in business combinations 0 0 35,321
Capitalized software acquired through vendor financing 0 0 2,047
Cash paid for:      
Interest 1,614 2,194 1,306
Income taxes $ 1,897 $ 3,068 $ 37
v3.26.1
Background and liquidity
 12 Months Ended
Jan. 31, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Background and liquidity Background and liquidity
(a) Background
Phreesia, Inc. (the “Company”) provides an integrated software, payments, and engagement platform designed to address three foundational challenges in healthcare delivery: access to care, affordability of care, and health patient outcomes. The Company’s platform is embedded directly into provider workflows and patient interactions, enabling healthcare organizations to activate patients, streamline administrative processes, and improve financial performance across the care continuum. The Company’s integrated platform is designed to address challenges patients and healthcare providers face in three core areas: Access, Affordability, and Outcomes.
Access: The Company’s solutions facilitate access to care by reducing friction in how patients find, schedule, and register for care, while enabling providers to improve capacity utilization and reduce administrative burden. Key capabilities include care discovery and scheduling through MediFind, the Company’s online provider directory, and self-scheduling tools; appointment optimization and referral management using AI-enabled workflows; and the Company’s AI-based smart answering solution patient communications supported by voice and messaging solutions.
Affordability: The Company’s solutions directly address affordability challenges and improve the patient experience while helping providers improve collections, accelerate cash flow, and reduce revenue cycle friction. Capabilities include eligibility and cost transparency tools, integrated payment solutions embedded in intake and post-visit workflows, and financing solutions that enable healthcare organizations to accelerate cash collections while offering flexible payment options to patients.
Outcomes: The Company’s solutions are designed to improve patient outcomes by promoting patient engagement, treatment adherence and satisfaction, while enabling healthcare stakeholders, including providers and life sciences organizations, to measure and influence patient behavior in a compliant and scalable manner. Capabilities include digital intake and clinical data capture, patient engagement and activation tools, and measurement and analytics solutions.
The Company was formed in May 2005. On November 12, 2025 (the “Closing Date”), the Company completed the acquisition (the “AccessOne Acquisition”) of AccessOne Parent Holdings, Inc. and its subsidiaries (collectively, “AccessOne”), which expands the Company’s addressable market for healthcare payments. The Company’s payment solutions now offer healthcare providers a trusted, scalable, compliant and operationally efficient healthcare payment card that accelerates cash flow. Upon the closing of the AccessOne Acquisition, AccessOne Parent Holdings, Inc. became a wholly owned subsidiary of the Company.
(b) Liquidity
For most of the Company’s history, the Company did not generate sufficient revenue to meet its operating expenses. Although the Company generated net income for the year ended January 31, 2026, it may incur net losses in the future. To date, the Company has primarily relied upon the proceeds from issuances of common stock, debt and preferred stock, as well as sales of Company products and services in the normal course of business, to fund its operations.
In connection with the AccessOne Acquisition, on the Closing Date, the Company entered into a bridge loan credit agreement (the “Bridge Credit Agreement”) with respect to a new, 364-day $110,000 secured term loan (the “Bridge Loan”). The net proceeds of the Bridge Loan were used to fund a portion of the purchase price of the AccessOne Acquisition. The Bridge Loan had an outstanding principal amount of $110,000 and a maturity date of November 11, 2026 and could be prepaid at any time without penalty. On January 28, 2026, the Company repaid $20,000 of the outstanding principal balance of the Bridge Loan. As of January 31, 2026, the outstanding principal balance of the Bridge Loan was $90,000.
On March 13, 2026 (the “Refinancing Date”), subsequent to the end of the fiscal year, the Company completed a refinancing whereby it terminated without penalty, and repaid all outstanding indebtedness and obligations under, the Bridge Loan and the Existing Capital One Credit Facility (as defined herein) using borrowings from a new, 5-year $275,000 senior secured revolving credit facility (the "New Capital One Credit Facility"), which matures on March 13, 2031. As the January 31, 2026 outstanding principal balance of the Bridge Loan was refinanced into
long-term debt prior to the issuance of the financial statements, the Company classified the outstanding principal balance of the Bridge Loan as long-term debt in the accompanying consolidated balance sheet as of January 31, 2026. The Bridge Credit Agreement, and the Existing Capital One Credit Facility, which had no outstanding borrowings, were terminated on the Refinancing Date. The unused borrowing capacity on the New Capital One Credit Facility is available to the Company for working capital, capital expenditures, permitted acquisitions and general corporate purposes. See Note 6 - Debt and finance leases and Note 20 - Subsequent events for more information regarding the Bridge Loan and the New Capital One Credit Facility.
Management believes that the Company’s cash and cash equivalents, along with cash generated in its normal operations will be sufficient to meet the Company’s needs for at least the next 12 months.
The Company may seek to obtain additional financing, if needed, to successfully implement its long-term strategy.
v3.26.1
Basis of presentation
 12 Months Ended
Jan. 31, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of presentation Basis of presentation
(a) Consolidated financial statements
The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and regulations of the Securities and Exchange Commission ("SEC") regarding annual financial reporting and include the accounts of Phreesia, Inc; its branch operation in Canada, its consolidated subsidiaries and its consolidated variable interest entity (or collectively, the "Company"). In addition to the subsidiaries the Company controls through its equity ownership, the Company consolidates a variable interest entity because it is the primary beneficiary. See Note 3 - Summary of significant accounting policies and Note 19 - Securitization program and variable interest entities for additional information on the Company’s variable interest entity.
(b) Fiscal year
The Company’s fiscal year ends on January 31. References to fiscal 2026, 2025 and 2024 refer to the fiscal years ending on January 31, 2026, 2025 and 2024, respectively.
(c) Reclassifications and Changes in Financial Statement Captions
The Company has presented interest expense and interest income separately on its consolidated statements of operations. The Company has separately presented interest expense and interest income for prior periods to conform to the current period classification. In prior periods, the Company had separately presented interest expense and interest income in the notes to its financial statements but had presented interest expense and interest income on a combined basis on its consolidated statements of operations because the individual amounts were not material.
The revenue line previously labeled “Payment processing fees” has been relabeled “Payment solutions” to reflect the expanded scope of the Company’s payments offerings following the AccessOne Acquisition, which closed on November 12, 2025. “Payment solutions” includes all revenue previously presented as “Payment processing fees” and all revenue from the operations acquired in the AccessOne Acquisition. Additionally, “Payment processing expense” has been relabeled “Payment solutions expense” and includes all expenses previously presented as “Payment processing expense” and direct costs of revenue related to the operations acquired in the AccessOne Acquisition. Prior period amounts have not been reclassified, as the Company did not own the acquired operations in prior periods and the change in presentation did not affect any previously reported amounts.
v3.26.1
Summary of significant accounting policies
 12 Months Ended
Jan. 31, 2026
Accounting Policies [Abstract]  
Summary of significant accounting policies Summary of significant accounting policies
(a) Use of estimates
The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. These judgments, estimates and assumptions are used for, but not limited to revenue recognition, the fair value of cardholder receivables, the fair value of deferred purchase price receivables, the fair value of due to provider liabilities, the allowance for doubtful accounts, contingent liabilities, the determination of the useful lives of long-lived assets, the capitalization, valuation and recoverability of long-lived assets, the fair value of securities underlying stock-based compensation and the fair value of identifiable assets and liabilities and deferred consideration in business acquisitions.
(b) Revenue recognition
The Company generates revenue primarily from providing integrated SaaS-based software and payment solutions for the healthcare industry. The Company derives revenue from subscription fees and related services generated from the Company’s healthcare services clients for access to the Company's solutions, payment processing fees based on patient payment volume and financing fees based on a portfolio of cardholder receivables, and fees from life sciences clients and other organizations for delivering qualified direct communications to patients who consent to receive this type of engagement using the Company's solutions.
The Company accounts for revenue from contracts with customers by applying the following steps:
•identification of the contract, or contracts, with a customer;
•identification of the performance obligations in the contract;
•determination of the transaction price;
•allocation of the transaction price to the performance obligations in the contract; and
•recognition of revenue when, or as, the Company satisfies a performance obligation.
Revenues are recognized when control of these services is transferred to the Company’s customers, in an amount that reflects the consideration it expects to be entitled to in exchange for those services.
The majority of the Company’s contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately when they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines the standalone selling prices based on its overall pricing objectives, taking into consideration market conditions, historical pricing information as priced in previous bundled contracts, as well as other factors such as product, customer type and geographic area. The Company typically establishes a range of SSPs for each of its performance obligations. The Company uses the residual method to estimate the SSP for certain performance obligations with highly variable pricing.
i.Subscription and related services
In most cases, the Company generates subscription fees from clients based on the number of healthcare services clients that utilize the Company's solutions and subscription fees for the Company’s self-service intake tablets (PhreesiaPads), on-site kiosks (Arrivals Kiosks) and any other solutions. The Company’s healthcare services clients are typically billed monthly in arrears, though in some instances healthcare services clients may opt to be billed monthly, quarterly or annually in advance. Subscription fees are typically auto-debited from client’s accounts every month. Revenue for healthcare services client subscriptions is recognized over the term of the respective healthcare services client contract. Substantially all of the Company’s subscription arrangements are considered service contracts, and the customer does not have the right to take possession of the software. Revenue for related services is recognized as it is delivered if the services are distinct from the subscription service and is recognized over the remaining non-cancelable subscription term if it is not distinct from the subscription service. In certain arrangements, the Company leases its PhreesiaPads and Arrivals Kiosks through operating leases to its customers. Accordingly, these revenue transactions are accounted for using Accounting Standards Codification (“ASC”) 842, Leases.
In addition, subscription and related services includes certain fees from clients for professional services associated with implementation services as well as travel and expense reimbursements, shipping and handling fees, sales of Phreesia hardware (PhreesiaPads and Arrivals Kiosks), on-site support and training. Certain professional services for implementation are not distinct from the Company's solutions and are therefore recognized over the term of the contract. Revenue from sales of distinct professional services, Phreesia hardware and training are recognized in the period they are delivered to clients.
ii.Payment solutions
The Company generates revenue from payment processing fees based on the levels of patient payment volume resulting from credit and debit card transactions (dollar value and number of card transactions) processed through Phreesia’s payment facilitator model. Payment processing fees are generally calculated as a percentage of the total transaction dollar value processed and/or a fee per transaction. The remainder of patient payment volume is composed of credit and debit card transactions for which Phreesia acts as a gateway to payment processors, and cash and check transactions.
The Company recognizes the payment processing fees when the transaction occurs (i.e., when the processing services are completed). The transaction amount is collected from the cardholder’s bank via the Company’s third-party payment processing partner and the card networks. The transaction amount is then remitted to its customers approximately two business days after the transaction occurs. At the end of each month, the Company bills its customers for any payment processing fees owed per its customer contractual agreements. Similarly, at the end of
each month, the Company remits payments to third-party payment processors and financial institutions for interchange and assessment fees, processing fees, and bank settlement fees.
The Company acts as the merchant of record for its customers and works with payment card networks and banks so that its customers do not need to manage the complex systems, rules, and requirements of the payment industry. The Company satisfies its performance obligations and therefore recognizes the transaction fees as revenue upon completion of a transaction. Revenue is recognized net of refunds, which arise from reversals of transactions initiated by the Company’s customers.
The payment processing fees collected from customers are recognized as revenue on a gross basis as the Company is the principal in the delivery of the managed payment solutions to the customer. The Company has concluded it is the principal because as the merchant of record, it controls the services before delivery to the customer, it is primarily responsible for the delivery of the services to its customers, it has latitude in establishing pricing with respect to the customer and other terms of service, it has sole discretion in selecting the third-party to perform the settlement, and it assumes the credit risk for the transaction processed. The Company also has the unilateral ability to accept or reject a transaction based on criteria established by the Company.
As the merchant of record, the Company is liable for settlement of the transactions processed and, accordingly, such costs are included in payment processing fees expense on the accompanying consolidated statements of operations.
Payment solutions revenue also includes financing fees based on a portfolio of cardholder receivables, comprised primarily of the following:
•Fees for servicing cardholder receivables. Servicing fee income is recognized as the services are performed. The Company evaluates whether servicing fees represent adequate compensation and whether a servicing asset or servicing liability should be recorded. The Company has determined that servicing fees approximate adequate compensation; therefore, no servicing asset or liability is recognized.
•Finance charges earned on cardholder receivables, which are recognized using a method that approximates the effective interest method over the contractual term. Accrual of finance charges ceases when an account becomes 90 days past due, and previously accrued but unpaid interest is reversed. Accrual resumes when the cardholder receivable returns to current status. Past due status is based on contractual terms of the cardholder receivable. Revenues for finance charges are recognized in accordance with ASC 310, Receivables.
iii.Network solutions
The Company's Network solutions revenue includes fees from life sciences companies and other organizations for qualified direct communications to patients who consent to receive this type of engagement, to help activate, engage and educate patients about topics critical to their health using the Company’s solutions.
The Company generates revenue from sales of digital marketing solutions to life sciences companies which is based largely on the delivery of messages at a contracted price per message to patients. Messaging campaigns are sold for a specified number of messages delivered to qualified patients over an expected time frame. Revenue is recognized as the messages are delivered.
(c) Transfers of financial assets
Transfers of an entire financial asset are accounted for as sales when control over the assets has been surrendered in accordance with the sale criteria of ASC 860, Transfers and Servicing. Control over transferred assets is deemed to be surrendered when (i) the assets have been isolated from the Company, (ii) the transferee obtains the right (free of conditions that constrain it from taking advantage of that right) to pledge or exchange the transferred assets, and (iii) the Company does not maintain effective control over the transferred assets through an agreement to repurchase them before their maturity. Upon a qualifying sale, the transferred assets are derecognized, and any assets obtained or liabilities incurred are initially recognized at fair value, including any retained beneficial interests (e.g., deferred purchase price receivable). Transfers that do not meet the sale criteria are accounted for as secured borrowings with a pledge of collateral.
(d) Variable interest entities
A variable interest entity (“VIE”) is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. The Company consolidates entities determined to be VIEs for which the Company is the primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly
impact the entity’s economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE. In evaluating primary beneficiary status, the Company identifies the activities that most significantly impact a VIE’s economic performance and the rights that provide the current ability to direct those activities, together with exposure to benefits or losses that could potentially be significant. The Company reassesses its primary beneficiary determination on an ongoing basis. See Note 19 - Securitization program and variable interest entities for more information on consolidated VIEs.
(e) Concentrations of credit risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable and settlement assets. For cardholder receivables, the Company does not bear credit risk from the patient cardholder, as the Company has full recourse to the healthcare provider for unpaid principal. Accordingly, the primary exposure relates to the healthcare provider’s obligation to remit the recourse payment under the financial services arrangement. For information regarding credit risk and maximum exposure to loss associated with the deferred purchase price receivable, refer to Note 19 — Securitization program and variable interest entities.
The Company’s cash and cash equivalents are held by established financial institutions. At times, the Company’s cash on deposit at financial institutions may be in excess of the Federal Deposit Insurance Corporation (“FDIC”) insurance limit. The Company does not require collateral from its customers and generally requires payment within 30 to 60 days of billing. Settlement assets are amounts due from well-established payment processing companies and normally take one to two business days to settle which mitigates the associated risk of concentration. The Company utilizes two third-party payment processors.
The Company’s customers are primarily physician’s offices and other healthcare services organizations located in the United States as well as pharmaceutical companies. The Company did not have any individual customers that represented more than 10% of total revenues for the years ended January 31, 2026, 2025 and 2024. As of both January 31, 2026 and January 31, 2025, the Company had receivables from at least one entity that accounted for at least 10% of total accounts receivable.
(f) Risks and uncertainties
The Company is subject to a variety of risk factors, including the economy, data privacy and security laws and government regulations. Additionally, the Company is subject to other risks associated with the markets in which it operates including reliance on third-party vendors, partners, and service providers. The Company has a substantial number of employees in Canada and India, and the Company supplements its workforce with contractors and consultants in domestic and international locations. Certain of the Company's service providers, including certain third-party software developers, are located in international locations subject to warfare and/or political and economic instability, such as Ukraine and India. As with any business, operation of the Company involves risk, including the risk of service interruption impacting the operations of the Company's business and the Company's customer’s facilities below expected levels of operation, shut downs due to the breakdown or failure of information technology and communications systems, changes in laws or regulations, political and economic instability, or catastrophic events such as fires, earthquakes, floods, explosions, global health concerns such as pandemics or other similar occurrences affecting the delivery of the Company’s products and services. The occurrence of any of these events could significantly reduce or eliminate revenues generated, or significantly increase the expenses of the Company's operations, adversely impacting the Company’s operating results and the Company's ability to meet the Company's obligations and commitments. See Note 6 - Debt and finance leases and Note 11 - Commitments and contingencies, for a summary of the Company’s contractual commitments as of January 31, 2026.
(g) Cost of revenue (excluding depreciation and amortization)
Cost of revenue (excluding depreciation and amortization) primarily consists of personnel expenses for implementation and technical support, infrastructure costs for operation of the Company’s solutions such as hosting fees, and certain fees paid to various third-party providers for the use of their technology, as well as costs to verify insurance eligibility and benefits. Personnel expenses consist of salaries, stock-based compensation, benefits and bonuses.
(h) Payment solutions expense
Payment solutions expense includes payment processing expenses such as interchange fees set by payment card networks that are ultimately paid to the card-issuing financial institution, and assessment fees paid to payment card networks, and fees paid to third-party payment processors and gateways. Payment solutions expense also includes fees payable to PNC in connection with the Securitization Program as well as direct costs of servicing cardholder receivables.
(i) Sales and marketing
Sales and marketing expense consists primarily of personnel costs, including salaries, stock-based compensation, benefits, bonuses and commission costs for the Company’s sales and marketing personnel. Sales and marketing expense also includes costs for advertising, promotional and other marketing activities, as well as certain fees paid to various third-party partners for sales lead generation. Advertising is expensed as incurred. Advertising expense was $1,754, $1,675 and $1,900 for the fiscal years ended January 31, 2026, 2025 and 2024, respectively.
(j) Research and development
Research and development expense consists of costs for the design, development, testing and enhancement of the Company’s products and services that do not meet the criteria for capitalization as internal-use software. These costs consist primarily of personnel costs, including salaries, stock-based compensation, benefits and bonuses for the Company’s development personnel. Research and development expense also includes third-party partner fees and third-party consulting fees.
(k) General and administrative
General and administrative expense consists primarily of personnel costs, including salaries, stock-based compensation, benefits and bonuses for the Company’s executive, finance, legal, human resources, information technology, and other administrative personnel. General and administrative expense also includes consulting, legal, security, accounting services and allocated overhead.
(l) Depreciation
Depreciation represents depreciation expense for PhreesiaPads and Arrivals Kiosks (collectively, Phreesia hardware), data center and other computer hardware and purchased computer software.
(m) Amortization
Amortization primarily represents amortization of the Company’s capitalized internal-use software related to the Company's solutions as well as amortization of acquired intangible assets.
(n) Cash, cash equivalents and restricted cash
The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. The Company's money market accounts meet the definition of cash equivalents. As of January 31, 2026, the Company was required to maintain $3,500 of liquidity, which included unrestricted cash and availability under its securitization agreements. The Company was in compliance with these requirements as of January 31, 2026.
Restricted cash totaled $1,691 and $0 as of January 31, 2026 and 2025, respectively. Restricted cash includes amounts the Company is contractually required to maintain in connection with its securitization program. The restricted cash balance is legally segregated and not available for general corporate purposes. See Note 19 - Securitization program and variable interest entities for more information on restricted cash.
(o) Settlement assets
Settlement assets represent amounts due from the Company’s payment processors for customer electronic processing transactions. Settlement assets are typically settled within one to two business days of the transaction date.
(p) Settlement obligations
Settlement obligations represent amounts due to customers for electronic processing transactions that have not been funded by the Company due to timing of settlement from the Company’s payment processors.
(q) Accounts receivable and allowance for doubtful accounts
Accounts receivable represent trade receivables net of allowances for any potential uncollectible amounts. The Company estimates the allowance for doubtful accounts as its current estimate of expected credit loss over the life of the instrument. The Company estimates its allowance for doubtful accounts by evaluating the Company’s ability to collect outstanding receivable balances considering various factors, including the age of the balance, the customer’s creditworthiness, payment history and financial condition, the condition of the industry as a whole, as well as expected future changes in credit losses. Write-offs of accounts receivable were not material during the fiscal years ended January 31, 2026, 2025 or 2024. As of January 31, 2026 and 2025, the Company has reserved $1,523 and $1,468, respectively, for the allowance for doubtful accounts.
Accounts receivable also includes unbilled accounts receivable (see Contract balances in Note 5(c)).
(r) Accrued interest and fees receivable and allowance for doubtful accounts
Accrued interest and fees receivable represent finance charges and late fees that have been billed but not yet collected on patient accounts, net of allowances for any potential uncollectible amounts. The Company has elected to exclude accrued interest and fees receivable from the financing receivables when estimating the allowance for credit losses. The allowance for credit losses on accrued interest and fees receivable is a valuation account that is deducted from the amortized cost basis of accrued interest and fees receivable to present the net amount expected to be collected. The allowance is adjusted through the provision for credit losses. Losses are charged off against the allowance for credit losses when the Company determines the balance to be uncollectible. The measurement of expected credit losses includes information about historical events and current conditions, with historical credit loss experience providing the basis for the estimation of expected credit losses. The Company uses an aging method to estimate credit losses, pooling the receivables based on levels of delinquency and historical loss rates, adjusted for current conditions.
(s) Property and equipment
Property and equipment, including PhreesiaPads and Arrivals Kiosks, are stated at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the related assets. Maintenance and repair costs are charged to operations as incurred while expenditures for major improvements are capitalized.
The Company depreciates property and equipment over the following estimated useful lives:
Useful life
(years)
PhreesiaPads and Arrivals Kiosks3
Computer equipment
3
Computer software
3 to 5
Hardware development
3
Upon sale or disposition of property and equipment, the cost and related accumulated depreciation are removed from their respective accounts and any gain or loss is reflected in the consolidated statements of operations.
(t) Capitalized internal-use software
The Company capitalizes certain costs incurred for the development of computer software for internal use. These costs relate to the development of its solutions. The Company capitalizes the costs during the development of the project, when it is determined that it is probable that the project will be completed, and the software will be used as intended. Costs related to preliminary project activities, post-implementation activities, training and maintenance are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life, which is generally three to five years. Management evaluates the useful lives of these assets on an annual basis and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. The Company exercises judgment in determining the point at which various projects may be capitalized, in assessing the ongoing value of the capitalized costs and in determining the estimated useful lives over which the costs are amortized. To the extent that the Company changes the manner in which it develops and tests new features and functionalities related to its solutions, assesses the ongoing value of capitalized assets or determines the estimated useful lives over which the costs are amortized, the amount of internal-use software development costs the Company capitalizes and amortizes could change in future periods. Refer to Note 4(d) for further detail on internal-use software costs capitalized during the period.
(u) Business combinations
The Company uses its best estimates and assumptions to accurately assign fair value to the tangible and intangible assets acquired and liabilities assumed at the acquisition date. The Company’s estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with the corresponding offset to goodwill. The Company continues to collect information and reevaluate these estimates and assumptions quarterly and records any adjustments to its estimates to goodwill provided that the Company is within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statements of operations.
When applicable, the consideration transferred for business combinations includes the acquisition-date fair value of deferred consideration liabilities. The Company recognizes interest expense to accrete deferred consideration liabilities to their settlement amount.
(v) Goodwill and intangible assets
Goodwill represents the excess of the consideration transferred over the fair value of the underlying net tangible and intangible assets acquired and liabilities assumed in connection with business combinations accounted for using the acquisition method of accounting. Goodwill is not amortized, but instead goodwill is required to be tested for impairment annually and under certain circumstances. The Company performs such testing of goodwill in the fourth quarter of each fiscal year, or as events occur or circumstances change that would more likely than not reduce the fair value below its carrying amount.
The testing of goodwill is performed at the reporting unit level. The Company’s reporting unit is the same as its operating segment. The test begins with a qualitative assessment to determine whether it is “more likely than not” that the fair value of the reporting unit is less than its carrying amount. If it is concluded that it is “more likely than not” that the fair value of a reporting unit is less than its carrying amount, the Company performs a quantitative goodwill impairment test by calculating the fair value of the reporting unit and comparing that fair value to the carrying value of the reporting unit. If the estimated fair value of the reporting unit is less than its carrying amount, the Company records a goodwill impairment to reduce the carrying amount of goodwill by the amount by which the fair value of the reporting unit is less than its carrying amount.
All other intangible assets associated with purchased intangibles, consisting of customer relationships, acquired technology, acquired trademarks and acquired licenses, are recorded at acquisition-date fair value less accumulated amortization and are amortized on a straight-line basis over their estimated remaining economic lives.
(w) Long-lived assets
Long-lived assets, such as property and equipment, intangible assets, capitalized internal-use software and operating lease right-of-use assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares the undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. There were no impairment charges recognized in the consolidated statements of operations during any of the periods presented.
(x) Income taxes
An asset and liability approach is used for financial accounting and reporting of current and deferred income taxes. Deferred income tax assets and liabilities are computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future. Such deferred income tax asset and liability computations are based on enacted tax laws and rates applicable to periods in which the differences are expected to affect taxable income or loss. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company recognizes the financial statement effects of income tax positions taken or expected to be taken in an income tax return when they are more likely than not, based on technical merits, to be sustained upon examination. Deferred tax assets and deferred tax liabilities are offset and presented as a single net amount for each tax-paying component within a tax jurisdiction. A tax-paying component is an individual entity or a group of entities that file a consolidated tax return in that jurisdiction. The Company measures income tax positions at the largest amount of tax benefit that is more likely than not to be realized upon settlement with a taxing authority that has full knowledge of all relevant information. U.S. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in the interim periods, and disclosure for income taxes.
The Company reviews and evaluates tax positions in its major jurisdictions and determines whether or not there are uncertain tax positions that require financial statement recognition and the recording of a tax liability or the reduction of a tax asset. The Company would recognize tax related interest and penalties, if applicable, as a component of its provision for income taxes.
(y) Segment information
Operating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company defines the term “chief operating decision maker” to be its Chief Executive Officer. The
Company’s Chief Executive Officer reviews the financial information presented on an entire company basis for purposes of allocating resources and evaluating the Company’s financial performance. Accordingly, the Company has determined that it operates in a single reportable operating segment. Additionally, substantially all of the Company's revenues and long-lived assets are located in the U.S. See Note 16 - Segments and geographic information - for additional information regarding the Company’s reportable segment.
(z) Stock-based compensation
The Company has stock-based compensation plans under which various types of equity-based awards are granted, including stock options, restricted stock units ("RSUs"), performance-based RSUs, and market-based performance stock units ("PSUs"). The Company recognizes the compensation cost for equity-classified stock-based awards based on the grant-date fair value of the award. That cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the award. For performance-based RSUs, the number of shares expected to vest is estimated at each reporting date based on management's expectations regarding the relevant performance criteria. The Company adjusts stock compensation expense for forfeitures of stock-based compensation awards in the periods the forfeitures occur.
The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield, and the value of the Company's common stock (which is estimated for awards granted prior to the Company’s IPO). The Company does not estimate forfeitures in recognizing stock-based compensation expense. The fair value of the RSUs is equal to the fair value of the Company's common stock on the grant date of the award. The fair value of market-based PSUs is estimated at the time of grant using a Monte Carlo simulation which compares Phreesia's projected total shareholder return ("TSR") to the projected TSR of the Russell 3000 Index (the "Peer Group") and estimates the value of shares to be issued based on the vesting conditions of the PSUs. The Monte Carlo simulation requires the use of inputs and assumptions such as the grant-date closing stock price, simulation, expected volatility, correlation coefficient to the Russell 3000 Index, risk-free interest rate and dividend yield.
During fiscal 2020, the Company adopted the Phreesia, Inc. 2019 Employee Stock Purchase Plan ("ESPP" or "the Plan"). The Company records compensation expense based on the grant date fair value per award granted multiplied by the number of awards granted to the employee for the purchase period. The number of awards granted to the employee for the purchase period is equal to the expected employee contributions divided by 85% of the closing stock price on the offering date.
For liability-classified performance-based stock bonus awards, at the beginning of the year, the Company offers eligible employees the option to elect to receive their year-end performance bonus in stock. Bonuses settled in stock are accounted for as stock-based compensation awards vesting based on a performance condition and are classified as liabilities because they represent a liability settled in a variable number of shares.
During fiscal 2023, the Company adopted the 2023 Inducement Award Plan (the "Inducement Plan"). The Inducement Plan allows the Company to grant equity-based incentive awards including stock options, RSUs and PSUs to employees of acquired companies to induce them to join the Company.
See Note 8 - Equity-based compensation, for additional information on stock-based compensation.
(aa) Fair value of financial instruments
Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for the sale of an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability that were developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect assumptions the Company believes other market participants would use in pricing the asset or liability that are developed based on the best information available in the circumstances. Financial assets and liabilities carried at fair value are required to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:
Level 1—Quoted prices in active markets for identical assets or liabilities.
Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.
Level 3—Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.
To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3 of the fair value hierarchy.
The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the total fair value amount is disclosed at the level appropriate for the lowest level input that is significant to the total fair value of the instrument.
(ab) Fair value option
The Company elected the fair value option to account for its cardholder receivables, deferred purchase price receivable, and amounts due to healthcare providers, effective November 12, 2025. The election was made for deferred purchase price receivables because those receivables can contractually be prepaid or otherwise settled in such a way that the Company would not recover substantially all of its recorded investment. The election was made for cardholder receivables and the due to provider liability to better align measurement and presentation of cardholder receivables and the due to provider liability, which is only payable upon receipt of cash flows from the cardholder receivables. Changes in the fair value of these instruments are recognized in other income, net. Finance fee income related to cardholder receivables is reflected in payment solutions revenues, and finance fee expense on due to healthcare providers is reflected in payment solutions expenses separate from changes in fair value recognized in earnings.
(ac) Equity offering costs
The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs will be recorded in stockholders’ equity as a reduction of additional paid-in capital generated as a result of the offering, to the extent there are sufficient proceeds. Should the equity financing no longer be considered probable of being consummated, all deferred offering costs would be charged to operating expenses in the accompanying consolidated statements of operations.
(ad) Foreign currency
The functional currency of the Company’s subsidiaries and branch in the U.S. and Canada is the U.S. Dollar. The functional currency of the Company’s subsidiary in India is the Indian Rupee. For subsidiaries with functional currencies other than the U.S. Dollar, the Company translates the functional currency financial statements into U.S. Dollars using the exchange rates at the balance sheet date for assets and liabilities, the period average exchange rates for revenues and expenses, and the historical exchange rates for equity transactions. The effects of foreign currency translation adjustments are recorded as accumulated other comprehensive loss within stockholders’ equity in the Company’s consolidated balance sheets. Foreign currency transaction gains and losses to re-measure monetary assets and liabilities into each entity’s functional currency are included in Other income (expense), net in the Company’s consolidated statements of operations.
(ae) Other income, net
Other income, net consists primarily of miscellaneous other income and expense items that are not attributable to the Company’s normal ongoing operations, changes in the fair value of financial instruments accounted for under the fair value option, and foreign currency-related gains and losses.
(af) Legal and loss contingencies
The Company periodically evaluates the development in litigation, claims and other legal matters. The Company records liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources when it is probable that a liability has been incurred and the amount can be reasonably estimated. The Company discloses legal proceedings when it is reasonably possible that a loss has been incurred. Legal costs incurred in connection with loss contingencies are expensed as incurred.
(ag) Earnings (loss) per share
The Company calculates basic net income (loss) per share attributable to common stockholders using the weighted-average number of outstanding shares of common stock during the period. Diluted net income (loss) per share attributable to common stockholders is computed using the weighted-average number of outstanding shares of common stock and the effect of potentially dilutive securities outstanding during the period. Potentially dilutive securities include RSUs, PSUs, stock options, liability awards and ESPP shares. If dilutive, such potentially dilutive securities are reflected in net income (loss) per share attributable to common stockholders using the treasury stock method.
In the Company’s earnings (loss) per share footnote, antidilutive securities outstanding at the end of each period are stated on the basis of the number of anti-dilutive securities outstanding as of the end of each applicable reporting period. In the Company’s earnings (loss) per share footnote, the calculation of anti-dilutive securities outstanding at the end of each period are not reduced for shares assumed repurchased using the treasury stock method.
In computing year-to-date diluted earnings per share, periods with a net loss were assumed to have net income for purposes of determining the weighted-average number of potentially dilutive common shares outstanding.
See Note 13 - Net income (loss) per share attributable to common stockholders for additional information regarding net income (loss) per share.
(ah) Derivative financial instruments and hedging activities
The Company conducts business in Canada and India, subjecting the Company to foreign exchange risk. The Company uses derivative financial instruments to manage foreign currency exchange risk. Derivative instruments are measured at fair value and recorded as either an asset or liability on the consolidated balance sheets. Gains and losses resulting from changes in fair value are accounted for depending on the use of the derivative and whether it is designated and qualifies for hedge accounting.
For derivative instruments designated as foreign currency cash flow hedges, which the Company uses to hedge the functional currency equivalent cash flows attributable to Canadian Dollar denominated payroll payments, the Company records the gains or losses resulting from changes in fair value of the derivative within accumulated other comprehensive income (loss) on the consolidated balance sheets and subsequently reclassified to the same line item as the hedged transaction on the consolidated statements of operations in the same period that the hedged transaction affects earnings. The Company includes cash flows related to foreign currency cash flow hedges within operating activities in its consolidated statements of cash flows as cash flows related to the hedged transaction are included in operating activities and as the Company’s derivative instruments do not contain a significant financing component.
For derivative instruments not designated as foreign currency cash flow hedges, which the Company uses as economic hedges of Canadian Dollar denominated payroll payments not hedged by derivative instruments designated as hedges, the Company records gains and losses resulting from changes in the fair value of the derivative within other income (expense) in its consolidated statements of operations, and the Company classifies cash flows within operating activities in its consolidated statements of cash flows.
The foreign currency forward contract is classified within Level 2 of the fair value hierarchy because the valuation inputs are based on quoted prices and market observable data of similar instruments in active markets, such as currency spot and forward rates.
(ai) Deferred purchase price receivables
The Company receives a deferred purchase price as partial consideration for transferring cardholder receivables to a third-party financial institution. The Company initially records the deferred purchase price receivable at fair value. In addition, the Company has elected the fair value option for the subsequent measurement of its deferred purchase price receivable. The Company records changes in the fair value of its deferred purchase price receivable within other income, net. The Company reflects finance fee income on deferred purchase price receivables within payment solutions revenues.
(aj) Cardholder receivables
The Company’s cardholder receivables consist of self-pay patient accounts originated by the Company. The Company has elected the fair value option with respect to its cardholder receivables. As a result, cardholder receivables are initially and subsequently reported at fair value in the Company’s consolidated balance sheets. The Company records changes in the fair value of its cardholder receivables within other income, net. Patient repayment terms require monthly payments based on revolving credit schedules. Cardholder receivables have an estimated
average contractual maturity of 15 months. The Company is responsible for billing, collecting, and remitting the amount equal to the principal payment, less a service fee, to the healthcare provider.
The Company has full recourse against the healthcare providers for unpaid principal. If, at any point in time, the patient fails to make three consecutive minimum monthly payments, the unpaid balance is returned to the healthcare provider in exchange for extinguishment of the related due to provider liability.
(ak) Due to healthcare providers
Due to healthcare providers represent a liability for cardholder receivable accounts which have been originated by the Company. The Company has elected the fair value option with respect to its due to healthcare providers liability. As a result, amounts due to healthcare providers are initially and subsequently reported at fair value in the Company’s consolidated balance sheets. The Company records changes in the fair value of its due to healthcare providers liability within other income, net. The due to healthcare providers liability is payable upon receipt of cash flows from the cardholder receivables. The due to healthcare provider liability is paid using cash flows from the cardholder receivables or is extinguished when the related cardholder receivables are returned to the healthcare provider.
(al) Debt facilities
The Company accounts for debt instruments in accordance with applicable U.S. GAAP. Debt obligations are classified as current or long-term based on their contractual maturity dates and the Company’s intent and ability to refinance on a long-term basis. Amounts contractually due within one year of the balance sheet date are classified as current liabilities unless the Company has both the intent and the ability to refinance the obligation on a long-term basis under an existing financing arrangement as of the balance sheet date.
The initial carrying value of debt is recorded at the principal amount borrowed, net of unamortized discounts, premiums, issuance costs, and other deferred financing fees. The Company determines the expected term of debt based on contractual maturity, adjusted for any substantive call, put, prepayment, or extension features that are reasonably certain to be exercised. Interest expense is recognized using the effective interest method, which requires the Company to estimate the effective interest rate that exactly discounts the expected future cash payments over the expected term of the instrument to the net carrying amount at issuance. This assessment requires judgment, particularly when debt includes variable interest rates, payment-in-kind features, or other nonstandard terms.
The Company evaluates debt agreements for embedded features, including conversion options, put or call features, contingent interest provisions, and other terms that may require bifurcation as embedded derivatives. Embedded features are assessed to determine whether they are clearly and closely related to the host instrument or meet the definition of a derivative requiring separate accounting. When required, bifurcated embedded derivatives are recorded at fair value with changes in fair value recognized in earnings. The Company also evaluates whether debt instruments should be accounted for under specialized guidance, including convertible instrument or modification and extinguishment accounting, when applicable.
The Company classifies short-term debt as long-term if it is refinanced onto long-term debt prior to the issuance of the financial statements.
(am) New accounting pronouncements
Impact of recently adopted accounting pronouncements
On February 1, 2025, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, on a prospective basis, upon which the Company has provided greater disaggregation of information in the rate reconciliation, by both amounts and percentages, among prescribed categories, such as state and local income taxes, foreign tax effects, changes in valuation allowances and nontaxable or nondeductible items, among others. The Company also provided disaggregation of income taxes paid by U.S. federal and state income taxes and foreign income taxes. See Note 12 - Income taxes.
During the year ended January 31, 2026, the Company did not adopt any other accounting pronouncements that materially impacted the Company's financial statements.
Recent accounting pronouncements not yet adopted
In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. In January 2025, the FASB issued ASU 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, Clarifying the Effective Date. The new standards require companies to disclose disaggregated information about certain income statement expense line items. The provisions of ASU 2024-03, as amended by ASU 2025-01, are effective for annual periods beginning after December 15, 2026, and interim reporting periods in fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company plans to adopt ASU 2024-03 and ASU 2025-01 for annual periods beginning in the fiscal year ending January 31, 2028 and for interim periods beginning in the fiscal year ending January 31, 2029. The Company is currently evaluating the impact that ASU 2024-03 and ASU 2025-01 will have on its financial statements and related disclosures. The Company does not expect the disclosure changes that result from the adoption of ASU 2024-03 and ASU 2025-01 to materially impact its consolidated financial statements.
In July 2025, the FASB issued ASU 2025‑05, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, which amends ASC 326‑20 to introduce a practical expedient available to all entities that permits entities to assume that current economic conditions as of the balance‑sheet date do not change over the remaining life of current accounts receivable and current contract assets arising from transactions within the scope of ASC 606. The amendments are effective for annual periods beginning after December 15, 2025, and interim periods within those years, with early adoption permitted. The Company is currently evaluating the impact that ASU 2025-05 will have on its consolidated financial statements and related disclosures.
In September 2025, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other-Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. The ASU amends the existing standard to remove all references to prescriptive and sequential software development project stages. Under this guidance, eligible software development costs will begin capitalization when management has authorized and committed to funding the software project, and it is probable that the project will be completed and the software will be used to perform the function intended. In evaluating whether it is probable the project will be completed; management is required to consider whether there is significant uncertainty associated with the development activities of the software. This guidance is effective for all annual periods beginning after December 15, 2027, and for interim periods within those annual reporting periods, with early adoption permitted. The guidance may be applied on a prospective basis, a modified basis for in-process projects, or a retrospective basis. The Company is currently evaluating the impact of this ASU to determine the impact on the consolidated financial statements and related disclosures.
There are no other recently issued accounting pronouncements the Company has not yet adopted that will materially impact the Company's consolidated financial statements.
v3.26.1
Composition of certain financial statement captions
 12 Months Ended
Jan. 31, 2026
Composition Of Certain Financial Statement [Abstract]  
Composition of certain financial statement captions Composition of certain financial statement captions
(a) Accrued expenses
Accrued expenses at January 31, 2026 and 2025 are as follows:
January 31,
20262025
Payroll-related expenses and taxes$12,535 $12,016 
Stock-based compensation liability7,652 6,135 
Payment processing fees liability7,056 6,578 
Acquisition-related liabilities119 844 
Income and other tax liabilities2,674 2,503 
Information technology5,546 4,562 
Other5,675 4,822 
Total accrued expenses
$41,257 $37,460 
(b) Property and equipment
Property and equipment at January 31, 2026 and 2025 are as follows:
January 31,
20262025
PhreesiaPads and Arrivals Kiosks$16,523 $15,763 
Computer equipment
84,380 77,704 
Computer software
12,887 14,114 
Hardware development
577 575 
Furniture and fixtures
4 — 
Leasehold improvements154 — 
Total property and equipment$114,525 $108,156 
Less: accumulated depreciation(94,193)(84,505)
Property and equipment — net$20,332 $23,651 
Depreciation expense related to property and equipment amounted to $12,972, $14,183 and $17,584 for the fiscal years ended January 31, 2026, 2025 and 2024, respectively.
Property and equipment - net and related depreciation expense includes assets acquired under finance leases. Assets acquired under finance leases included in computer equipment were $49,009 at January 31, 2026 and 2025. Accumulated amortization of assets under finance leases was $42,060 and $34,815 at January 31, 2026 and 2025, respectively. See Note 10 - Leases for additional information regarding finance leases.
(c) Capitalized internal-use software
For the fiscal years ended January 31, 2026, 2025 and 2024, the Company capitalized $14,907, $16,846 and $19,521 of costs related to the Company's solutions, respectively.
During the fiscal years ended January 31, 2026, 2025 and 2024 amortization expense related to capitalized internal-use software was $13,399, $10,222 and $9,527, respectively.
(d) Intangible assets and goodwill
On November 12, 2025, the Company acquired AccessOne Parent Holdings, Inc. (together with its subsidiaries, “AccessOne”) (the "AccessOne Acquisition"). The Company acquired certain intangible assets and goodwill in connection with the AccessOne Acquisition. See Note 18 - Acquisitions for additional information.
The following presents the details of intangible assets as of January 31, 2026 and 2025.
Useful LifeJanuary 31,
(years)
2026
2025
Acquired technology
5 to 7
$22,910 $9,310 
Customer relationship
7 to 15
53,940 17,940 
License156,200 6,200 
Trademarks
12 to 15
10,200 3,100 
Total intangible assets, gross carrying value$93,250 $36,550 
Less: accumulated amortization(13,489)(8,407)
Net carrying value$79,761 $28,143 
The weighted-average remaining useful life for acquired technology in years was 5.4 and 5.1 as of January 31, 2026 and 2025, respectively. The remaining useful life for customer relationships in years was 8.6 and 11.6 as of January 31, 2026 and 2025, respectively. The remaining useful life for the license to the Patient Activation Measure ("PAM"®) in years was 10.8 and 11.8 as of January 31, 2026 and 2025, respectively. The remaining useful life for the trademarks in years was 12.0 and 13.5 as of January 31, 2026 and 2025, respectively.
Amortization expense associated with intangible assets for the fiscal years ended January 31, 2026, 2025 and 2024 was $5,082, $3,481 and $2,376, respectively.
The estimated amortization expense for intangible assets for the next five years and thereafter is as follows as of January 31, 2026:
January 31, 2026
2027
$10,516 
2028
10,516 
2029
10,415 
2030
10,215 
2031
9,761 
Thereafter28,338 
Total$79,761 
The following table presents a roll-forward of goodwill for the years ended January 31, 2026 and 2025:
Balance, January 31, 2024$75,845 
Balance, January 31, 2025
$75,845 
Goodwill acquired during the year ended January 31, 2026
94,219 
Balance, January 31, 2026
$170,064 
As of January 31, 2026, the Company completed its quarterly triggering event assessments and determined that the decline in the market value of its publicly-traded stock, which resulted in a corresponding decline in its market capitalization, constituted a triggering event. Due to the decline in the Company’s market capitalization during the year, the Company has evaluated whether changes in the Company’s market capitalization indicate that the
carrying value of goodwill in the Company’s single reporting unit is impaired. As of January 31, 2026, the Company’s market capitalization exceeded the carrying value of the Company’s equity by over 100%. As a result, the Company does not believe that changes in the Company’s market capitalization during the year indicate that the carrying amount of the Company’s goodwill is impaired as of January 31, 2026.
As of January 31, 2025, the Company determined that it was more likely than not that the fair value of its single reporting unit exceeded its carrying value. As a result, the Company does not believe that the Company’s goodwill was impaired as of January 31, 2025.
The Company did not record any impairments of goodwill during the years ended January 31, 2026, 2025 or 2024.
(e) Accounts receivable
Accounts Receivable as of January 31, 2026 and 2025 are as follows:
January 31,
20262025
Billed$93,296 $70,342 
Unbilled5,680 4,743 
Total accounts receivable, gross$98,976 $75,085 
Less: accounts receivable allowances(1,523)(1,468)
Total accounts receivable$97,453 $73,617 
Activity in the Company's allowance for doubtful accounts was as follows for the years ended January 31, 2026 and 2025:
Balance, January 31, 2024
$1,392 
Bad debt expense1,054 
Write-offs and adjustments(978)
Balance, January 31, 2025
$1,468 
Bad debt expense1,021 
Write-offs and adjustments(966)
Balance, January 31, 2026
$1,523 
The Company’s allowance for doubtful accounts represents the current estimate of expected future losses based on prior bad debt experience as well as considerations for specific customers as applicable. The Company's accounts receivable are considered past due when they are outstanding past the due date listed on the invoice to the customer. Write-offs of accounts receivable were not material during the fiscal years ended January 31, 2026, 2025 or 2024.
(f) Prepaid and other current assets
Prepaid and other current assets as of January 31, 2026 and 2025 are as follows:
January 31,
20262025
Prepaid software and business systems$7,246 $6,849 
Prepaid data center expenses4,661 3,558 
Prepaid insurance1,721 912 
Other prepaid expenses and other current assets4,350 4,552 
Total prepaid and other current assets$17,978 $15,871 
(g) Cloud computing implementation costs
The Company enters into cloud computing service contracts to support its sales and marketing, product development and administrative activities. The Company capitalizes certain implementation costs for cloud computing arrangements that meet the definition of a service contract. The Company includes these capitalized implementation costs within prepaid expenses and other current assets and within other assets on its consolidated balance sheets. Once placed in service, the Company amortizes these costs over the remaining subscription term to the same caption in the consolidated statements of operations as the related cloud subscription. Capitalized
implementation costs for cloud computing arrangements accounted for as service contracts were $1,532 as of January 31, 2026 and 2025, respectively. Accumulated amortization of capitalized implementation costs for these arrangements was $1,532 and $1,432 as of January 31, 2026 and 2025, respectively. These arrangements were fully amortized during the year ended January 31, 2026.
(h) Other income, net
Other income, net for the years ended January 31, 2026, 2025 and 2024 was income of $2,953, $1,956 and $44, respectively. Other income, net for the years ended January 31, 2026 and 2024 were composed primarily of miscellaneous other income and expense as well as foreign exchange gains and losses due to changes in rates, as well as gains on instruments accounted for under the fair value option for the year ended January 31, 2026. Other income, net for the year ended January 31, 2025 included a $2,345 gain on the ConnectOnCall settlement, partially offset by foreign exchange losses.
v3.26.1
Revenue and contract costs
 12 Months Ended
Jan. 31, 2026
Revenue from Contract with Customer [Abstract]  
Revenue and contract costs Revenue and contract costs
(a) Disaggregation of revenue
Revenue from the Company’s contracts with its customers are disaggregated by service offering on the accompanying consolidated statements of operations. The Company’s core service offerings are: subscription and related services; payment solutions, which include payment processing fees and financing fees; and network solutions, which provides a channel for life sciences companies and other organizations to deliver compliant, personalized engagements to patients who use the Company’s solutions. In addition, substantially all of the Company’s revenue is derived from customers in the United States.
The following table represents a summary of sources of revenue:
January 31,
20262025
2024
Revenue from contracts with customers
$467,819 $410,484 $345,992 
Revenue from other sources12,772 9,329 10,307 
Total revenues
$480,591 $419,813 $356,299 
(b) Remaining performance obligations
The Company does not disclose the value of unsatisfied performance obligations as the majority of its contracts relate to either contracts with an original term of one year or less or contracts with variable consideration (i.e., the Company’s payment solutions revenue).
(c) Contract balances
Unbilled accounts receivable is a contract asset related to the delivery of the Company’s subscription and related services and for its life sciences revenue for which the related billings will occur in a future period. Contract assets and contract liabilities are reported on a net basis for each customer contract. Deferred revenue is a contract liability primarily related to billings in advance of revenue recognition from the Company's subscription and life sciences services and, to a lesser extent, professional services and other revenues described above. Deferred revenue is recognized as the Company satisfies its performance obligations. The Company generally invoices its customers in monthly or quarterly installments for subscription services. Accordingly, the deferred revenue balance does not generally represent the total contract value of a subscription arrangement. Deferred revenue that will be recognized during the succeeding 12-month period is recorded as current deferred revenue on the accompanying consolidated balance sheets. Deferred revenue that will be recognized subsequent to the succeeding 12-month period is recorded as long-term deferred revenue on the accompanying consolidated balance sheets.
The following table represents a roll-forward of contract assets:
January 31,
20262025
Beginning balance$4,743 $3,375 
Amount transferred to receivables from beginning balance of contract assets(4,706)(3,375)
Contract asset additions, net of reclassification to receivables5,643 4,743 
Ending balance$5,680 $4,743 
The following table represents a roll-forward of deferred revenue:
 January 31,
20262025
Beginning balance$32,877 $24,210 
Revenue recognized that was included in deferred revenue at the beginning of the period(31,719)(23,335)
Deferred revenue added from acquisitions8,475 — 
Other current year activity in deferred revenue40,133 32,002 
Ending balance$49,766 $32,877 
(d) Cost to obtain a contract
The Company capitalizes certain incremental costs to obtain customer contracts and amortizes these costs over a period of benefit that the Company has estimated to be three to five years. The Company determined the period of benefit by taking into consideration its customer contracts, its technology and other factors. Amortization expense is included in sales and marketing expenses in the accompanying consolidated statements of operations and totaled $570 and $1,815 for the years ended January 31, 2026 and 2025, respectively. The Company periodically reviews these deferred contract acquisition costs to determine whether events or changes in circumstances have occurred that could impact the period of benefit. During the year ended January 31, 2025, the Company updated its estimate of the period of benefit from five years to three years for certain deferred contract acquisition costs. The Company recorded $1,198 of additional amortization during the year ended January 31, 2025 to amortize deferred contract amortization costs over their updated remaining period of benefit. There were no impairment losses recorded during the periods presented.
The following table represents a roll-forward of deferred contract acquisition costs:
January 31,
20262025
Beginning balance$984 $1,754 
Additions to deferred contract acquisition costs334 1,045 
Amortization of deferred contract acquisition costs(570)(1,815)
Ending balance$748 $984 
Deferred contract acquisition costs, current (to be amortized in next 12 months)$410 $401 
Deferred contract acquisition costs, non-current338 583 
Total deferred contract acquisition costs$748 $984 
v3.26.1
Debt and finance leases
 12 Months Ended
Jan. 31, 2026
Debt Disclosure [Abstract]  
Finance leases and other debt Debt and finance leases
As of January 31, 2026 and 2025, the Company had the following outstanding debt and finance lease liabilities:
January 31,
20262025
Bridge loan
$90,000 $— 
Finance leases7,431 14,256 
Accrued interest and payments2,062 24 
Financing arrangements595 1,913 
Total debt and finance lease liabilities
$100,088 $16,193 
Less: current portion of debt and finance lease liabilities
(7,971)(8,043)
Long-term debt and finance lease liabilities
$92,117 $8,150 
(a) Bridge Loan
In connection with the AccessOne acquisition, on the Closing Date, the Company entered into the Bridge Credit Agreement with respect to a new, 364-day $110,000 secured term loan. The net proceeds of the Bridge Loan were used to fund a portion of the purchase price of the AccessOne Acquisition. The Bridge Loan matures on November 11, 2026 and bears interest at a per annum rate equal to the three month SOFR rate plus a margin of 4.0% per annum. The interest rate applicable to the Bridge Loan increases by 0.5% every three months following the closing date of November 12, 2025.
During the three months ended January 31, 2026, the Company repaid $20,000 of the outstanding principal balance of the Bridge Loan. As of January 31, 2026, the Company had $90,000 outstanding under the Bridge Facility. The Company incurred $3,122 in debt issuance costs and original issue discount related to the Bridge Loan.
Subsequent to the end of the fiscal year, in connection with the Refinancing, the Company terminated without penalty, and repaid all outstanding indebtedness and obligations under, the Bridge Loan. All security agreements and related financing arrangements entered into with the Company’s former lenders under the Bridge Loan were terminated substantially concurrently with the effectiveness of the New Capital One Credit Agreement. As the January 31, 2026 outstanding principal balance of the Bridge Loan was refinanced onto long-term debt prior to the issuance of the financial statements, the Company classified the outstanding principal balance of the Bridge Loan as long-term debt in the accompanying consolidated balance sheet as of January 31, 2026.
(b) Finance leases
See Note 10 - Leases for more information regarding finance leases.
(c) Existing Capital One Credit Agreement
In December 2023, the Company entered into the Existing Capital One Credit Agreement for a new 5-year $50,000 senior secured asset-based revolving credit facility maturing in December 2028, which includes a swingline sub-limit of at least $5,000 and a letter of credit sub-limit of at least $5,000. The Existing Capital One Credit Facility was entered into with Capital One acting as administrative agent and replaced the Company’s previous senior secured revolving credit facility with SVB. The Company recorded a $1,118 loss on extinguishment of debt in connection with the termination of the SVB Facility. The Capital One Credit Facility gave the Company additional financial flexibility and was available to the Company for working capital and general corporate purposes. The Existing Capital One Credit Facility bore interest at a rate per annum based on SOFR or a Base Rate as specified in the Existing Capital One Credit Agreement. As of January 31, 2026, the interest rate on the Existing Capital One Credit Facility was 6.7%. In addition to any principal and interest due under the Capital One Credit Facility, the Company was required to pay an annual fee equal to 0.25% of the unused balance of the facility. Additionally, the Company incurred creditor and third-party fees of $778 upon entering into the Capital One Credit Facility. The Company recorded the fees to deferred financing costs, included within other assets on its consolidated balance sheets, and we amortized the costs over the term of the Capital One Credit Facility.
On November 12, 2025, the Company entered into an amendment (the “First Amendment”) to the Existing Capital One Credit Facility. The First Amendment amended the covenant limiting acquisitions to permit the AccessOne Acquisition, amended the covenant limiting additional indebtedness to accommodate the Bridge Loan, and amended the security interest supporting the Existing Capital One Credit Facility to permit the security interests granted in connection with the Bridge Loan. The amendment included further changes to sections governing mandatory and voluntary prepayments, negative covenants and events of default to accommodate the existence of
the Bridge Loan. The First Amendment also shortened the maturity of the Existing Capital One Credit Facility to align with the maturity of the Bridge Credit Agreement. In connection with the First Amendment, the Company recognized a $501 loss on extinguishment of debt related to debt issuance costs of the Existing Capital One Credit Facility.
The Existing Capital One Credit Agreement contained customary affirmative and negative covenants, including limitations on the Company’s ability to incur additional indebtedness, create liens, make certain investments, pay dividends, or engage in mergers and acquisitions.
The obligations under the Existing Capital One Credit Facility were secured by a first priority security interest in substantially all of the tangible and intangible assets at certain of the Company's U.S. subsidiaries, and by pledges of the equity of certain of the Company's U.S. subsidiaries, in each case subject to customary exclusions.
The Existing Capital One Credit Facility included financial covenants including, but not limited to requiring the Company to maintain minimum Consolidated EBITDA, minimum Liquidity, a minimum Consolidated Fixed Charge Coverage Ratio a restriction on the amount of dividends and limiting the amount of cash and cash equivalents the Company holds outside Capital One, each as defined in the Existing Capital One Credit Agreement. The Company was in compliance with all covenants related to the Existing Capital One Credit Facility as of January 31, 2026.
Subsequent to the end of the fiscal year, the Existing Capital One Credit Agreement was terminated without penalty in connection with the Refinancing. All security agreements and related financing arrangements entered into with the Company’s former lenders under the Existing Capital One Credit Facility were terminated substantially concurrently with the effectiveness of the New Capital One Credit Agreement.
(d) Financing agreements
In June 2023, the Company entered into a software licensing financing agreement (the "financing agreement") in order to finance its software and service licenses. As of January 31, 2026, there was $595 in outstanding principal and interest due under the financing agreement. The financing agreement requires the Company to pay $123 per month for 36 months beginning August 2023. The effective interest rate on the financing agreement is 10.5% per annum.
Maturities of debt and finance leases in each of the next five years and thereafter are as follows:
 Total
Bridge Loan
Finance LeasesOther Debt
Fiscal year ending January 31,
2027(1)
$97,971 $90,000 $5,314 $2,657 
2028
2,117 — 2,117 — 
2029
— — — — 
2030
— — — — 
2031
— — — — 
Thereafter
— — — — 
Total maturities of debt and finance leases
$100,088 $90,000 $7,431 $2,657 
(1) As of January 31, 2026, the Company had a Bridge Loan outstanding. Subsequent to year-end and prior to the issuance of the financial statements, the Company refinanced this obligation with long-term debt. Accordingly, the bridge loan has been classified as long-term on the balance sheet.
v3.26.1
Stockholders' equity
 12 Months Ended
Jan. 31, 2026
Equity [Abstract]  
Stockholders' equity Stockholders' equity
(a) Common stock
The Company closed its initial public offering (“IPO”) on July 22, 2019 and filed an Amended and Restated Certificate of Incorporation authorizing the issuance of up to 500,000,000 shares of common stock, par value $0.01 per share.
In connection with the acquisition of Comsort, Inc. d/b/a MediFind (“MediFind”), on June 30, 2023, the Company issued 150,786 shares of its common stock, to the former owners of MediFind as partial consideration to acquire MediFind. On July 3, 2023, the Company filed a prospectus supplement to register the shares with the SEC.
In connection with the acquisition of Access eForms, LLC (“Access eForms”), on August 11, 2023, the Company issued 1,096,436 shares of its common stock, to the former members of Access eForms as partial consideration to
acquire Access eForms. On August 14, 2023, the Company filed a prospectus supplement to register the shares with the SEC.
(b) Treasury stock
The Company's equity-based compensation plan allows for the grant of non-vested stock options, restricted stock units (“RSUs”) and total shareholder return ("TSR") performance-based stock units ("PSUs") to its employees pursuant to the terms of its stock option and incentive plans (See Note 8). Until September 2023, under the provision of the plans, for RSU and PSU awards, unless otherwise elected, employee participants fulfilled their related income tax withholding obligation by having shares withheld at the time of vesting. The shares withheld were then transferred to the Company's treasury stock at cost.
Beginning in September 2023, employee participants fulfilled their related tax withholding obligation by selling vested shares at the time of vesting in non-discretionary transactions pursuant to the Company’s mandatory sell-to-cover policy (sell-to-cover). The proceeds from the employee participants’ sales of vested shares are remitted to the Company to cover the tax withholding payments to tax authorities. No shares are transferred to the Company’s treasury stock in connection with tax withholdings funded by an employee participant’s sale of vested shares to cover taxes.
(c) Stock repurchase program
In March 2025, the Company’s Board of Directors authorized a stock repurchase program. Under the program, the Company may repurchase up to 2.5 million shares of its common stock from time to time through open market purchases, privately negotiated transactions, block purchases or other methods that comply with applicable securities laws, including repurchase plans that satisfy the conditions of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The stock repurchase program does not obligate the Company to repurchase any dollar amount or number of shares of its common stock, and the program may be modified, suspended or discontinued at any time without prior notice. The 1% U.S. federal excise tax on certain repurchases of stock by publicly traded U.S. corporations enacted as part of the Inflation Reduction Act of 2022 applies to repurchases pursuant to the Company’s stock repurchase program. There were no repurchases during the year ended January 31, 2026.
(d) Accumulated other comprehensive loss
Activity in accumulated other comprehensive loss was as follows for the fiscal year ended January 31, 2026:
 
Unrealized gain on cash flow hedges
Foreign currency translation adjustment
Accumulated other comprehensive loss
Balance as of January 31, 2024$— $— $— 
Other comprehensive loss— (51)(51)
Balance as of January 31, 2025
$— $(51)$(51)
Balance, January 31, 2025$— $(51)$(51)
Other comprehensive income (loss) before reclassifications
182 (198)(16)
Amounts reclassified from accumulated other comprehensive loss(315)— (315)
Net current period other comprehensive loss$(133)$(198)$(331)
Balance, January 31, 2026
$(133)$(249)$(382)
There was no balance or activity in accumulated other comprehensive loss prior to January 31, 2024. As the Company records a valuation allowance against its U.S. deferred tax assets and substantially all of the Company’s accumulated other comprehensive income originated in the U.S., other comprehensive income did not include income tax expense, and the amounts reclassified from accumulated other comprehensive income (loss) for unrealized gain (loss) on cash flow hedges did not include income tax expense.
v3.26.1
Equity-based compensation
 12 Months Ended
Jan. 31, 2026
Share-Based Payment Arrangement [Abstract]  
Equity-based compensation Equity-based compensation
(a) Equity award plans
In January 2018, the Board of Directors adopted the Company’s 2018 Stock Option Plan as amended, (the "2018 Stock Option Plan") which provided for the issuance of options to purchase up to 3,048,490 shares of the Company’s common stock to officers, directors, employees, and consultants. The option exercise price per share is determined by the Board of Directors based on the estimated fair value of the Company’s common stock.
In June 2019, the Board of Directors adopted the Company’s 2019 Stock Option and Incentive Plan (the "2019 Plan"), which replaced the 2018 Stock Option Plan upon the completion of the IPO. The 2019 Plan allows the Compensation Committee of the Board of Directors (the "Compensation Committee") to make equity-based incentive awards including stock options, RSUs and PSUs to the Company’s officers, employees, directors, and consultants. The initial reserve for the issuance of awards under this plan was 2,139,683 shares of common stock. The initial number of shares reserved and available for issuance automatically increased on February 1, 2020 and automatically increases each February 1 thereafter by 5% of the number of shares of common stock outstanding on the immediately preceding January 31 (or such lesser number of shares determined by the Compensation Committee). As the 2018 Stock Option Plan was replaced by the 2019 Plan, all grants of stock options, RSUs and PSUs during the years ended January 31, 2026, 2025 and 2024 were made pursuant to the 2019 plan, respectively.
In June 2019, the Board of Directors also adopted the Company's 2019 Employee Stock Purchase Plan (the "ESPP"), which became effective immediately prior to the effectiveness of the registration statement for the Company’s initial public offering. The total shares of common stock initially reserved under the ESPP was limited to 855,873 shares.
The Company's incentive bonuses allow eligible employees to elect to receive all or a portion of their incentive compensation in the form of immediately vested restricted stock units instead of cash.
In July 2023, the Board of Directors also adopted the Company’s 2023 Inducement Award Plan (the “Inducement Plan”). The Inducement Plan allows the Compensation Committee of the Board of Directors (the "Compensation Committee") or its delegates to make equity-based incentive awards including stock options, RSUs and PSUs to employees of acquired companies to induce them to join the Company. The total shares of common stock initially reserved under the Inducement Plan was 500,000 shares.
As of January 31, 2026, there are 6,583,030 shares available for future grant pursuant to the 2019 Plan after factoring in the automatic increase that occurs on February 1 of each fiscal year, as well as an additional 131,404 shares available for future grant pursuant to the ESPP. The ESPP has two six-month offering periods each calendar year beginning in January and July. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a 15% discount through payroll deductions. As of January 31, 2026, there were 5,896 outstanding restricted stock units and 485,217 shares available for future grant under the Inducement Plan.
(b) Summary of stock-based compensation
The following table sets forth stock-based compensation by type of award:
For the fiscal years ended
January 31,
 202620252024
RSUs$37,814 $44,696 $53,474 
PSUs17,608 13,174 9,206 
Liability awards12,242 9,316 9,047 
ESPP833 1,149 1,256 
Stock options (1)
241 2 45 
Total stock-based compensation$68,738 $68,337 $73,028 
(1) Payments to stockholders of AccessOne in connection with AccessOne stock options accelerated in connection with the AccessOne acquisition.
The following table sets forth the presentation of stock-based compensation in the Company's consolidated financial statements:
For the fiscal years ended
January 31,
 202620252024
Stock-based compensation expense recorded to additional paid-in capital$56,255 $59,021 $63,981 
Stock-based compensation expense recorded to accrued expenses12,242 9,316 9,047 
Stock-based compensation expense paid in cash (1)
241 — — 
Total stock-based compensation$68,738 $68,337 $73,028 
Less: stock-based compensation expense capitalized as internal-use software(1,286)(1,362)(1,415)
Stock-based compensation expense per consolidated statements of operations$67,452 $66,975 $71,613 
(1) Payments to stockholders of AccessOne in connection with stock issued for stock options accelerated in connection with the AccessOne acquisition.
The Company recorded a tax benefit of $1,593 related to stock compensation awards granted to Canadian employees during the year ended January 31, 2026. There was no tax benefit or expense recorded for the year ended January 31, 2025. During the years ended January 31, 2026 and 2025, the Company reduced stock compensation expense by $431 and $1,333, respectively, for improbable-to-probable modifications of stock compensation awards.
(c) Restricted stock units
The Company has issued RSUs to employees and independent directors that vest based on a time-based condition. RSUs granted to employees prior to January 2021, pursuant to a time-based condition, 10% of the restricted stock units vest after one year, 20% vest after two years, 30% vest after three years and 40% vest after four years (“10/20/30/40”). The restricted stock units expire seven years from the grant date.
During the year ended January 31, 2023, the Company modified the vesting of RSUs granted subsequent to January 1, 2021 for employees other than its named executive officers listed in its 2022 proxy statement ("2022 NEOs") and other members of its executive management team. Pursuant to the modified vesting schedule, RSUs granted after January 1, 2021 for employees other than 2022 NEOs and other members of its executive management team, vest 6.25% each quarter over four years based on continued service. For 2022 NEOs and other members of the Company's executive management team, RSUs granted from January 1, 2022 through December 31, 2022 vest 6.25% each quarter over four years based on continued service. RSUs granted during fiscal 2024 vest 25% each year over four years based on continued service and RSUs granted during fiscal 2025 and 2026 generally vest following a 10/20/30/40 vesting schedule.
Additionally, at the beginning of each fiscal year, the Company provides certain employees the option to settle their incentive bonus in immediately vested RSUs. RSUs granted to settle bonus awards are included in RSUs granted
and vested in the table below. See section (g) Liability awards below for additional information regarding share-settled bonus awards.
Restricted stock units
Unvested, January 31, 2023
3,917,753 
Granted during year (1)
2,419,679 
Vested(1,912,432)
Forfeited and expired(624,790)
Unvested, January 31, 2024
3,800,210 
Granted during year
2,135,391 
Vested(1,897,716)
Forfeited and expired(439,937)
Unvested, January 31, 2025
3,597,948 
Granted during year
1,883,490 
Vested(1,578,301)
Forfeited and expired (410,175)
Unvested, January 31, 2026
3,492,962 
(1) Includes 24,125 awards granted pursuant to the 2023 Inducement Award Plan.
As of January 31, 2026, there is $67,299 remaining of total unrecognized compensation costs related to these awards. The total unrecognized costs are expected to be recognized over a weighted-average term of 2.8 years.
For the years ended January 31, 2026, 2025 and 2024, the weighted-average grant date fair value of restricted stock units granted was $24.03, $21.93 and $29.08 respectively.
(d) Stock options
Options granted under the equity award plans have a maximum term of ten years and vest over a period determined by the Board of Directors (generally four years from the date of grant or the commencement of the grantee’s employment with the Company). Options generally vest 25% at the one-year anniversary of the grant date, after which point they generally vest pro rata on a monthly basis.
Stock option activity for the fiscal years ended January 31, 2026, 2025 and 2024 is as follows:
Number of
options		Weighted-
average
exercise price		Weighted-
average
remaining
contractual life
(in years)		Aggregate intrinsic
value
Outstanding — January 31, 20231,385,193 $6.26 
Granted during the year— $— 
Exercised(249,247)$3.42 
Forfeited and expired(12,508)$5.87 
Outstanding and expected to vest — January 31, 2024
1,123,438 $6.89 4.54$20,884 
Outstanding — January 31, 20241,123,438 $6.89 
Granted during the year— $— 
Exercised(220,523)$4.64 
Forfeited and expired(3,534)$20.67 
Outstanding and expected to vest — January 31, 2025
899,381 $7.39 3.66$18,952 
Outstanding — January 31, 2025899,381 $7.39 
Granted during the year— $— 
Exercised(237,516)$6.12 
Forfeited and expired(1,649)$10.60 
Outstanding and expected to vest — January 31, 2026
660,216 $7.84 2.83$3,767 
Exercisable — January 31, 2026
660,216 $7.84 2.83$3,767 
Amount vested during year ended January 31, 2026
— $— 

The aggregate intrinsic value represents the total pre-tax intrinsic value (the difference between the Company’s estimated stock price at the time of exercise and the exercise price, multiplied by the number of related in-the-money options) that would have been received by the option holders had they exercised their options at the end of the period. This amount changes based on the market value of the Company’s common stock. The total intrinsic value of options exercised for the years ended January 31, 2026, 2025 and 2024 (based on the difference between the Company’s estimated stock price on the exercise date and the respective exercise price, multiplied by the number of options exercised), was $4,671, $4,210 and $6,059, respectively.
As of January 31, 2026, all compensation cost related to stock options issued to employees has been recorded and there is no unrecognized compensation cost remaining related to stock options issued to employees.
(e) TSR performance-based stock units ("PSUs")
The Company grants PSUs to certain members of its management team. PSUs vest over approximately three years from the grant date upon satisfaction of both time-based requirements and market targets based on Phreesia's TSR relative to the TSR of each member of the Russell 3000 Index (the "Peer Group"). Depending on the percentage level at which the market-based condition is satisfied, the number of shares vesting could be between 0% and 220% of the number of PSUs originally granted. PSUs granted during the years ended January 31, 2026, 2025 and 2024 vest in a maximum of 220% of the number of PSUs originally granted. To earn the target number of PSUs (which represents 100% of the number of PSUs granted), the Company must perform at the 55th percentile for PSUs granted in fiscal 2026 and 2025 and the 60th percentile for PSUs granted in fiscal 2024, with the maximum
number of PSUs earned if the Company performed at least at the 90th percentile. If Phreesia's TSR for the performance period is negative, the maximum number of PSUs that can be earned will be capped at 100%.
The Company estimated the fair value of the PSUs using a Monte Carlo Simulation model that projected TSR for Phreesia and each member of the Peer Group over the performance period. The Company recognizes the grant date fair value of PSUs as compensation expense over the vesting period.
The fair value of the PSUs granted during the fiscal years ended January 31, 2026, 2025 and 2024, respectively, was estimated using the following assumptions:
Fiscal years ended January 31,
 202620252024
Correlation coefficient0.4490 0.5305 0.5238 
Valuation date stock price$20.29 $25.19 $22.94 
Simulation term3.0 years3.0 years3.0 years
Volatility54.31 %64.18 %64.58 %
Risk-free rate3.56 %4.24 %4.05 %
Dividend yield— %— %— %
Weighted-average fair value of grants$29.22 $42.86 $36.42 
Market-based PSU activity for the years ended January 31, 2026, 2025 and 2024 are as follows:
Performance
stock units
Outstanding, February 1, 2023
648,233 
Granted during the year ended January 31, 2024
576,680 
Vested(67,251)
Forfeited and expired(117,443)
Outstanding, February 1, 2024
1,040,219 
Granted during the year ended January 31, 2025
434,269 
Vested(255,269)
Forfeited(14,248)
Outstanding, February 1, 2025
1,204,971 
Granted during the year ended January 31, 2026
358,000 
Vested(214,702)
Forfeited— 
Outstanding, January 31, 2026
1,348,269 
As of January 31, 2026, unrecognized compensation cost for the PSUs was $27,359, to be recognized over a weighted-average remaining vesting period of 2.1 years, subject to the participants' continued employment with the Company.
(f) Employee stock purchase plan
The ESPP is a compensatory plan because it provides participants with terms that are more favorable than those offered to other holders of the Company's common stock. Employees purchase shares at the lesser of (1) 85% of the closing stock price on the first day of the offering period or (2) 85% of the closing stock price on the last day of the offering period. The ESPP is structured as a qualified employee stock purchase plan under Section 423 of the U.S. Internal Revenue Code of 1986.
The fair value of shares granted under the ESPP during the year ended January 31, 2026 was estimated using a Black-Scholes pricing model with the following assumptions:
Year ended
January 31, 2026
Year ended
January 31, 2025
Year ended
January 31, 2024
Risk-free interest rate
3.83 %4.74 %5.30 %
Expected dividends
nonenonenone
Expected term (in years)
0.49 years0.49 years0.49 years
Volatility
51.31 %52.96 %62.41 %
During the fiscal years ended January 31, 2026, 2025 and 2024, the Company issued 124,869, 158,262 and 141,121 shares of common stock, respectively, for the ESPP. In connection with these issuances, during the years ended January 31, 2026, 2025 and 2024 the Company recorded increases of $2,224, $2,819 and $3,234, respectively, to additional paid-in capital within stockholders' equity. As of January 31, 2026, unrecognized compensation cost related to the ESPP was $390, to be recognized over the next five months.
(g) Liability awards
At the beginning of each year, the Company provides eligible employees the option to elect to receive all or a portion of their incentive compensation in the form of immediately vested restricted stock units instead of cash. Restricted stock units issued to settle liability awards are covered by the 2019 Plan. Share-settled bonus awards will be settled at a value equal to 115% of the cash bonuses. These share-settled bonus awards vest based on the achievement of the Company’s predefined performance targets. As share-settled bonus awards will be settled in a variable number of shares, the Company classifies share-settled bonus awards as liabilities, within accrued expenses in the accompanying consolidated balance sheets until they are settled in shares and included in stockholders' equity. The Company's share-settled bonus awards are settled semiannually. During the year-ended January 31, 2026, the Company settled $10,499 of share-settled bonus awards by issuing 425,182 immediately vested RSUs. See (c) Restricted stock units above for additional discussion regarding RSUs.
v3.26.1
Fair value measurements
 12 Months Ended
Jan. 31, 2026
Fair Value Disclosures [Abstract]  
Fair value measurements Fair value measurements
The following table presents information about the Company's assets and liabilities that are measured at fair value on a recurring basis as of January 31, 2026 and indicates the classification of each item within the fair value hierarchy:
 Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant Other Observable Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Balance as of January 31, 2026
Assets
Money market mutual funds$44,945 $— $— $44,945 
Cardholder receivables(1)
— — 86,053 86,053 
Deferred purchase price receivable— — 23,425 23,425 
Total assets$44,945 $— $109,478 $154,423 
Liabilities
Foreign currency forward contracts
$— $148 $— $148 
Due to healthcare providers(2)
— — 83,385 83,385 
Total liabilities$— $148 $83,385 $83,533 
(1) The aggregate unpaid principal balance of cardholder receivables was $147,471 as of January 31, 2026. The difference between the aggregate fair value and the aggregate unpaid principal balance of cardholder receivables primarily reflects market‑participant assumptions for credit losses (defaults and recoveries), timing of collections, and liquidity/required returns embedded in the discounted cash flow valuation approach.
(2) The aggregate unpaid principal balance of due to healthcare providers was $144,802 as of January 31, 2026. The difference between the aggregate fair value and the aggregate unpaid principal balance of amounts due to healthcare providers primarily reflects market‑participant assumptions, timing of collections, and liquidity/required returns embedded in the discounted cash flow valuation approach similar to the related cardholder receivables.
The following table presents information about the Company's assets and liabilities that are measured at fair value on a recurring basis as of January 31, 2025 and indicates the classification of each item within the fair value hierarchy:
 Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant Other Observable Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Balance as of January 31, 2025
Assets
Money market mutual funds$66,588 $— $— $66,588 
Total assets$66,588 $— $— $66,588 
The carrying value of the Company’s accounts receivable and accounts payable approximate fair value due to the short-term nature of these instruments. As of January 31, 2026, the carrying value of the Company's debt approximated fair value because the interest rates approximated market rates and the related maturities are relatively short-term.
The Company did not have any transfers of assets and liabilities between levels of the fair value measurement hierarchy during the years ended January 31, 2026 and 2025.
The Company did not have any nonrecurring fair value measurements as of January 31, 2026 and 2025.
There were no changes in valuation techniques for any class of assets or liabilities measured at fair value during the periods presented.
Assets and Liabilities Measured at Fair Value on a Recurring Basis using Significant Unobservable Inputs (Level 3)
The Company’s cardholder receivables, deferred purchase price receivable, and amounts due to healthcare providers do not trade in active markets with readily observable prices. Accordingly, fair value is determined using
valuation techniques that incorporate significant unobservable inputs and require significant management judgment. These assets and liabilities are classified as Level 3 within the fair value hierarchy.
Cardholder receivables
The fair value of cardholder receivables is estimated using a discounted cash flow model incorporating key input and risk‑adjustment factors, including default assumptions, recovery rates on defaulted assets, and repayment rates. Sensitivities are applied to these inputs. The resulting risk‑adjusted cash flows are discounted using a market‑based yield range based on current personal loan market rates, with emphasis on yields observed for consumer credit grades comparable to the underlying receivable pool. The most significant assumptions include the discount rate and the expected default rate. Because the valuation incorporates significant unobservable inputs, cardholder receivables are classified as Level 3 within the fair value hierarchy.
Deferred purchase price receivable
The fair value of the deferred purchase price receivable is estimated using a discounted cash flow model incorporating key input and risk‑adjustment factors, including discount rates and expected repayment rates. Other assumptions and inputs considered in estimating the fair value of deferred purchase price receivables include the applied credit facility advance rate, funded and unfunded monthly repayment rates, funded and unfunded monthly recourse/default rates, funded and unfunded monthly finance charge rates, funded and unfunded monthly late fee rates, issuer‑level default rates, and issuer‑level recovery rates. Sensitivities are applied to these inputs. The resulting risk‑adjusted cash flows are discounted using a market‑based applied yield informed by the deferred purchase price receivable’s relative risk/return profile and return requirements for comparable market investments. Because significant unobservable inputs are used, the deferred purchase price receivable is classified as Level 3 within the fair value hierarchy.
Due to healthcare providers
The fair value of due to healthcare providers is estimated using a discounted cash flow model incorporating key input and risk‑adjustment factors similar to the related cardholder receivables including the discount rate and the expected default rate. Other inputs and assumptions considered in estimating the fair value of due to healthcare providers include recovery rates on defaulted assets and repayment rates. Sensitivities are applied to these inputs. The resulting risk‑adjusted cash flows are discounted using a market‑based yield range based on current personal loan market rates, with emphasis on yields observed for consumer credit grades comparable to the underlying receivable pool. Due to healthcare providers is settled using cash received from collections of the cardholder receivables or extinguished when cardholder receivables are repurchased by healthcare providers if patients default. Because the valuation incorporates significant unobservable inputs, due to healthcare providers are classified as Level 3 within the fair value hierarchy.
Cardholder receivables
The following table summarizes the activity related to the aggregate fair value of the Company’s cardholder receivables:
 
January 31, 2026
Beginning balance
$— 
Acquisitions(1)
93,191 
Originations17,585 
Sales and settlements
(14,577)
Cash collections
(12,709)
Gains (losses) recognized in earnings2,563 
Ending balance
$86,053 
(1) Represents the Closing Date fair value of cardholder receivables. See Note 18 - Acquisitions.
Total gains (losses) recognized in earnings are included in other income, net for the year ended January 31, 2026.
For the period from November 12, 2025 through January 31, 2026, the Company did not recognize significant gains or losses attributable to changes in instrument‑specific credit risk for cardholder receivables. During the period, credit‑related inputs did not change materially relative to the Closing Date assumptions, and changes in fair value primarily reflected movements in discount rates and lower expected cash flows associated with decreases in the unfunded cardholder receivables balance. The Company estimates the portion of a period’s fair value change
attributable to instrument‑specific credit risk by remeasuring fair value using its discounted cash flow model while holding discount rate assumptions constant and isolating the effect of credit‑specific assumptions.
Deferred purchase price receivable
The following table summarizes the activity related to the aggregate fair value of the Company’s deferred purchase price receivable:
 January 31, 2026
Beginning balance$— 
Acquisitions(1)
24,519 
Deferred purchase price received for sale of receivables886 
Cash Collections(3,000)
Gains (losses) recognized in earnings1,020 
Ending balance$23,425 
(1) Represents the Closing Date fair value of deferred purchase price receivable. See Note 18 - Acquisitions.
Total gains (losses) recognized in earnings are included in other income, net for the year ended January 31, 2026.
The following sensitivity analysis shows the potential decrease of the fair value of the Company’s deferred purchase price receivable based on hypothetical changes in key assumptions including the discount rate and repayment rate as of January 31, 2026:
Discount RateRepayment Rate
10% adverse change$(257)$(1,261)
20% adverse change$(373)$(1,987)
Due to healthcare providers
The following table summarizes the activity related to the aggregate fair value of amounts due to healthcare providers:
 January 31, 2026
Beginning balance$— 
Acquisitions(1)
90,454 
Additions(2)
17,585 
Cash remittances to healthcare providers(27,217)
Gains (losses) recognized in earnings2,563 
Ending balance$83,385 
(1) Represents the Closing Date fair value of due to healthcare providers. See Note 18 - Acquisitions.
(2) Represents new obligations arising from patient payments or receivable activity before remittance.
Total gains (losses) recognized in earnings are included in other income, net for the year ended January 31, 2026.

Significant Unobservable Inputs and Sensitivity—Level 3 Measurements
The following tables present the range and weighted‑average of the significant unobservable inputs used in Level 3 fair value measurements:
Cardholder receivables
January 31, 2026
Unobservable Input
Minimum
Maximum
Weighted- Average(1)
Discount rate
14.21%15.21%14.71%
Default rate
27.00%33.00%30.00%
(1) Weighted-average shown as a representative midpoint within the disclosed range.
Deferred purchase price receivable
January 31, 2026
Unobservable Input
Minimum
Maximum
Weighted- Average(1)
Discount rate
7.25%10.75%9.00%
Funded monthly repayment rate4.50%5.50%5.00%
(1) Weighted-average shown as a representative midpoint within the disclosed range.
Due to healthcare providers
January 31, 2026
Unobservable Input
Minimum
Maximum
Weighted- Average(1)
Discount rate
14.21%15.21%14.71%
Default rate
27.00%33.00%30.00%
(1) Weighted-average shown as a representative midpoint within the disclosed range.
The Company’s Level 3 fair value measurements are sensitive to changes in the significant unobservable inputs used in the valuation models. Changes in these inputs, in isolation or in combination, could result in materially different fair value measurements. The following discussion describes the directional impact of changes in key unobservable inputs on the fair value of the Company’s Level 3 assets and liabilities.
Cardholder receivables
The fair value of cardholder receivables is primarily sensitive to assumptions related to the discount rate and default rate. Increases in the discount rate or default rate would result in a lower fair value measurement. Conversely, decreases in the discount rate or default rate would result in a higher fair value measurement.
Deferred purchase price receivable
The fair value of the deferred purchase price receivable is primarily sensitive to assumptions related to the discount rate and repayment rates. Increases in the discount rate would result in a lower fair value measurement, while increases in repayment rates would result in a higher fair value measurement. Conversely, decreases in the discount rate would result in a higher fair value measurement, and decreases in repayment rates would result in a lower fair value measurement.
Due to healthcare providers
The fair value of amounts due to healthcare providers is primarily sensitive to assumptions related to the discount rate and default rate. Increases in the discount rate or default rate would result in a lower fair value measurement of the liability. Conversely, decreases in the discount rate or default rate would result in a higher fair value measurement of the liability.
v3.26.1
Leases
 12 Months Ended
Jan. 31, 2026
Leases [Abstract]  
Leases Leases
(a) Phreesia as Lessee
The Company leases third-party data center space and office space in the U.S under operating leases that expire on various dates through June 2028. Certain of these arrangements have escalating rent payment provisions or optional renewal clauses. The table below only considers lease obligations through the renewal date as the Company is not reasonably certain to elect the option to extend its leases beyond the option date. No arrangements contain residual value guarantees or restrictions imposed on the leases. The Company is also committed to pay a portion of the actual operating expenses under certain of these lease agreements. These operating expenses are not included in the table below.
The Company has also entered into various finance lease arrangements for computer equipment. These agreements are typically three years and are secured by the underlying equipment.
Supplemental balance sheet information related to operating and finance leases as of January 31, 2026 and 2025 was as follows:
January 31,
20262025
Operating leases:
Lease right-of-use assets$2,002 $1,477 
Lease liabilities, current$1,254 $964 
Lease liabilities, non-current1,107 646 
Total operating lease liabilities$2,361 $1,610 
Finance leases:
Property and equipment, at cost$49,009 $49,009 
Accumulated depreciation(42,060)(34,815)
Property and equipment, net$6,949 $14,194 
Lease liabilities, current (included in Current portion of debt and finance lease liabilities)
$5,314 $6,825 
Lease liabilities, non-current (included in Long-term debt and finance lease liabilities)
2,117 7,431 
Total finance lease liabilities$7,431 $14,256 
For office leases and leased equipment, the Company has elected the practical expedient to not separate lease and non-lease components, and as such, the variable lease cost primarily represents variable payments such as common area maintenance, utilities and equipment maintenance.
As of January 31, 2026, for operating leases, the weighted-average remaining lease term is 2.0 years and the weighted-average discount rate is 7.5%. As of January 31, 2026, for finance leases, the weighted-average remaining lease term is 1.4 years and the weighted-average discount rate is 7.8%.
The components of lease expense for the years ended January 31, 2026, 2025 and 2024 were as follows:
Fiscal years ended
January 31,
202620252024
Operating leases:
Operating lease cost$954 $983 $740 
Variable lease cost— — 47 
Total operating lease cost$954 $983 $787 
Finance leases:
Amortization of right-of-use assets$7,245 $7,416 $6,742 
Interest on lease liabilities879 980 580 
Total finance lease cost$8,124 $8,396 $7,322 
Amortization of right-of-use assets for finance leases is included within depreciation expense on the Company's consolidated statements of operations.
The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2026:
January 31, 2026
OperatingFinance
Maturity of lease liabilities
Fiscal year ending January 31,
2027
$1,318 $5,688 
2028
793 2,169 
2029
292 — 
Total future minimum lease payments$2,403 $7,857 
Less: interest(42)(426)
Present value of lease liabilities$2,361 $7,431 
Other supplemental cash flow information for the years ended January 31, 2026, 2025 and 2024 was as follows:
Fiscal years ended
January 31,
202620252024
Supplemental cash flow information
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash used for operating leases$1,147 $1,023 $1,238 
Operating cash used for finance leases$879 $980 $535 
Financing cash used for finance leases$6,825 $7,811 $6,779 
(b) Phreesia as Lessor
In connection with the patient intake and registration process, Phreesia offers its customers the ability to lease PhreesiaPads and Arrivals Kiosks along with their monthly subscription. The Company accounts for these rentals as leases. The Company elected the practical expedient to not separate lease and non-lease components. More specifically, all contractual hardware maintenance is included with the hardware lease components. The leases contain no variable lease payments, no options to extend the lease that are reasonably certain to be exercised, and do not give the lessee an option to purchase the hardware at the end of the lease term. Additionally, the lease term does not represent a major part of the remaining economic life of the assets, and the present value of the lease payments does not equal or exceed substantially all of the fair value of the assets. As a result, all leased hardware in the SaaS arrangements is classified as operating leases.
During the years ended January 31, 2026, 2025 and 2024, the Company recognized $9,102, $9,329 and $10,307, respectively in subscription and related services revenue related to the leasing of PhreesiaPads and Arrivals Kiosks.
Future lease payments receivable under operating leases were immaterial as of January 31, 2026 and 2025, except for those with terms of one year or less.
During the year ended January 31, 2026, the Company recognized immaterial sublease income associated with AccessOne’s subleased office space, which remains in place through the term of the head lease ending June 30, 2028.
Leases Leases
(a) Phreesia as Lessee
The Company leases third-party data center space and office space in the U.S under operating leases that expire on various dates through June 2028. Certain of these arrangements have escalating rent payment provisions or optional renewal clauses. The table below only considers lease obligations through the renewal date as the Company is not reasonably certain to elect the option to extend its leases beyond the option date. No arrangements contain residual value guarantees or restrictions imposed on the leases. The Company is also committed to pay a portion of the actual operating expenses under certain of these lease agreements. These operating expenses are not included in the table below.
The Company has also entered into various finance lease arrangements for computer equipment. These agreements are typically three years and are secured by the underlying equipment.
Supplemental balance sheet information related to operating and finance leases as of January 31, 2026 and 2025 was as follows:
January 31,
20262025
Operating leases:
Lease right-of-use assets$2,002 $1,477 
Lease liabilities, current$1,254 $964 
Lease liabilities, non-current1,107 646 
Total operating lease liabilities$2,361 $1,610 
Finance leases:
Property and equipment, at cost$49,009 $49,009 
Accumulated depreciation(42,060)(34,815)
Property and equipment, net$6,949 $14,194 
Lease liabilities, current (included in Current portion of debt and finance lease liabilities)
$5,314 $6,825 
Lease liabilities, non-current (included in Long-term debt and finance lease liabilities)
2,117 7,431 
Total finance lease liabilities$7,431 $14,256 
For office leases and leased equipment, the Company has elected the practical expedient to not separate lease and non-lease components, and as such, the variable lease cost primarily represents variable payments such as common area maintenance, utilities and equipment maintenance.
As of January 31, 2026, for operating leases, the weighted-average remaining lease term is 2.0 years and the weighted-average discount rate is 7.5%. As of January 31, 2026, for finance leases, the weighted-average remaining lease term is 1.4 years and the weighted-average discount rate is 7.8%.
The components of lease expense for the years ended January 31, 2026, 2025 and 2024 were as follows:
Fiscal years ended
January 31,
202620252024
Operating leases:
Operating lease cost$954 $983 $740 
Variable lease cost— — 47 
Total operating lease cost$954 $983 $787 
Finance leases:
Amortization of right-of-use assets$7,245 $7,416 $6,742 
Interest on lease liabilities879 980 580 
Total finance lease cost$8,124 $8,396 $7,322 
Amortization of right-of-use assets for finance leases is included within depreciation expense on the Company's consolidated statements of operations.
The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2026:
January 31, 2026
OperatingFinance
Maturity of lease liabilities
Fiscal year ending January 31,
2027
$1,318 $5,688 
2028
793 2,169 
2029
292 — 
Total future minimum lease payments$2,403 $7,857 
Less: interest(42)(426)
Present value of lease liabilities$2,361 $7,431 
Other supplemental cash flow information for the years ended January 31, 2026, 2025 and 2024 was as follows:
Fiscal years ended
January 31,
202620252024
Supplemental cash flow information
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash used for operating leases$1,147 $1,023 $1,238 
Operating cash used for finance leases$879 $980 $535 
Financing cash used for finance leases$6,825 $7,811 $6,779 
(b) Phreesia as Lessor
In connection with the patient intake and registration process, Phreesia offers its customers the ability to lease PhreesiaPads and Arrivals Kiosks along with their monthly subscription. The Company accounts for these rentals as leases. The Company elected the practical expedient to not separate lease and non-lease components. More specifically, all contractual hardware maintenance is included with the hardware lease components. The leases contain no variable lease payments, no options to extend the lease that are reasonably certain to be exercised, and do not give the lessee an option to purchase the hardware at the end of the lease term. Additionally, the lease term does not represent a major part of the remaining economic life of the assets, and the present value of the lease payments does not equal or exceed substantially all of the fair value of the assets. As a result, all leased hardware in the SaaS arrangements is classified as operating leases.
During the years ended January 31, 2026, 2025 and 2024, the Company recognized $9,102, $9,329 and $10,307, respectively in subscription and related services revenue related to the leasing of PhreesiaPads and Arrivals Kiosks.
Future lease payments receivable under operating leases were immaterial as of January 31, 2026 and 2025, except for those with terms of one year or less.
During the year ended January 31, 2026, the Company recognized immaterial sublease income associated with AccessOne’s subleased office space, which remains in place through the term of the head lease ending June 30, 2028.
Leases Leases
(a) Phreesia as Lessee
The Company leases third-party data center space and office space in the U.S under operating leases that expire on various dates through June 2028. Certain of these arrangements have escalating rent payment provisions or optional renewal clauses. The table below only considers lease obligations through the renewal date as the Company is not reasonably certain to elect the option to extend its leases beyond the option date. No arrangements contain residual value guarantees or restrictions imposed on the leases. The Company is also committed to pay a portion of the actual operating expenses under certain of these lease agreements. These operating expenses are not included in the table below.
The Company has also entered into various finance lease arrangements for computer equipment. These agreements are typically three years and are secured by the underlying equipment.
Supplemental balance sheet information related to operating and finance leases as of January 31, 2026 and 2025 was as follows:
January 31,
20262025
Operating leases:
Lease right-of-use assets$2,002 $1,477 
Lease liabilities, current$1,254 $964 
Lease liabilities, non-current1,107 646 
Total operating lease liabilities$2,361 $1,610 
Finance leases:
Property and equipment, at cost$49,009 $49,009 
Accumulated depreciation(42,060)(34,815)
Property and equipment, net$6,949 $14,194 
Lease liabilities, current (included in Current portion of debt and finance lease liabilities)
$5,314 $6,825 
Lease liabilities, non-current (included in Long-term debt and finance lease liabilities)
2,117 7,431 
Total finance lease liabilities$7,431 $14,256 
For office leases and leased equipment, the Company has elected the practical expedient to not separate lease and non-lease components, and as such, the variable lease cost primarily represents variable payments such as common area maintenance, utilities and equipment maintenance.
As of January 31, 2026, for operating leases, the weighted-average remaining lease term is 2.0 years and the weighted-average discount rate is 7.5%. As of January 31, 2026, for finance leases, the weighted-average remaining lease term is 1.4 years and the weighted-average discount rate is 7.8%.
The components of lease expense for the years ended January 31, 2026, 2025 and 2024 were as follows:
Fiscal years ended
January 31,
202620252024
Operating leases:
Operating lease cost$954 $983 $740 
Variable lease cost— — 47 
Total operating lease cost$954 $983 $787 
Finance leases:
Amortization of right-of-use assets$7,245 $7,416 $6,742 
Interest on lease liabilities879 980 580 
Total finance lease cost$8,124 $8,396 $7,322 
Amortization of right-of-use assets for finance leases is included within depreciation expense on the Company's consolidated statements of operations.
The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2026:
January 31, 2026
OperatingFinance
Maturity of lease liabilities
Fiscal year ending January 31,
2027
$1,318 $5,688 
2028
793 2,169 
2029
292 — 
Total future minimum lease payments$2,403 $7,857 
Less: interest(42)(426)
Present value of lease liabilities$2,361 $7,431 
Other supplemental cash flow information for the years ended January 31, 2026, 2025 and 2024 was as follows:
Fiscal years ended
January 31,
202620252024
Supplemental cash flow information
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash used for operating leases$1,147 $1,023 $1,238 
Operating cash used for finance leases$879 $980 $535 
Financing cash used for finance leases$6,825 $7,811 $6,779 
(b) Phreesia as Lessor
In connection with the patient intake and registration process, Phreesia offers its customers the ability to lease PhreesiaPads and Arrivals Kiosks along with their monthly subscription. The Company accounts for these rentals as leases. The Company elected the practical expedient to not separate lease and non-lease components. More specifically, all contractual hardware maintenance is included with the hardware lease components. The leases contain no variable lease payments, no options to extend the lease that are reasonably certain to be exercised, and do not give the lessee an option to purchase the hardware at the end of the lease term. Additionally, the lease term does not represent a major part of the remaining economic life of the assets, and the present value of the lease payments does not equal or exceed substantially all of the fair value of the assets. As a result, all leased hardware in the SaaS arrangements is classified as operating leases.
During the years ended January 31, 2026, 2025 and 2024, the Company recognized $9,102, $9,329 and $10,307, respectively in subscription and related services revenue related to the leasing of PhreesiaPads and Arrivals Kiosks.
Future lease payments receivable under operating leases were immaterial as of January 31, 2026 and 2025, except for those with terms of one year or less.
During the year ended January 31, 2026, the Company recognized immaterial sublease income associated with AccessOne’s subleased office space, which remains in place through the term of the head lease ending June 30, 2028.
v3.26.1
Commitments and contingencies
 12 Months Ended
Jan. 31, 2026
Commitments and Contingencies Disclosure [Abstract]  
Commitments and contingencies Commitments and contingencies
(a) Indemnifications
The Company’s agreements with certain customers include certain provisions for indemnifying customers against liabilities if its services infringe a third-party’s intellectual property rights. It is not possible to determine the maximum potential amount under these indemnification obligations due to the limited history of prior indemnification claims and the unique facts and circumstances that may be involved in each particular agreement. To date, the Company has not incurred any material costs as a result of such provisions and has not accrued any liabilities related to such obligations in its consolidated financial statements.
In addition, the Company has indemnification agreements with its directors and its executive officers that require it, among other things, to indemnify its directors and executive officers for costs associated with any fees, expenses,
judgments, fines and settlement amounts incurred by any of those persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by us, arising out of that person’s services as a director or officer or that person’s services provided to any other company or enterprise at the Company’s request. The Company maintains director and officer insurance coverage that may enable it to recover a portion of any future indemnification amounts paid. To date, there have been no claims under any of the Company’s directors and executive officers indemnification provisions.
(b) Legal proceedings
Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.
The Company is involved in legal proceedings from time to time that arise in the normal course of business. In the opinion of management, such routine claims and lawsuits are not significant, and the Company does not expect them to have a material adverse effect on its business, financial condition, results of operations, or liquidity, except as noted below.
On May 12, 2024, the Company learned of a cybersecurity incident impacting the ConnectOnCall service, an application created by a subsidiary the Company acquired in October 2023. All systems have been restored, and the Company believes that it maintains a sufficient level of insurance coverage related to such events, and the related incremental costs incurred to date are not material.
Between December 24, 2024 and the date of this report, 14 related putative class action complaints were filed against ConnectOnCall.com, LLC and Phreesia, Inc., in the United States District Court for the Eastern District of New York (the “ConnectOnCall Case”). The cases have been consolidated as In re ConnectOnCall.com Data Breach Litigation. Plaintiffs purport to represent a nationwide class and state-specific subclasses of individuals who allegedly had personally identifiable information and personal health information stolen because of the ConnectOnCall incident. Plaintiffs assert a variety of common law claims seeking monetary damages, disgorgement restitution, attorneys’ fees, interest, declaratory relief, and injunctive relief related to the incident.
The Company expects to continue to incur legal and professional services expenses associated with this litigation in future periods. The Company will recognize these expenses as services are received, net of probable insurance recoveries. The Company and the plaintiffs engaged in a mediation, and on March 2, 2026, the plaintiffs filed an amended motion for preliminary approval of a settlement with the court which remains pending. Due to the uncertainties surrounding the pending preliminary approval, the Company has not recorded a loss contingency liability for the above litigation as of January 31, 2026, because the Company cannot reasonably estimate a range of possible losses at this time.
(c) Other contractual commitments
Other contractual commitments consist primarily of non-cancelable purchase commitments to support the Company’s technology infrastructure as well as commitments related to its acquisition.
Future minimum payments under the Company’s non-cancelable contractual commitments as of January 31, 2026 are presented in the table below.
Purchase obligations
Fiscal year ending January 31,
2027
$11,621 
2028
4,705 
2029
742 
Total$17,068 
v3.26.1
Income taxes
 12 Months Ended
Jan. 31, 2026
Income Tax Disclosure [Abstract]  
Income taxes Income taxes
The Company recorded a tax benefit of $11,246 and tax expense $2,716 and $1,543, for the years ended January 31, 2026, 2025 and 2024, respectively. The Company's tax benefit and tax expense was 125.8%, 4.9% and 1.1% of loss before income taxes for the years ended January 31, 2026, 2025 and 2024, respectively. For the year ended January 31, 2026, the Company's effective tax rate differs from the U.S. statutory tax rate of 21% primarily because the Company records a valuation allowance against its U.S. deferred tax assets, due to the release of valuation allowance attributable to taxable temporary differences recorded in connection with the acquisition of
AccessOne, and due to foreign income tax expense related to its Canadian branch and its subsidiary in India. For the years ended January 31, 2025 and 2024, the Company's effective tax rate differs from the U.S. statutory tax rate of 21% primarily because the Company records a valuation allowance against its U.S. deferred tax assets and due to foreign income tax expense related to its Canadian branch and its subsidiary in India.
Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. Management of the Company has evaluated the positive and negative evidence pertaining to the realizability of its deferred tax assets, including the Company’s history of losses, and concluded that it is more likely than not that the Company will not recognize the benefits for the majority of its deferred tax assets. On the basis of this evaluation, the Company has recorded a valuation allowance against its deferred tax assets that are not more likely than not to be realized at both January 31, 2026 and 2025.
The following table sets forth the Company’s income (loss) before income taxes disaggregated between domestic and foreign for fiscal 2026, 2025 and 2024:
Fiscal years ended January 31,
202620252024
Domestic $(13,505)$(63,782)$(138,629)
Foreign4,565 7,971 3,287 
Total loss before income taxes$(8,940)$(55,811)$(135,342)
The Company's income tax provision consisted of the following for fiscal 2026, 2025 and 2024:
Fiscal years ended January 31,
202620252024
Current tax
Federal$— $— $— 
State356 102 76 
Foreign1,669 2,400 1,239 
Deferred tax
Federal(12,581)214 38 
State903 — — 
Foreign(1,593)— 190 
Total provision for income taxes$(11,246)$2,716 $1,543 
The Company adopted ASU No. 2023-09 on a prospective basis effective February 1, 2025. A reconciliation of the statutory U.S. federal rate and effective rate for the year ended January 31, 2026, after the adoption of ASU 2023-09, is as follows:
Fiscal years ended January 31, 2026
Amount%
Federal income tax benefit at statutory rate$(1,877)21 %
State and local tax, net of federal benefit994 (11)%
Foreign tax effects
India 68 (1)%
Canada(275)3 %
Federal tax credits(1,034)12 %
Changes in valuation allowances on federal deferred tax assets(18,857)211 %
Effect of nontaxable or non-deductible items on federal income taxes
Stock based compensation5,056 (57)%
Transaction Cost1,730 (19)%
Capitalized Internal-Use Software2,049 (23)%
Section 162(m)656 (8)%
Other125 (1)%
Changes in unrecognized tax benefits119 (1)%
Benefit for income taxes$(11,246)126 %
The majority of effect of state and local income taxes presented is generated by Texas.
The following table sets forth the Company’s income taxes paid by major jurisdiction for fiscal 2026 (in thousands):
Fiscal years ended January 31, 2026
Federal
$— 
State and local
Texas
7 
Total state and local7 
Foreign
India
516 
Canada
1,374 
Total foreign1,890 
Total income taxes paid$1,897 
A reconciliation of the statutory U.S. federal income tax rate to the Company's effective tax rate for fiscal 2025 and 2024 prior to the adoption of ASU 2023-09 is as follows:
Fiscal years ended January 31,
20252024
Federal income tax benefit at statutory rate21 %21 %
State and local tax, net of federal benefit4 %3 %
Permanent differences1 %— %
Equity compensation(6)%— %
Foreign taxes(3)%(1)%
Other— %— %
Change in valuation allowance(22)%(24)%
Effective income tax rate(5)%(1)%
The significant components of the Company's deferred tax assets and liabilities as of January 31, 2026 and 2025 are as follows:
January 31,
Deferred tax assets:20262025
Net operating loss carryforwards$170,985 $160,998 
Stock based compensation12,125 9,495 
Accruals, reserves, and other expenses(1)
3,809 3,129 
Disallowed interest expense— 969 
Depreciation and amortization— 1,412 
Capitalized R&D Expense(1)
23,835 23,897 
Cardholder Receivable15,779 — 
Other109 — 
Total deferred tax assets$226,642 $199,900 
Less: valuation allowance(176,652)(188,712)
Net deferred tax assets$49,990 $11,188 
Deferred tax liabilities:
Depreciation and amortization$(7,741)$— 
Intangible assets(12,818)(340)
Capitalized internal-use-software(1)
(14,623)(11,074)
Due to Healthcare Provider(15,660)— 
Other(1)
(2,053)(258)
Total deferred tax liabilities$(52,895)$(11,672)
Net deferred tax liabilities$(2,905)$(484)
(1) Prior year amounts have been reclassified to conform to the current year presentation.
The net deferred tax liabilities amounts presented above are presented in the consolidated balance sheet as long-term deferred tax assets of $1,593 and $0 as of January 31, 2026 and 2025, respectively, and long-term deferred tax liabilities of $4,498 and $484 as of January 31, 2026 and 2025, respectively.
The Company has accumulated a U.S. Federal net operating loss carryforward of approximately $587,240 and $596,509 as of January 31, 2026 and 2025, respectively. This carryforward may be available to offset future U.S. Federal income tax liabilities and began expiring in 2025. As of January 31, 2026, the Company's foreign branch had no net operating loss carryforwards. The Company’s unutilized research and development tax credit carryforwards may be carried forward for a period of up to 20 years.
Due to the uncertainty regarding the ability to realize the benefit of the U.S. deferred tax assets primarily relating to net operating loss carryforwards, valuation allowances have been established to reduce the U.S. deferred tax assets to an amount that is more likely than not to be realized.
On the basis of this evaluation, as of January 31, 2026 and 2025, the Company recorded a valuation allowance of $176,652 and $188,712, respectively, to recognize only the portion of the deferred tax asset that is more likely than not to be realized. The $12,060 decrease in the valuation allowance recorded during the fiscal year ended January 31, 2026 relates primarily to a $13,069 release of valuation allowance for Phreesia. AccessOne’s federal deferred tax liabilities are a source of income for the Company’s historic federal deferred tax assets and are offset by the Company’ deferred tax assets resulting in the release of valuation allowance to the extent of such offset outside of acquisition accounting.
Under Section 382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change” (generally defined as a greater than 50% change by value in its equity ownership over a three-year period), the corporation’s ability to use its pre-ownership change net operating loss carryforwards and other pre-ownership change tax attributes to offset its post-change income may be limited. As of January 31, 2026, the Company has U.S. net operating loss carryforwards of approximately $587,240. The Company has completed a Section 382 study through January 31, 2026 and as a result the analysis identified ownership changes on November 30, 2006, February 2, 2009 and April 30, 2020. The ownership change in 2006 resulted in approximately $316 of NOLs that
were generated in 2005 and 2006 that have or will expire unutilized due to Section 382 annual limitations. As such, these NOLs have been removed from the deferred tax asset table. The ownership change in 2009 resulted in limitation of approximately $12,388 of NOLs but as of 2024 became fully available for use. The ownership change in 2020 resulted in limitation of approximately $136,020 of NOLs but as of 2023 became fully available for use.
The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal, state, and foreign jurisdictions, where applicable. The Company’s tax years are still open from 2021 to present and, to the extent utilized in future years' tax returns, net operating loss carryforwards at January 31, 2026 will remain subject to examination until the respective tax year is closed.
The Company records unrecognized tax benefits as liabilities or as reductions to deferred tax assets and adjusts these balances when its judgment changes as a result of the evaluation of new information previously not available. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. As of January 31, 2026 the Company has reduced the balance of deferred tax assets for $1,910 of unrecognized tax benefits. The Company’s unrecognized tax benefits would not affect the effective tax rate if recognized because the Company has a valuation allowance against the majority of its U.S. deferred tax assets. As of January 31, 2026, the Company had no accrued interest or penalties related to uncertain tax positions.
The following is a roll-forward of the Company's total gross unrecognized tax benefits for fiscal 2026:
Balance, January 31, 2023$— 
Increases for income tax positions related to prior years844 
Increases for income tax positions related to current years396 
Balance, January 31, 2024
$1,240 
Increases for income tax positions related to prior years— 
Increases for income tax positions related to current years365 
Balance, January 31, 2025
$1,605 
Increases for income tax positions related to prior years— 
Increases for income tax positions related to current years305 
Balance, January 31, 2026
$1,910 
v3.26.1
Net income (loss) per share attributable to common stockholders
 12 Months Ended
Jan. 31, 2026
Earnings Per Share [Abstract]  
Net income (loss) per share attributable to common stockholders Net income (loss) per share attributable to common stockholders
(a) Net income (loss) per share attributable to common stockholders
Basic and diluted net income (loss) per share attributable to common stockholders was calculated as follows:
Fiscal years ended January 31,
202620252024
Basic net income (loss) per share
Numerator:
Net income (loss)
$2,306 $(58,527)$(136,885)
Denominator:
Weighted-average shares of common stock outstanding, basic
59,737,915 57,589,687 54,561,449 
Basic net income (loss) per share attributable to common stockholders:
$0.04 $(1.02)$(2.51)
Diluted net income (loss) per share
Numerator:
Net income (loss)
$2,306 $(58,527)$(136,885)
Denominator:
Number of shares used for basic net income (loss) per computation59,737,915 57,589,687 54,561,449 
RSUs
698,122 — — 
PSUs
555,972 — — 
Stock options
335,357 — — 
Liability awards
148,271 — — 
ESPP
19,241 — — 
Weighted-average shares of common stock outstanding, diluted
61,494,878 57,589,687 54,561,449 
Diluted net income (loss) per share attributable to common stockholders:
$0.04 $(1.02)$(2.51)
(b) Potential dilutive securities
The Company excludes potential dilutive securities, which include stock options, RSUs, PSUs, liability awards and grants under the Company's ESPP from the computation of diluted net income (loss) per share when the effect of including the securities would be anti-dilutive. The following potential shares of common stock, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net income (loss) per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
Fiscal years ended January 31,
202620252024
Stock options to purchase common stock, restricted stock units and performance stock awards1,580,596 6,577,715 7,273,621 
Employee stock purchase plan109,152 71,848 91,452 
Total1,689,748 6,649,563 7,365,073 
v3.26.1
Retirement savings plan
 12 Months Ended
Jan. 31, 2026
Retirement Benefits [Abstract]  
Retirement savings plan Retirement savings plan
On February 20, 2008, the Company established a retirement savings plan under Section 401(k) of the Internal Revenue Code (the “Plan”). The Plan covers substantially all U.S. full-time employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax and post-tax basis. Company contributions to the Plan may be made at the discretion of the Board of Directors of the Company. The Company did not make any contributions in the years ended January 31, 2026, 2025 or 2024.
v3.26.1
Related party transactions
 12 Months Ended
Jan. 31, 2026
Related Party Transactions [Abstract]  
Related party transactions Related party transactions
For the years ended January 31, 2026 and 2025, the Company recognized revenue totaling $1,124 and $1,343, respectively, for advertisements placed by a pharmaceutical company. One of the Company's independent members of its Board of Directors serves on the board of directors of this pharmaceutical company. As of
January 31, 2026 and 2025, accounts receivable from the pharmaceutical company totaled $450 and $116, respectively.
For the year ended January 31, 2024, the Company recognized general and administrative expenses totaling $118 for software agreements with a software company. One of the Company's independent members of its Board of Directors served as the chief executive officer and a member of the board of directors for this software company until May 2023. This software company was no longer considered a related party subsequent to May 2023.
v3.26.1
Segments and geographic information
 12 Months Ended
Jan. 31, 2026
Segment Reporting [Abstract]  
Segments and geographic information Segments and geographic information
Operating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company defines the term “chief operating decision maker” to be its Chief Executive Officer. The Company’s Chief Executive Officer reviews the financial information presented on an entire company basis for purposes of allocating resources and evaluating its financial performance. Accordingly, the Company has determined that it operates in a single reportable operating segment, managed on a consolidated basis, which the Company refers to as the Technology solutions segment.
The Technology solutions segment provides comprehensive software solutions that improve the operational and financial performance of healthcare organizations and improve health outcomes by helping patients take a more active role in their care. The Technology solutions segment’s solutions include SaaS-based integrated tools that manage patient access, registration and payments. Additionally, the Technology solutions segment has tools to communicate with patients about their health, which have demonstrated increased rates of preventive care and vaccinations. Additionally, Technology solutions segment’s solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to better understand their patients and connect them to needed services, resulting in improved health outcomes. The Technology solutions segment also provides life sciences companies, government entities, patient advocacy, public interest and not-for-profit and other organizations with a channel for direct communication with patients. The Technology solutions segment also provides additional products and services such as the trusted, scalable, compliant and operationally efficient healthcare payment card that accelerates cash flow and the MediFind provider directory, which helps patients find care based on providers' specialty and condition expertise. The Technology solutions segment offers its healthcare services clients the ability to lease tablets ("PhreesiaPads") and on-site kiosks ("Arrivals Kiosks") along with their monthly subscription.
The chief operating decision maker uses net income (loss) in assessing the performance of and allocating resources to the Technology solutions segment. The chief operating decision maker uses actual versus budgeted net income (loss) in evaluating the performance of the Technology solutions segment.
The accounting policies of the Technology solutions segment are the same as described in Note 3 - Summary of significant accounting policies. As the Company operates in a single operating segment managed on a consolidated basis, the revenues of the Technology solutions segment are equal to the Company’s total revenues presented on the accompanying consolidated statements of operations. Additionally, revenues for each significant group of products and services is presented on the accompanying consolidated statements of operations. As the Company has only one operating segment, the Company does not have inter-segment sales or transfers. Additionally, the measure of segment profit for the Technology solutions segment is equal to the Company’s net loss presented on the accompanying consolidated statements of operations.
The following table presents the Company’s segment revenue, segment profit (loss), significant segment expenses, and other segment items, as well as a reconciliation from segment profit (loss) to consolidated net income (loss).
Fiscal years ended January 31,
202620252024
Revenue
$480,591 $419,813 $356,299 
Labor costs (1)
193,362224,792238,533
Payment solutions expense
82,75868,70762,986
Third-party non-labor operating expenses
102,95589,55090,159
Stock-based compensation
67,45266,97571,613
Other segment items
31,75828,31629,893
Segment net income (loss)
$2,306 $(58,527)$(136,885)
Reconciliation of profit or loss
Adjustments and reconciling items
$— $— $— 
Consolidated net income (loss)
$2,306 $(58,527)$(136,885)
(1) Excludes stock-based compensation expense which is presented separately
Other segment items include depreciation and amortization, interest expense, interest income, income tax (benefit) expense, loss on extinguishment of debt and other income, net.
The total segment assets for the Technology solutions segment are equal to the total assets presented on the accompanying consolidated balance sheets. The following table presents other quantitative segment disclosures for the fiscal years ended January 31, 2026, 2025 and 2024, respectively.
Fiscal years ended January 31,
202620252024
Depreciation and amortization
$31,453 $27,886 $29,487 
Interest expense
$(6,953)$(2,347)$(1,854)
Interest income
$2,173 $2,677 $4,065 
Loss on extinguishment of debt$(501)$— $(1,118)
Gain on settlement (included in other income, net)
$— $2,345 $— 
Income tax benefit (expense)
$11,246 $(2,716)$(1,543)
Expenditures for long-lived assets
$176,246 $25,940 $96,474 
v3.26.1
Derivative instruments and hedging activities
 12 Months Ended
Jan. 31, 2026
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative instruments and hedging activities Derivative instruments and hedging activities
Cash Flow Hedges
During the year ended January 31, 2026, the Company entered into two foreign currency forward contracts to buy Canadian Dollars in exchange for U.S. Dollars in order to hedge the functional currency equivalent cash flows related to the Company’s Canadian Dollar denominated payroll payments. The Company does not hold any derivatives for trading or speculative purposes.
As of January 31, 2026, the notional value of the foreign currency forward contract that the Company held to buy Canadian Dollars in exchange for U.S. Dollars was a total of 16,100 Canadian Dollars, including a notional value of 14,490 Canadian Dollars designated as a foreign currency cash flow hedge and a notional value of 1,610 not designated as a foreign currency cash flow hedge.
The fair values of outstanding derivative foreign currency forward contract was as follows:
January 31,
Consolidated balance sheet location
2026
2025
Foreign currency cash flow hedges
Accrued expenses
$133 $— 
Non-designated hedges
Accrued expenses
14 — 
The effect of derivative instruments on the Company’s consolidated statements of operations were as follows:
Consolidated statements of operations location
Fiscal years ended January 31,
2026
2025
2024
Foreign currency cash flow hedges
Expenses$(315)$— $— 
Foreign currency cash flow hedges
Income tax benefit (expense)
— — — 
Non-designated hedges
Other income, net
217 — — 
Pre-tax gains (losses) associated with cash flow hedges were as follows:
Consolidated statements of operations and Statements of comprehensive income (loss) locations
Fiscal years ended January 31,
 
2026
2025
2024
Gains recognized in accumulated other comprehensive income (included in assessment of effectiveness)
Unrealized gain on cash flow hedge
$182 $— $— 
Gains reclassified from accumulated other comprehensive income into income (effective portion)Expenses(315)— — 
Tax effect reclassified from accumulated other comprehensive income into income (effective portion)
Income tax benefit (expense)
— — — 
As of January 31, 2026, the foreign currency forward contract had a maturity of 3 months. As of January 31, 2026, the Company estimates that the entire $133 of the net loss recorded in accumulated other comprehensive income (loss) related to its foreign currency cash flow hedge will be reclassified into loss within the next 12 months.
See Note 3 - Summary of significant accounting policies and Note 9 - Fair value measurements for additional disclosures for derivatives and hedging.
v3.26.1
Acquisitions
 12 Months Ended
Jan. 31, 2026
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Acquisitions Acquisitions
AccessOne Acquisition
On the Closing Date, the Company completed the acquisition of 100% of the outstanding equity of AccessOne Parent Holdings, Inc. for aggregate consideration transferred of approximately $163,666. The consideration was paid entirely in cash at closing, subject to customary working capital and other post-closing adjustments, and was funded using a combination of cash on hand and proceeds from the Bridge Loan (see Note 6 - Debt and finance leases). AccessOne is a technology‑enabled healthcare financial services platform that helps patients manage out‑of‑pocket medical expenses while providing healthcare providers with solutions to improve access to care and the collection of self‑pay patient receivables. The AccessOne Acquisition was accounted for as a business combination. The Company acquired AccessOne to expand its payment solutions capabilities and enhance its ability to support patients and healthcare providers through integrated financial and payment workflows.
The total preliminary purchase consideration including amounts deposited into escrow is $163,666. This includes the base purchase price of $160,000, plus estimated adjustments for working capital and closing cash.
All amounts are preliminary and subject to change as the Company finalizes valuation procedures, deferred tax analyses, and closing statement amounts. Any measurement‑period adjustments will be recognized in the period determined and will reflect facts and circumstances that existed as of the Closing Date.
The following table summarizes the calculation of cash paid for the AccessOne Acquisition, net of cash acquired per the Company's consolidated statements of cash flows for the year ended January 31, 2026.
Cash consideration paid to sellers$163,666 
Less: cash and restricted cash acquired
(10,474)
Cash paid for acquisitions, net of cash and restricted cash acquired per statements of cash flows
$153,192 
Acquisition-related costs for professional and advisory services totaled $9,223 for the year ended January 31, 2026. These costs were expensed as incurred and are presented within general and administrative expense in the Company's consolidated statements of operations.
The Company's financial results for the year ended January 31, 2026 reflect inclusion of the business operations of AccessOne from the Closing Date, which contributed $9,679 of revenue and $251 of net income. The post‑acquisition results reflect only a partial period and include integration-related costs, and therefore are not indicative of AccessOne’s full‑year performance.
The following table summarizes the preliminary purchase price allocation of the fair values of the assets acquired and liabilities assumed at the Closing Date:
Amounts Recognized as of the Closing Date
(Preliminary)
Cash and restricted cash$10,474 
Accounts receivable708 
Cardholder receivables42,537 
Deferred purchase price receivable19,615 
Accrued interest and fees receivable394 
Other current assets376 
Property and equipment255 
Operating lease right-of-use assets1,439 
Identified intangible assets acquired56,700 
Goodwill94,219 
Long-term cardholder receivables50,654 
Long-term deferred purchase price receivable4,904 
Other assets208 
Total assets acquired282,483 
Current portion of operating lease liabilities(685)
Accounts payable(651)
Accrued liabilities(1,434)
Current portion of due to healthcare providers(40,669)
Deferred revenue(8,522)
Other current liabilities(166)
Long-term deferred revenue(39)
Operating lease liabilities, non-current(1,174)
Long-term deferred tax liabilities(15,692)
Long-term due to healthcare providers(49,785)
Total purchase price$163,666 
The Company, with the assistance of a third-party appraiser, estimated the fair value of assets acquired and liabilities assumed by using available market information and various valuation methods that require judgment related to estimates. The Company estimated the preliminary fair value of customer relationships under the multi-period excess earnings method which involved the use of significant assumptions with respect to revenue growth rates, contributory asset charges, asset adjustments and add backs, customer attrition rate, discount rate, and terminal growth rate. The Company estimated the preliminary fair value of the developed technology and trademark using the relief from royalty method which incorporates assumptions for obsolescence, attrition, royalty rates, tax rate, and discount rate.
Refer to Note 9 – Fair value measurements for descriptions of the valuation methods and assumptions related to cardholder receivables, deferred purchase price receivable, and due to healthcare providers.
The preliminary fair value estimates and assumptions regarding certain tangible assets acquired and liabilities assumed, and the valuation of intangible assets acquired and income taxes are subject to change as additional information is obtained during the measurement period.
Cardholder receivables represent the primary class of originated receivables and are not purchased financial assets with credit deterioration as of the Closing Date. The following table presents the fair value, gross contractual amounts receivable, and the Company’s best estimate of contractual cash flows not expected to be collected for cardholder receivables as of the Closing Date:
Cardholder Receivables
(Preliminary)
Fair value$93,191 
Gross contractual amounts receivable$157,208 
Best estimate of contractual cash flows not expected to be collected$58,735 
Goodwill represents the excess of the consideration transferred over the fair value of the underlying net identifiable assets and is attributable primarily to expected synergies, including anticipated revenue growth and cost efficiencies, and the value of the assembled workforce of AccessOne. Goodwill is not deductible for U.S. federal income tax purposes.
The following table sets forth the preliminary amounts, allocated to the intangible assets identified and their estimated useful lives as of the Closing Date:
Estimated Useful Life
(in Years)		Fair Value
Trademark12$7,100 
Technology613,600 
Customer relationships836,000 
Total identifiable intangible assets acquired$56,700 
The weighted-average amortization period for acquired intangible assets as of the date of acquisition is 8 years.
Pro forma results
The unaudited pro forma financial information presented below was derived from historical financial records of Phreesia and AccessOne and presents the operating results for the periods presented as if the AccessOne Acquisition occurred on February 1, 2024. The pro forma results include adjustments that are directly attributable to the transaction and factually supportable. Except for pro forma adjustments of $9.2 million for acquisition-related costs, the pro forma adjustments are expected to have a continuing impact on the Company’s results. Pro forma adjustments primarily reflect (i) incremental amortization of acquired intangible assets, (ii) interest expense associated with the Bridge Loan used to finance a portion of the consideration for the AccessOne Acquisition, (iii) acquisition-related costs, and (iv) related income tax effects.
Accordingly, the following unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operations of the combined company would have been if the AccessOne Acquisition had occurred at the beginning of fiscal year 2025, nor are they indicative of future results of operations:
Year ended January 31,
20262025
Revenue
$516,438 $469,030 
Net income (loss)$2,168 $(61,929)
MediFind, Access and ConnectOnCall acquisitions
On June 30, 2023, the Company entered into an agreement to acquire 100% of the outstanding equity of MediFind for aggregate consideration payable of $8,871 (the "MediFind Acquisition"). A portion of the consideration was paid in cash at closing (subject to a customary working capital adjustment) with the remainder of the consideration settled through the issuance of 150,786 shares of the Company's common stock to certain stockholders of MediFind. MediFind is a consumer-facing healthcare product that helps patients - especially those with serious, chronic and rare diseases - find better care faster. The MediFind Acquisition was accounted for as a business combination. The Company acquired MediFind to reinforce its commitment to patient-centered care and expand its offerings to consumers.
On August 11, 2023, the Company entered into an agreement to acquire 100% of the outstanding equity of Access eForms for aggregate consideration payable of $37,411 (the “Access eForms Acquisition”). A portion of the consideration was paid in cash at closing (subject to a customary working capital adjustment) with the remainder of the consideration settled through the issuance of 1,096,436 shares of the Company's common stock to the holders of the outstanding equity of Access eForms. Access eForms is an innovative electronic forms management and automation provider that helps hospitals across the country streamline workflows, improve compliance and deliver a better patient experience. The Access eForms Acquisition was accounted for as a business combination. The
Company acquired Access eForms to enhance and build on its existing functionality in the acute care space and to expand its network of clients and partners.
On October 3, 2023, the Company entered into an agreement to acquire 100% of the outstanding equity of ConnectOnCall for aggregate consideration payable of $13,946 (the “ConnectOnCall Acquisition”). A portion of the consideration was paid in cash at closing with the remainder of the consideration payable in seven quarterly installments beginning in fiscal year 2024. The first installment was paid in January 2024. ConnectOnCall is an automated medical answering solution that routes and triages after-hours calls and manages high daytime call volumes. The ConnectOnCall solution is built on real-time Electronic Health Record (“EHR”) integrations, enhancing the control and transparency of patient information for providers or practices when returning calls. The Company acquired ConnectOnCall to expand its offerings to provider organizations, helping them make the call-triaging process more efficient and less expensive.
The following table summarizes the estimated acquisition-date fair value of consideration transferred for each acquisition:
MediFindAccessConnectOnCallTotal
Cash consideration paid to sellers$4,195 $6,766 $3,946 $14,907 
Equity consideration paid to sellers4,676 30,645 — 35,321 
Liabilities incurred to sellers— — 10,000 10,000 
Total fair value of acquisition consideration$8,871 $37,411 $13,946 $60,228 

The acquisition-date fair value of equity consideration transferred was estimated using the closing stock price on the acquisition date for each acquisition. The acquisition-date fair value of liabilities incurred to sellers was estimated based on the timing of payments and an appropriate credit-adjusted discount rate of 9.3% per annum, determined with the assistance of a third-party appraiser. The Company accrues interest on the liability at 9.3% per annum. Until the settlement of the liability on January 31, 2025, the Company recorded $732 and $294 of interest expense on the liability incurred to sellers during the years ended January 31, 2025 and January 31, 2024, respectively. See Note 4 - Composition of certain financial statement captions for additional information regarding the settlement of the liabilities incurred to the sellers of ConnectOnCall.
The following table summarizes the calculation of cash paid for each acquisition, net of cash acquired per the Company's consolidated statements of cash flows for the fiscal year ended January 31, 2024.

MediFindAccessConnectOnCallTotal
Cash consideration paid to sellers$4,195 $6,766 $3,946 $14,907 
Less: cash acquired(231)(80)(23)(334)
Cash paid for acquisitions, net of cash acquired per statements of cash flows$3,964 $6,686 $3,923 $14,573 
The purchase price was allocated to the tangible assets acquired, the identifiable intangible assets acquired and the liabilities assumed based on their acquisition-date estimated fair values or other measurement bases specified by Accounting Standards Codification Topic 805, Business Combinations.
During the year ended January 31, 2024, the Company incurred $3,106 of acquisition related costs for the MediFind, Access and ConnectOnCall acquisitions. These costs are primarily included within general and administrative expenses in the consolidated statements of operations.
v3.26.1
Securitization program and variable interest entities
 12 Months Ended
Jan. 31, 2026
Transfers and Servicing of Financial Assets [Abstract]  
Securitization program and variable interest entities Securitization program and variable interest entities
(a) Program overview and structure
The Company sells eligible entire cardholder receivables through a securitization program (the “Securitization Program”). The disclosures that follow are aggregated for similar transfers of cardholder receivables under the Securitization Program. The Company had no transfers accounted for as secured borrowings for the years ended January 31, 2026 or 2025. Cardholder receivables are originated by AccessOne MedCard and then sold to AccessOne Funding, LLC (“AccessOne Funding”), a special‑purpose entity, for an amount equal to their face value. AccessOne Funding sells entire cardholder receivables to PNC Bank (“PNC”), an unaffiliated financial institution, for an initial cash purchase price (equal to the nominal amount of such receivables) and the right to receive a deferred purchase price, pursuant to the Securitization Program.
Transfers that meet the sale criteria under ASC 860 are accounted for as sales, and the related receivables are derecognized, as the assets are legally isolated, PNC has the ability to pledge or exchange the assets, and the Company does not maintain effective control. During the period from November 12, 2025 and January 31, 2026, the Company received cash proceeds of $13,691. The Company did not recognize significant gains or losses related to transfers accounted for as sales during the year ended January 31, 2026. The total principal of cardholder receivables outstanding in the program was $166,745, of which $143,320 had been derecognized, and $23,425 continues to be recognized on the consolidated balance sheet as of January 31, 2026. This is comprised primarily of the deferred purchase price receivable.
As of January 31, 2026, the funded receivables within the Securitization Program were predominantly current, with 92.7% classified as current, 4.7% less than 30 days past due, 1.6% between 30 and 89 days past due, 1.0% between 90 and 120 days past due, and no receivables more than 120 days past due. The substantial majority of healthcare providers in the Securitization Program have borrower credit ratings above A‑. For the period November 12, 2025 through January 31, 2026, the Company did not recognize credit losses on cardholder receivables transferred and derecognized under the Securitization Program. Losses arising from patient non‑payment are borne by healthcare providers under the recourse terms. Defaulted receivables are repaid by the provider. Accordingly, the Company has not recorded credit losses nor a corresponding liability for off-balance sheet credit risk.
As of January 31, 2026, the unfunded cardholder receivables were predominantly current, with 90.5% classified as current, 5.1% between 30 and 59 days past due, 2.4% between 60 and 89 days past due, and 2.0% 90 days or more past due. For the period November 12, 2025 through January 31, 2026, the Company did not recognize credit losses on unfunded cardholder receivables because, under the recourse terms, losses from patient non‑payment are borne by healthcare providers and defaulted receivables are repaid by or returned to the provider. Accordingly, the Company has not recorded credit losses related to these unfunded receivables.
The Securitization Program includes customary credit enhancement features, including a retained deferred purchase price and a reserve cash account. The deferred purchase price is a beneficial interest representing a right to receive certain cash flows from the Securitization Program. The Company receives cash and a deferred purchase price as consideration for the sale of cardholder receivables to PNC. The deferred purchase price functions as a credit enhancement and is settled from collections on the securitized cardholder receivables by the Company. Repayment of the deferred purchase price is conditional on the performance of the securitized cardholder receivables. The Securitization Program term ends on May 4, 2026 and may be renewed with the consent of the parties.
Refer to Note 9 – Fair value measurements for activity within deferred purchase price receivable for the year ended January 31, 2026.
(b) Servicing
The Company services cardholder receivables sold to PNC. The unpaid principal balance of cardholder receivables was $166,745 as of January 31, 2026. The Company recognizes servicing fee income assessed on the payment balances collected. Servicing fee income of $4,861 is presented within payment solutions in the consolidated statements of operations for the year ended January 31, 2026.
Continuing involvement with transferred assets consists primarily of servicing activities and the deferred purchase price. Cash flows on the deferred purchase price are affected by the performance of the securitized receivables. The Company’s maximum exposure to loss related to transferred financial assets is equal to the $23,425 carrying amount of its deferred purchase price receivable as of January 31, 2026. The Company does not provide liquidity facilities, guarantees or other support beyond customary servicing obligations and standard representations and warranties.
The Company, through AccessOne MedCard, makes certain representations, warranties and covenants regarding the transferred receivables and regarding AccessOne MedCard’s servicing of those receivables. The representations, warranties and covenants are intended to ensure that the purchasers of the receivables and related servicing will receive the type of assets and level of servicing that it has bargained to purchase. These representations and warranties do not expose the Company to risk of default on payment of the transferred receivables. Additionally, it is unlikely that these representations and warranties will expose the Company to any other significant losses. The Company evaluated this arrangement and determined that no liability was required as of January 31, 2026, as no losses were considered probable or reasonably estimable.
(c) Reserve cash account
The Securitization Program requires a reserve cash account equal to 1.0% of outstanding securitized cardholder receivables. Restricted cash related to the Securitization Program totaled $1,691 as of January 31, 2026.
(d) Securitization costs
The Company incurs securitization-related costs. Securitization-related costs of $3,052 were included in payment solutions expense in the consolidated statements of operations for the year ended January 31, 2026. The Company records an asset for securitization costs relating to future periods. As of January 31, 2026, the unamortized balance of deferred securitization costs was not material.
(e) Variable interest entities
In the ordinary course of business, the Company engages in certain activities that are not reflected on the consolidated balance sheets, generally referred to as off-balance sheet arrangements. These activities typically involve transactions with VIEs. AccessOne Funding is a wholly owned special‑purpose entity utilized in the Securitization Program. AccessOne Funding was established solely to facilitate the sale of entire cardholder receivables under the Securitization Program on behalf of the Company. Although AccessOne Funding is included in the Company’s consolidated financial statements, it is a separate legal entity with separate creditors.
AccessOne Funding’s equity investment at risk is not sufficient to permit AccessOne Funding to finance its activities without additional subordinated financial support. The activities that most significantly impact AccessOne Funding’s economic performance include facilitating the transfer of cardholder receivables pursuant to the Securitization Program and overseeing compliance with Securitization Program on behalf of the Company. The Company, through its control over these activities, has the current ability to direct these significant activities. The Company’s obligation to absorb losses or right to receive benefits that could potentially be significant arises primarily from its retained deferred purchase price beneficial interest and servicing arrangements, which expose the Company to variability in residual cash flows and servicing economics based on the performance of the securitized cardholder receivables. Accordingly, AccessOne Funding is a VIE for which the Company is the primary beneficiary. The Company reassesses on an ongoing basis whether it is the primary beneficiary of AccessOne Funding and whether any Securitization Program changes would require a change in consolidation conclusions. Reconsideration events include, among others, amendments to the Securitization Program or servicing arrangements, changes in decision‑making rights, or modifications that alter the Company’s exposure to AccessOne Funding’s variability.
Assets and liabilities of AccessOne Funding are included in the Company’s consolidated financial statements based on their nature within the respective line items. As of January 31, 2026, AccessOne Funding’s assets primarily consisted of deferred purchase price receivable of $23,425 and restricted cash of $1,691. As of January 31, 2026, AccessOne Funding did not have any significant liabilities. AccessOne Funding’s assets are restricted and may be used only to settle obligations of AccessOne Funding. The Company’s exposure to AccessOne Funding’s variability primarily relates to the fair value of the retained deferred purchase price beneficial interest. The Company’s involvement with AccessOne Funding affects results of operations primarily through changes in the fair value of the deferred purchase price receivable, which are recorded in other income, net in the consolidated statements of operations. Cash flows related to AccessOne Funding consist primarily of collections applied to the deferred purchase price receivable.
The Company’s exposure to variability is not expected to extend beyond the fair value of these arrangements. During the year ended January 31, 2026, there were no material changes in the Company’s risk exposure related to AccessOne Funding. AccessOne Funding’s creditors and interest holders have no recourse to the Company beyond these arrangements.
The Company evaluated interests in other legal entities and concluded that no other VIEs require consolidation. The Company did not have significant variable interests in unconsolidated VIEs as of January 31, 2026 and 2025.
(f) Covenants
As of January 31, 2026, the Company is required to maintain $3,500 of liquidity, which included unrestricted cash and availability under its securitization agreements. The Company was in compliance with all Securitization Program covenants as of January 31, 2026.
v3.26.1
Subsequent events
 12 Months Ended
Jan. 31, 2026
Subsequent Events [Abstract]  
Subsequent events Subsequent events
New Capital One Credit Facility and Refinancing of Bridge Loan
On the Refinancing Date, the Company and certain of its subsidiaries entered into the New Capital One Credit Agreement providing for a senior secured revolving credit facility up to an aggregate principal amount of $275,000, of which $92,000 was borrowed on the Refinancing Date, and which includes a swingline sublimit of $20,000 and a letter of credit sublimit of $10,000. The unused borrowing capacity on the New Capital One Credit Facility is available to the Company for working capital, capital expenditures, permitted acquisitions and general corporate purposes. The New Capital One Credit Agreement includes financial covenants including, but not limited to, requiring the Company to maintain a maximum Total Net Leverage Ratio and a minimum Fixed Charge Coverage Ratio, each as defined in the New Capital One Credit Agreement.
The New Capital One Credit Agreement bears interest at a rate per annum based on SOFR or a Base Rate as specified in the New Capital One Credit Agreement. Swingline loans must be Base Rate loans. The Company is permitted to repay the Credit Facility, in whole or in part, without penalty or premium, subject to certain notice periods.
The Company will pay an unused line fee equal to the product of (i) a commitment fee percentage ranging from 0.25% to 0.40% per annum based on the applicable total net leverage ratio and (ii) the unused portion of the revolving commitments under the Credit Facility.
On the Refinancing Date, in connection with the entry into the New Capital One Credit Facility, the Company terminated without penalty, and repaid all outstanding indebtedness and obligations under, the Bridge Loan and the Existing Capital One Credit Facility. All security agreements and related financing arrangements entered into with the Company’s former lenders under the Bridge Loan and the Existing Capital One Credit Facility were terminated substantially concurrently with the effectiveness of the New Capital One Credit Agreement.
v3.26.1
Insider Trading Arrangements
 3 Months Ended
Jan. 31, 2026
shares
Trading Arrangements, by Individual  
Non-Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Terminated false
Lisa Egbuonu-Davis [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement On December 16, 2025, Lisa Egbuonu-Davis, a member of the Company’s Board of Directors, adopted a Rule 10b5-1 Trading Plan that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Dr. Egbuonu-Davis’s Rule 10b5-1 Trading Plan, which expires on December 31, 2026, provides for the sale of up to 3,082 shares of our common stock.
Name Lisa Egbuonu-Davis
Title Board of Directors
Rule 10b5-1 Arrangement Adopted true
Adoption Date December 16, 2025
Expiration Date December 31, 2026
Arrangement Duration 380 days
Aggregate Available 3,082
Allison Hoffman [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
On December 19, 2025, Allison Hoffman, the General Counsel and Secretary of the Company, adopted a Rule 10b5-1 Trading Plan that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Ms. Hoffman’s Rule 10b5-1 Trading Plan, which expires on September 30, 2026, provides for the sale of (i) up to 29,941 shares of common stock, net of the number of shares sold to cover Ms. Hoffman’s taxes (ii) an additional number of shares that are receivable upon the future vesting of certain equity awards to be granted in connection with Ms. Hoffman’s fiscal year 2026 bonus and first half of fiscal year 2027 bonus, net of any shares sold by Ms. Hoffman to satisfy applicable taxes and (iii) 100% of her vested PSUs granted in 2023, net of the number of shares sold to cover Ms. Hoffman’s taxes pursuant to the terms of her Rule 10b5-1 Trading Plan. The number of shares to be granted pursuant to Ms. Hoffman’s fiscal year 2026 bonus and first half of fiscal year 2027 bonus, the number of PSUs to be awarded to Ms. Hoffman at the end of the relevant performance periods, and the number of shares to be sold by Ms. Hoffman to cover taxes, and thus the exact number of shares to be sold pursuant to Ms. Hoffman’s Rule 10b5-1 Trading Plan, can only be determined upon the occurrence of future vesting events.
Name Allison Hoffman
Title General Counsel and Secretary
Rule 10b5-1 Arrangement Adopted true
Adoption Date December 19, 2025
Expiration Date September 30, 2026
Arrangement Duration 285 days
Aggregate Available 29,941
Yvonne Hui [Member]  
Trading Arrangements, by Individual  
Name Yvonne Hui
Title Chief Accounting Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date January 15, 2026
Expiration Date September 21, 2026
Aggregate Available 8,875
Amy VanDuyn [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
On January 21, 2026, Amy VanDuyn, the Senior Vice President, Human Resources of the Company, adopted a Rule 10b5-1 Trading Plan that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c). Ms. VanDuyn’s Rule 10b5-1 Trading Plan, which expires on January 20, 2027, provides for the sale of up to 24,184 shares of common stock, net of the number of shares sold to cover Ms. VanDuyn’s taxes.
Name Amy VanDuyn
Title Senior Vice President, Human Resources
Rule 10b5-1 Arrangement Adopted true
Adoption Date January 21, 2026
Expiration Date January 20, 2027
Arrangement Duration 364 days
Aggregate Available 24,184
Michael Weintraub [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
On December 15, 2025, Michael Weintraub, a member of the Company’s Board of Directors, adopted a Rule 10b5-1 Trading Plan that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Weintraub’s Rule 10b5-1 Trading Plan, which expires on March 31, 2027, provides for the sale of up to 40,000 shares of common stock.
Name Michael Weintraub
Title Board of Directors
Rule 10b5-1 Arrangement Adopted true
Adoption Date December 15, 2025
Expiration Date March 31, 2027
Arrangement Duration 471 days
Aggregate Available 40,000
Gandhi Termination [Member] | Balaji Gandhi [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
On January 6, 2026, Balaji Gandhi, the Chief Financial Officer of the Company, terminated a trading arrangement for the sale of common stock (a “Rule 10b5-1 Trading Plan”). Mr. Gandhi’s terminated Rule 10b5-1 Trading Plan was adopted on June 24, 2025, would have expired on September 30, 2026 if not earlier terminated and provided for the sale of (i) up to 36,069 shares of our common stock, net of the number of shares sold to cover Mr. Gandhi’s taxes, (ii) an additional number of shares receivable upon the vesting of certain equity awards that may be granted pursuant to Mr. Gandhi’s first half of fiscal year 2026 bonus, full fiscal year 2026 bonus, and first half of fiscal year 2027 bonus, net of any shares sold in non-discretionary transactions pursuant to our mandatory sell-to-cover policy to cover Mr. Gandhi’s tax withholding obligations in connection with the vesting and settlement of RSUs and (iii) 100% of his vested PSUs granted in 2023, net of the number of shares sold to cover Mr. Gandhi’s taxes. As of the date of termination of the Rule 10b5-1 Trading Plan, Mr. Gandhi had sold no shares of common stock under its terms.
Name Balaji Gandhi
Title Chief Financial Officer
Rule 10b5-1 Arrangement Terminated true
Termination Date January 6, 2026
Expiration Date September 30, 2026
Aggregate Available 36,069
Gandhi Adoption [Member] | Balaji Gandhi [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
On January 21, 2026, Mr. Gandhi adopted a new Rule 10b5-1 Trading Plan that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c). Mr. Gandhi’s Rule 10b5-1 Trading Plan, which expires on January 29, 2027, provides for the sale of (i) up to 42,519 shares of our common stock, net of the number of shares sold to cover Mr. Gandhi’s taxes, (ii) an additional number of shares receivable upon the vesting of certain equity awards that may be granted pursuant to Mr. Gandhi’s fiscal year 2026 bonus and first half of fiscal year 2027 bonus, net of any shares sold in non-discretionary transactions pursuant to our mandatory sell-to-cover policy to
cover Mr. Gandhi’s tax withholding obligations in connection with the vesting and settlement of RSUs and (iii) 100% of his vested PSUs granted in 2023 and 2024, net of the number of shares sold to cover Mr. Gandhi’s taxes. The number of shares to be granted pursuant to Mr. Gandhi’s fiscal year 2026 bonus and first half of fiscal year 2027 bonus, the number of PSUs to be awarded to Mr. Gandhi at the end of the relevant performance periods, and the number of shares to be sold by Mr. Gandhi to cover taxes, and thus the exact number of shares to be sold pursuant to Mr. Gandhi’s modified Rule 10b5-1 Trading Plan, can only be determined upon the occurrence of future vesting events.
Name Mr. Gandhi
Rule 10b5-1 Arrangement Adopted true
Adoption Date January 21, 2026
Expiration Date January 29, 2027
Arrangement Duration 373 days
Aggregate Available 42,519
Hui Adoption [Member] | Yvonne Hui [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
On September 16, 2025, Yvonne Hui, the Chief Accounting Officer of the Company, adopted a Rule 10b5-1 Trading Plan that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c). Ms. Hui’s Rule 10b5-1 Trading Plan, which expires on September 21, 2026, provides for the sale of (i) up to 8,875 shares of our common stock, net of the number of shares sold to cover Ms. Hui’s taxes and (ii) an additional number of shares receivable upon the vesting of certain equity awards that may be granted pursuant to Ms. Hui’s fiscal year 2026 bonus and first half of fiscal year 2027 bonus, net of any shares sold in non-discretionary transactions pursuant to our mandatory sell-to-cover policy to cover Ms. Hui’s tax withholding obligations in connection with the vesting and settlement of RSUs.
On January 15, 2026, Ms. Hui modified her Rule 10b5-1 Trading Plan to provide for the sale of shares received upon the vesting of certain equity awards granted pursuant to Ms. Hui’s first half of fiscal year 2026 bonus, net of any shares sold in non-discretionary transactions pursuant to our mandatory sell-to-cover policy to cover Ms. Hui’s tax withholding obligations in connection with the vesting and settlement of RSUs.
Arrangement Duration 249 days
v3.26.1
Insider Trading Policies and Procedures
 12 Months Ended
Jan. 31, 2026
Insider Trading Policies and Procedures [Line Items]  
Insider Trading Policies and Procedures Adopted true
v3.26.1
Cybersecurity Risk Management and Strategy Disclosure
 12 Months Ended
Jan. 31, 2026
Cybersecurity Risk Management, Strategy, and Governance [Line Items]  
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
Our cybersecurity risk management program is informed by recognized industry standards and frameworks and incorporates elements of the same, including elements of the National Institute of Standards and Technology Cybersecurity Framework and The Health Information Trust Alliance (HITRUST) Common Security Framework. Additionally, we are certified as a PCI-DSS Level 1 Service Provider. The Company’s cybersecurity program utilizes a cross functional, multilayered defense-in-depth approach designed to: (i) identify, prevent and mitigate cybersecurity threats to the Company; (ii) preserve the confidentiality, security and availability of the information that we collect and store; (iii) protect the Company’s intellectual property; (iv) maintain the confidence of our customers, clients and business partners; and (v) provide appropriate public disclosure and required notices of cybersecurity risks and incidents when required.
Our cybersecurity program includes safeguards that are designed to protect the Company’s information systems from cybersecurity threats. Such safeguards include firewalls, automated intrusion detection systems, anti-malware functionality and access controls, which are evaluated and improved through periodic vulnerability assessments and ongoing cybersecurity threat intelligence. We have established and maintain an incident response plan that addresses the Company’s response to and recovery from a cybersecurity incident. The incident response plan is tested and evaluated on an annual basis.
The Company’s cybersecurity program is supported by engagement of third-party service providers who help identify, assess and respond to cybersecurity risks. For example, the Company regularly engages third parties to perform and facilitate assessments on our cybersecurity measures, including information security maturity assessments, audits, tabletop exercises, threat modeling and independent reviews of our information security control environment and operating effectiveness. The results of such assessments, audits and reviews are reported to leadership, the Audit Committee, and/or the Board, as appropriate, and the Company adjusts its cybersecurity policies, standards, processes and practices as appropriate based on the information provided by the assessments, audits and reviews.
As part of our cybersecurity risk management program, we maintain a risk-based approach to identifying and overseeing cybersecurity risks presented by third parties, including vendors, service providers and other external users of the Company’s systems, as well as the systems of third parties that could adversely impact our business. Further, all personnel are required to undergo cybersecurity training during onboarding and, thereafter, on an annual basis to reinforce the Company’s information security policies, standards and practices. Additionally, we conduct extensive cybersecurity assessments of potential acquisition targets to understand potential threats and mitigate risks, and the acquisition integration process includes alignment with relevant information security policies and procedures following completion of the transaction. We maintain cyber liability insurance to help mitigate potential liabilities resulting from cybersecurity issues, although our insurance may not cover all types of cybersecurity incidents or all losses that we incur.
We have not identified any cybersecurity incidents or threats that have materially affected us or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition. However, like other companies in our industry, we and our third-party vendors have experienced and will likely experience threats and security incidents that could affect our information or systems. See Item 1A “Risk Factors” in this Annual Report on Form 10-K for more information.
Cybersecurity Risk Management Processes Integrated [Flag] true
Cybersecurity Risk Management Processes Integrated [Text Block]
Our cybersecurity risk management program is informed by recognized industry standards and frameworks and incorporates elements of the same, including elements of the National Institute of Standards and Technology Cybersecurity Framework and The Health Information Trust Alliance (HITRUST) Common Security Framework. Additionally, we are certified as a PCI-DSS Level 1 Service Provider. The Company’s cybersecurity program utilizes a cross functional, multilayered defense-in-depth approach designed to: (i) identify, prevent and mitigate cybersecurity threats to the Company; (ii) preserve the confidentiality, security and availability of the information that we collect and store; (iii) protect the Company’s intellectual property; (iv) maintain the confidence of our customers, clients and business partners; and (v) provide appropriate public disclosure and required notices of cybersecurity risks and incidents when required.
Our cybersecurity program includes safeguards that are designed to protect the Company’s information systems from cybersecurity threats. Such safeguards include firewalls, automated intrusion detection systems, anti-malware functionality and access controls, which are evaluated and improved through periodic vulnerability assessments and ongoing cybersecurity threat intelligence. We have established and maintain an incident response plan that addresses the Company’s response to and recovery from a cybersecurity incident. The incident response plan is tested and evaluated on an annual basis.
Cybersecurity Risk Management Third Party Engaged [Flag] true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] false
Cybersecurity Risk Board of Directors Oversight [Text Block] The Company’s Board of Directors (the “Board”) maintains oversight responsibility over the Company’s enterprise risk management (“ERM”) program, which incorporates the Company’s cybersecurity risk management program.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] The Board’s oversight of cybersecurity risk management is supported by the Audit Committee of the Board (the “Audit Committee”), which regularly interacts with the Company’s ERM function, the Company’s Chief Technology Officer, along with other members of management including the Chief Information Security Officer and the Chief Privacy Officer.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] The Board’s oversight of cybersecurity risk management is supported by the Audit Committee of the Board (the “Audit Committee”), which regularly interacts with the Company’s ERM function, the Company’s Chief Technology Officer, along with other members of management including the Chief Information Security Officer and the Chief Privacy Officer.
The Board and the Audit Committee each receive quarterly presentations and reports from the Company’s Chief Technology Officer and/or General Counsel on cybersecurity risks, which address a wide range of topics including, among others, recent developments, evolving standards, vulnerability assessments, third-party and independent reviews, the threat environment, technological trends and information security considerations arising with respect to the Company’s peers and third party service providers. The Board and the Audit Committee also receive prompt and timely information regarding any cybersecurity incident that meets established reporting thresholds under the Company’s incident response plan.
Cybersecurity Risk Role of Management [Text Block] The Board’s oversight of cybersecurity risk management is supported by the Audit Committee of the Board (the “Audit Committee”), which regularly interacts with the Company’s ERM function, the Company’s Chief Technology Officer, along with other members of management including the Chief Information Security Officer and the Chief Privacy Officer.
The Company’s Chief Information Security Officer is principally responsible for day-to-day management of the Company’s cybersecurity risk management program and reports to the Chief Technology Officer. The Chief Information Security Officer has more than 15 years of cybersecurity experience, including leadership roles at four publicly traded companies. He is a Certified Information Systems Security Professional, holds a M.S. in Security Technologies from the University of Minnesota and is an alumnus of the FBI Citizen’s Academy. The Chief Technology Officer has served in various leadership roles in information technology and information security at the Company for over 15 years and holds a B.S. in computer science from Worcester Polytechnic Institute. The Chief Technology Officer reports directly to the Chief Executive Officer and works in coordination with the other members of the leadership team, which includes our General Counsel, President, Provider Solutions, President, Network Solutions and Chief Financial Officer. The Chief Technology Officer oversees a team of security professionals, which is led by the Chief Information Security Officer. The security team includes approximately 40 security professionals, 30 of whom are security engineers or analysts. The security team’s functions include identity and access management; security operations and incident response; governance, risk, and compliance; security architecture; third-party risk management, and application security.
The Board and the Audit Committee each receive quarterly presentations and reports from the Company’s Chief Technology Officer and/or General Counsel on cybersecurity risks, which address a wide range of topics including, among others, recent developments, evolving standards, vulnerability assessments, third-party and independent reviews, the threat environment, technological trends and information security considerations arising with respect to the Company’s peers and third party service providers. The Board and the Audit Committee also receive prompt and timely information regarding any cybersecurity incident that meets established reporting thresholds under the Company’s incident response plan.
Cybersecurity Risk Management Positions or Committees Responsible [Flag] true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]
The Company’s Chief Information Security Officer is principally responsible for day-to-day management of the Company’s cybersecurity risk management program and reports to the Chief Technology Officer. The Chief Information Security Officer has more than 15 years of cybersecurity experience, including leadership roles at four publicly traded companies. He is a Certified Information Systems Security Professional, holds a M.S. in Security Technologies from the University of Minnesota and is an alumnus of the FBI Citizen’s Academy. The Chief Technology Officer has served in various leadership roles in information technology and information security at the Company for over 15 years and holds a B.S. in computer science from Worcester Polytechnic Institute. The Chief Technology Officer reports directly to the Chief Executive Officer and works in coordination with the other members of the leadership team, which includes our General Counsel, President, Provider Solutions, President, Network Solutions and Chief Financial Officer. The Chief Technology Officer oversees a team of security professionals, which is led by the Chief Information Security Officer. The security team includes approximately 40 security professionals, 30 of whom are security engineers or analysts. The security team’s functions include identity and access management; security operations and incident response; governance, risk, and compliance; security architecture; third-party risk management, and application security.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block] The Chief Information Security Officer has more than 15 years of cybersecurity experience, including leadership roles at four publicly traded companies.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]
The Board and the Audit Committee each receive quarterly presentations and reports from the Company’s Chief Technology Officer and/or General Counsel on cybersecurity risks, which address a wide range of topics including, among others, recent developments, evolving standards, vulnerability assessments, third-party and independent reviews, the threat environment, technological trends and information security considerations arising with respect to the Company’s peers and third party service providers. The Board and the Audit Committee also receive prompt and timely information regarding any cybersecurity incident that meets established reporting thresholds under the Company’s incident response plan.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] true
v3.26.1
Summary of significant accounting policies (Policies)
 12 Months Ended
Jan. 31, 2026
Accounting Policies [Abstract]  
Consolidated financial statements Consolidated financial statementsThe accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and regulations of the Securities and Exchange Commission ("SEC") regarding annual financial reporting and include the accounts of Phreesia, Inc; its branch operation in Canada, its consolidated subsidiaries and its consolidated variable interest entity (or collectively, the "Company").
Fiscal year Fiscal year
The Company’s fiscal year ends on January 31. References to fiscal 2026, 2025 and 2024 refer to the fiscal years ending on January 31, 2026, 2025 and 2024, respectively.
Reclassifications and Changes in Financial Statement Captions Reclassifications and Changes in Financial Statement Captions
The Company has presented interest expense and interest income separately on its consolidated statements of operations. The Company has separately presented interest expense and interest income for prior periods to conform to the current period classification. In prior periods, the Company had separately presented interest expense and interest income in the notes to its financial statements but had presented interest expense and interest income on a combined basis on its consolidated statements of operations because the individual amounts were not material.
The revenue line previously labeled “Payment processing fees” has been relabeled “Payment solutions” to reflect the expanded scope of the Company’s payments offerings following the AccessOne Acquisition, which closed on November 12, 2025. “Payment solutions” includes all revenue previously presented as “Payment processing fees” and all revenue from the operations acquired in the AccessOne Acquisition. Additionally, “Payment processing expense” has been relabeled “Payment solutions expense” and includes all expenses previously presented as “Payment processing expense” and direct costs of revenue related to the operations acquired in the AccessOne Acquisition. Prior period amounts have not been reclassified, as the Company did not own the acquired operations in prior periods and the change in presentation did not affect any previously reported amounts.
Use of estimates Use of estimates
The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. These judgments, estimates and assumptions are used for, but not limited to revenue recognition, the fair value of cardholder receivables, the fair value of deferred purchase price receivables, the fair value of due to provider liabilities, the allowance for doubtful accounts, contingent liabilities, the determination of the useful lives of long-lived assets, the capitalization, valuation and recoverability of long-lived assets, the fair value of securities underlying stock-based compensation and the fair value of identifiable assets and liabilities and deferred consideration in business acquisitions.
Revenue recognition Revenue recognition
The Company generates revenue primarily from providing integrated SaaS-based software and payment solutions for the healthcare industry. The Company derives revenue from subscription fees and related services generated from the Company’s healthcare services clients for access to the Company's solutions, payment processing fees based on patient payment volume and financing fees based on a portfolio of cardholder receivables, and fees from life sciences clients and other organizations for delivering qualified direct communications to patients who consent to receive this type of engagement using the Company's solutions.
The Company accounts for revenue from contracts with customers by applying the following steps:
•identification of the contract, or contracts, with a customer;
•identification of the performance obligations in the contract;
•determination of the transaction price;
•allocation of the transaction price to the performance obligations in the contract; and
•recognition of revenue when, or as, the Company satisfies a performance obligation.
Revenues are recognized when control of these services is transferred to the Company’s customers, in an amount that reflects the consideration it expects to be entitled to in exchange for those services.
The majority of the Company’s contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately when they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines the standalone selling prices based on its overall pricing objectives, taking into consideration market conditions, historical pricing information as priced in previous bundled contracts, as well as other factors such as product, customer type and geographic area. The Company typically establishes a range of SSPs for each of its performance obligations. The Company uses the residual method to estimate the SSP for certain performance obligations with highly variable pricing.
i.Subscription and related services
In most cases, the Company generates subscription fees from clients based on the number of healthcare services clients that utilize the Company's solutions and subscription fees for the Company’s self-service intake tablets (PhreesiaPads), on-site kiosks (Arrivals Kiosks) and any other solutions. The Company’s healthcare services clients are typically billed monthly in arrears, though in some instances healthcare services clients may opt to be billed monthly, quarterly or annually in advance. Subscription fees are typically auto-debited from client’s accounts every month. Revenue for healthcare services client subscriptions is recognized over the term of the respective healthcare services client contract. Substantially all of the Company’s subscription arrangements are considered service contracts, and the customer does not have the right to take possession of the software. Revenue for related services is recognized as it is delivered if the services are distinct from the subscription service and is recognized over the remaining non-cancelable subscription term if it is not distinct from the subscription service. In certain arrangements, the Company leases its PhreesiaPads and Arrivals Kiosks through operating leases to its customers. Accordingly, these revenue transactions are accounted for using Accounting Standards Codification (“ASC”) 842, Leases.
In addition, subscription and related services includes certain fees from clients for professional services associated with implementation services as well as travel and expense reimbursements, shipping and handling fees, sales of Phreesia hardware (PhreesiaPads and Arrivals Kiosks), on-site support and training. Certain professional services for implementation are not distinct from the Company's solutions and are therefore recognized over the term of the contract. Revenue from sales of distinct professional services, Phreesia hardware and training are recognized in the period they are delivered to clients.
ii.Payment solutions
The Company generates revenue from payment processing fees based on the levels of patient payment volume resulting from credit and debit card transactions (dollar value and number of card transactions) processed through Phreesia’s payment facilitator model. Payment processing fees are generally calculated as a percentage of the total transaction dollar value processed and/or a fee per transaction. The remainder of patient payment volume is composed of credit and debit card transactions for which Phreesia acts as a gateway to payment processors, and cash and check transactions.
The Company recognizes the payment processing fees when the transaction occurs (i.e., when the processing services are completed). The transaction amount is collected from the cardholder’s bank via the Company’s third-party payment processing partner and the card networks. The transaction amount is then remitted to its customers approximately two business days after the transaction occurs. At the end of each month, the Company bills its customers for any payment processing fees owed per its customer contractual agreements. Similarly, at the end of
each month, the Company remits payments to third-party payment processors and financial institutions for interchange and assessment fees, processing fees, and bank settlement fees.
The Company acts as the merchant of record for its customers and works with payment card networks and banks so that its customers do not need to manage the complex systems, rules, and requirements of the payment industry. The Company satisfies its performance obligations and therefore recognizes the transaction fees as revenue upon completion of a transaction. Revenue is recognized net of refunds, which arise from reversals of transactions initiated by the Company’s customers.
The payment processing fees collected from customers are recognized as revenue on a gross basis as the Company is the principal in the delivery of the managed payment solutions to the customer. The Company has concluded it is the principal because as the merchant of record, it controls the services before delivery to the customer, it is primarily responsible for the delivery of the services to its customers, it has latitude in establishing pricing with respect to the customer and other terms of service, it has sole discretion in selecting the third-party to perform the settlement, and it assumes the credit risk for the transaction processed. The Company also has the unilateral ability to accept or reject a transaction based on criteria established by the Company.
As the merchant of record, the Company is liable for settlement of the transactions processed and, accordingly, such costs are included in payment processing fees expense on the accompanying consolidated statements of operations.
Payment solutions revenue also includes financing fees based on a portfolio of cardholder receivables, comprised primarily of the following:
•Fees for servicing cardholder receivables. Servicing fee income is recognized as the services are performed. The Company evaluates whether servicing fees represent adequate compensation and whether a servicing asset or servicing liability should be recorded. The Company has determined that servicing fees approximate adequate compensation; therefore, no servicing asset or liability is recognized.
•Finance charges earned on cardholder receivables, which are recognized using a method that approximates the effective interest method over the contractual term. Accrual of finance charges ceases when an account becomes 90 days past due, and previously accrued but unpaid interest is reversed. Accrual resumes when the cardholder receivable returns to current status. Past due status is based on contractual terms of the cardholder receivable. Revenues for finance charges are recognized in accordance with ASC 310, Receivables.
iii.Network solutions
The Company's Network solutions revenue includes fees from life sciences companies and other organizations for qualified direct communications to patients who consent to receive this type of engagement, to help activate, engage and educate patients about topics critical to their health using the Company’s solutions.
The Company generates revenue from sales of digital marketing solutions to life sciences companies which is based largely on the delivery of messages at a contracted price per message to patients. Messaging campaigns are sold for a specified number of messages delivered to qualified patients over an expected time frame. Revenue is recognized as the messages are delivered.
Transfers of financial assets Transfers of financial assets
Transfers of an entire financial asset are accounted for as sales when control over the assets has been surrendered in accordance with the sale criteria of ASC 860, Transfers and Servicing. Control over transferred assets is deemed to be surrendered when (i) the assets have been isolated from the Company, (ii) the transferee obtains the right (free of conditions that constrain it from taking advantage of that right) to pledge or exchange the transferred assets, and (iii) the Company does not maintain effective control over the transferred assets through an agreement to repurchase them before their maturity. Upon a qualifying sale, the transferred assets are derecognized, and any assets obtained or liabilities incurred are initially recognized at fair value, including any retained beneficial interests (e.g., deferred purchase price receivable). Transfers that do not meet the sale criteria are accounted for as secured borrowings with a pledge of collateral.
Variable interest entities In addition to the subsidiaries the Company controls through its equity ownership, the Company consolidates a variable interest entity because it is the primary beneficiary.Variable interest entities
A variable interest entity (“VIE”) is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. The Company consolidates entities determined to be VIEs for which the Company is the primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly
impact the entity’s economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE. In evaluating primary beneficiary status, the Company identifies the activities that most significantly impact a VIE’s economic performance and the rights that provide the current ability to direct those activities, together with exposure to benefits or losses that could potentially be significant. The Company reassesses its primary beneficiary determination on an ongoing basis.
Concentrations of credit risk and Risks and uncertainties Concentrations of credit risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable and settlement assets. For cardholder receivables, the Company does not bear credit risk from the patient cardholder, as the Company has full recourse to the healthcare provider for unpaid principal. Accordingly, the primary exposure relates to the healthcare provider’s obligation to remit the recourse payment under the financial services arrangement. For information regarding credit risk and maximum exposure to loss associated with the deferred purchase price receivable, refer to Note 19 — Securitization program and variable interest entities.
The Company’s cash and cash equivalents are held by established financial institutions. At times, the Company’s cash on deposit at financial institutions may be in excess of the Federal Deposit Insurance Corporation (“FDIC”) insurance limit. The Company does not require collateral from its customers and generally requires payment within 30 to 60 days of billing. Settlement assets are amounts due from well-established payment processing companies and normally take one to two business days to settle which mitigates the associated risk of concentration. The Company utilizes two third-party payment processors.
The Company’s customers are primarily physician’s offices and other healthcare services organizations located in the United States as well as pharmaceutical companies.Risks and uncertaintiesThe Company is subject to a variety of risk factors, including the economy, data privacy and security laws and government regulations. Additionally, the Company is subject to other risks associated with the markets in which it operates including reliance on third-party vendors, partners, and service providers. The Company has a substantial number of employees in Canada and India, and the Company supplements its workforce with contractors and consultants in domestic and international locations. Certain of the Company's service providers, including certain third-party software developers, are located in international locations subject to warfare and/or political and economic instability, such as Ukraine and India. As with any business, operation of the Company involves risk, including the risk of service interruption impacting the operations of the Company's business and the Company's customer’s facilities below expected levels of operation, shut downs due to the breakdown or failure of information technology and communications systems, changes in laws or regulations, political and economic instability, or catastrophic events such as fires, earthquakes, floods, explosions, global health concerns such as pandemics or other similar occurrences affecting the delivery of the Company’s products and services. The occurrence of any of these events could significantly reduce or eliminate revenues generated, or significantly increase the expenses of the Company's operations, adversely impacting the Company’s operating results and the Company's ability to meet the Company's obligations and commitments.
Cost of revenue (excluding depreciation and amortization) Cost of revenue (excluding depreciation and amortization)
Cost of revenue (excluding depreciation and amortization) primarily consists of personnel expenses for implementation and technical support, infrastructure costs for operation of the Company’s solutions such as hosting fees, and certain fees paid to various third-party providers for the use of their technology, as well as costs to verify insurance eligibility and benefits. Personnel expenses consist of salaries, stock-based compensation, benefits and bonuses.
Payment solutions expense Payment solutions expense
Payment solutions expense includes payment processing expenses such as interchange fees set by payment card networks that are ultimately paid to the card-issuing financial institution, and assessment fees paid to payment card networks, and fees paid to third-party payment processors and gateways. Payment solutions expense also includes fees payable to PNC in connection with the Securitization Program as well as direct costs of servicing cardholder receivables.
Sales and marketing Sales and marketingSales and marketing expense consists primarily of personnel costs, including salaries, stock-based compensation, benefits, bonuses and commission costs for the Company’s sales and marketing personnel. Sales and marketing expense also includes costs for advertising, promotional and other marketing activities, as well as certain fees paid to various third-party partners for sales lead generation. Advertising is expensed as incurred.
Research and development Research and development
Research and development expense consists of costs for the design, development, testing and enhancement of the Company’s products and services that do not meet the criteria for capitalization as internal-use software. These costs consist primarily of personnel costs, including salaries, stock-based compensation, benefits and bonuses for the Company’s development personnel. Research and development expense also includes third-party partner fees and third-party consulting fees.
General and administrative General and administrative
General and administrative expense consists primarily of personnel costs, including salaries, stock-based compensation, benefits and bonuses for the Company’s executive, finance, legal, human resources, information technology, and other administrative personnel. General and administrative expense also includes consulting, legal, security, accounting services and allocated overhead.
Depreciation and Amortization Depreciation
Depreciation represents depreciation expense for PhreesiaPads and Arrivals Kiosks (collectively, Phreesia hardware), data center and other computer hardware and purchased computer software.
Amortization
Amortization primarily represents amortization of the Company’s capitalized internal-use software related to the Company's solutions as well as amortization of acquired intangible assets.
Cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash
The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. The Company's money market accounts meet the definition of cash equivalents. As of January 31, 2026, the Company was required to maintain $3,500 of liquidity, which included unrestricted cash and availability under its securitization agreements. The Company was in compliance with these requirements as of January 31, 2026.
Restricted cash totaled $1,691 and $0 as of January 31, 2026 and 2025, respectively. Restricted cash includes amounts the Company is contractually required to maintain in connection with its securitization program. The restricted cash balance is legally segregated and not available for general corporate purposes.
Settlement assets Settlement assets
Settlement assets represent amounts due from the Company’s payment processors for customer electronic processing transactions. Settlement assets are typically settled within one to two business days of the transaction date.
Settlement obligations Settlement obligations
Settlement obligations represent amounts due to customers for electronic processing transactions that have not been funded by the Company due to timing of settlement from the Company’s payment processors.
Accounts receivable and allowance for doubtful accounts Accounts receivable and allowance for doubtful accountsAccounts receivable represent trade receivables net of allowances for any potential uncollectible amounts. The Company estimates the allowance for doubtful accounts as its current estimate of expected credit loss over the life of the instrument. The Company estimates its allowance for doubtful accounts by evaluating the Company’s ability to collect outstanding receivable balances considering various factors, including the age of the balance, the customer’s creditworthiness, payment history and financial condition, the condition of the industry as a whole, as well as expected future changes in credit losses. Write-offs of accounts receivable were not material during the fiscal years ended January 31, 2026, 2025 or 2024.
Accrued interest and fees receivable and allowance for doubtful accounts Accrued interest and fees receivable and allowance for doubtful accounts
Accrued interest and fees receivable represent finance charges and late fees that have been billed but not yet collected on patient accounts, net of allowances for any potential uncollectible amounts. The Company has elected to exclude accrued interest and fees receivable from the financing receivables when estimating the allowance for credit losses. The allowance for credit losses on accrued interest and fees receivable is a valuation account that is deducted from the amortized cost basis of accrued interest and fees receivable to present the net amount expected to be collected. The allowance is adjusted through the provision for credit losses. Losses are charged off against the allowance for credit losses when the Company determines the balance to be uncollectible. The measurement of expected credit losses includes information about historical events and current conditions, with historical credit loss experience providing the basis for the estimation of expected credit losses. The Company uses an aging method to estimate credit losses, pooling the receivables based on levels of delinquency and historical loss rates, adjusted for current conditions.
Property and equipment Property and equipment
Property and equipment, including PhreesiaPads and Arrivals Kiosks, are stated at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the related assets. Maintenance and repair costs are charged to operations as incurred while expenditures for major improvements are capitalized.
The Company depreciates property and equipment over the following estimated useful lives:
Useful life
(years)
PhreesiaPads and Arrivals Kiosks3
Computer equipment
3
Computer software
3 to 5
Hardware development
3
Upon sale or disposition of property and equipment, the cost and related accumulated depreciation are removed from their respective accounts and any gain or loss is reflected in the consolidated statements of operations.
Capitalized internal-use software Capitalized internal-use software
The Company capitalizes certain costs incurred for the development of computer software for internal use. These costs relate to the development of its solutions. The Company capitalizes the costs during the development of the project, when it is determined that it is probable that the project will be completed, and the software will be used as intended. Costs related to preliminary project activities, post-implementation activities, training and maintenance are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life, which is generally three to five years. Management evaluates the useful lives of these assets on an annual basis and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. The Company exercises judgment in determining the point at which various projects may be capitalized, in assessing the ongoing value of the capitalized costs and in determining the estimated useful lives over which the costs are amortized. To the extent that the Company changes the manner in which it develops and tests new features and functionalities related to its solutions, assesses the ongoing value of capitalized assets or determines the estimated useful lives over which the costs are amortized, the amount of internal-use software development costs the Company capitalizes and amortizes could change in future periods. Refer to Note 4(d) for further detail on internal-use software costs capitalized during the period.
Business combinations Business combinations
The Company uses its best estimates and assumptions to accurately assign fair value to the tangible and intangible assets acquired and liabilities assumed at the acquisition date. The Company’s estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with the corresponding offset to goodwill. The Company continues to collect information and reevaluate these estimates and assumptions quarterly and records any adjustments to its estimates to goodwill provided that the Company is within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statements of operations.
When applicable, the consideration transferred for business combinations includes the acquisition-date fair value of deferred consideration liabilities. The Company recognizes interest expense to accrete deferred consideration liabilities to their settlement amount.
Goodwill and intangible assets Goodwill and intangible assets
Goodwill represents the excess of the consideration transferred over the fair value of the underlying net tangible and intangible assets acquired and liabilities assumed in connection with business combinations accounted for using the acquisition method of accounting. Goodwill is not amortized, but instead goodwill is required to be tested for impairment annually and under certain circumstances. The Company performs such testing of goodwill in the fourth quarter of each fiscal year, or as events occur or circumstances change that would more likely than not reduce the fair value below its carrying amount.
The testing of goodwill is performed at the reporting unit level. The Company’s reporting unit is the same as its operating segment. The test begins with a qualitative assessment to determine whether it is “more likely than not” that the fair value of the reporting unit is less than its carrying amount. If it is concluded that it is “more likely than not” that the fair value of a reporting unit is less than its carrying amount, the Company performs a quantitative goodwill impairment test by calculating the fair value of the reporting unit and comparing that fair value to the carrying value of the reporting unit. If the estimated fair value of the reporting unit is less than its carrying amount, the Company records a goodwill impairment to reduce the carrying amount of goodwill by the amount by which the fair value of the reporting unit is less than its carrying amount.
All other intangible assets associated with purchased intangibles, consisting of customer relationships, acquired technology, acquired trademarks and acquired licenses, are recorded at acquisition-date fair value less accumulated amortization and are amortized on a straight-line basis over their estimated remaining economic lives.
Long-lived assets Long-lived assets
Long-lived assets, such as property and equipment, intangible assets, capitalized internal-use software and operating lease right-of-use assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares the undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. There were no impairment charges recognized in the consolidated statements of operations during any of the periods presented.
Income taxes Income taxes
An asset and liability approach is used for financial accounting and reporting of current and deferred income taxes. Deferred income tax assets and liabilities are computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future. Such deferred income tax asset and liability computations are based on enacted tax laws and rates applicable to periods in which the differences are expected to affect taxable income or loss. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company recognizes the financial statement effects of income tax positions taken or expected to be taken in an income tax return when they are more likely than not, based on technical merits, to be sustained upon examination. Deferred tax assets and deferred tax liabilities are offset and presented as a single net amount for each tax-paying component within a tax jurisdiction. A tax-paying component is an individual entity or a group of entities that file a consolidated tax return in that jurisdiction. The Company measures income tax positions at the largest amount of tax benefit that is more likely than not to be realized upon settlement with a taxing authority that has full knowledge of all relevant information. U.S. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in the interim periods, and disclosure for income taxes.
The Company reviews and evaluates tax positions in its major jurisdictions and determines whether or not there are uncertain tax positions that require financial statement recognition and the recording of a tax liability or the reduction of a tax asset. The Company would recognize tax related interest and penalties, if applicable, as a component of its provision for income taxes.
Segment information Segment information
Operating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company defines the term “chief operating decision maker” to be its Chief Executive Officer. The
Company’s Chief Executive Officer reviews the financial information presented on an entire company basis for purposes of allocating resources and evaluating the Company’s financial performance. Accordingly, the Company has determined that it operates in a single reportable operating segment. Additionally, substantially all of the Company's revenues and long-lived assets are located in the U.S. See Note 16 - Segments and geographic information - for additional information regarding the Company’s reportable segment.
Stock-based compensation Stock-based compensation
The Company has stock-based compensation plans under which various types of equity-based awards are granted, including stock options, restricted stock units ("RSUs"), performance-based RSUs, and market-based performance stock units ("PSUs"). The Company recognizes the compensation cost for equity-classified stock-based awards based on the grant-date fair value of the award. That cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the award. For performance-based RSUs, the number of shares expected to vest is estimated at each reporting date based on management's expectations regarding the relevant performance criteria. The Company adjusts stock compensation expense for forfeitures of stock-based compensation awards in the periods the forfeitures occur.
The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield, and the value of the Company's common stock (which is estimated for awards granted prior to the Company’s IPO). The Company does not estimate forfeitures in recognizing stock-based compensation expense. The fair value of the RSUs is equal to the fair value of the Company's common stock on the grant date of the award. The fair value of market-based PSUs is estimated at the time of grant using a Monte Carlo simulation which compares Phreesia's projected total shareholder return ("TSR") to the projected TSR of the Russell 3000 Index (the "Peer Group") and estimates the value of shares to be issued based on the vesting conditions of the PSUs. The Monte Carlo simulation requires the use of inputs and assumptions such as the grant-date closing stock price, simulation, expected volatility, correlation coefficient to the Russell 3000 Index, risk-free interest rate and dividend yield.
During fiscal 2020, the Company adopted the Phreesia, Inc. 2019 Employee Stock Purchase Plan ("ESPP" or "the Plan"). The Company records compensation expense based on the grant date fair value per award granted multiplied by the number of awards granted to the employee for the purchase period. The number of awards granted to the employee for the purchase period is equal to the expected employee contributions divided by 85% of the closing stock price on the offering date.
For liability-classified performance-based stock bonus awards, at the beginning of the year, the Company offers eligible employees the option to elect to receive their year-end performance bonus in stock. Bonuses settled in stock are accounted for as stock-based compensation awards vesting based on a performance condition and are classified as liabilities because they represent a liability settled in a variable number of shares.
During fiscal 2023, the Company adopted the 2023 Inducement Award Plan (the "Inducement Plan"). The Inducement Plan allows the Company to grant equity-based incentive awards including stock options, RSUs and PSUs to employees of acquired companies to induce them to join the Company.
Fair value of financial instruments Fair value of financial instruments
Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for the sale of an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability that were developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect assumptions the Company believes other market participants would use in pricing the asset or liability that are developed based on the best information available in the circumstances. Financial assets and liabilities carried at fair value are required to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:
Level 1—Quoted prices in active markets for identical assets or liabilities.
Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.
Level 3—Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.
To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3 of the fair value hierarchy.
The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the total fair value amount is disclosed at the level appropriate for the lowest level input that is significant to the total fair value of the instrument.
Fair value option Fair value option
The Company elected the fair value option to account for its cardholder receivables, deferred purchase price receivable, and amounts due to healthcare providers, effective November 12, 2025. The election was made for deferred purchase price receivables because those receivables can contractually be prepaid or otherwise settled in such a way that the Company would not recover substantially all of its recorded investment. The election was made for cardholder receivables and the due to provider liability to better align measurement and presentation of cardholder receivables and the due to provider liability, which is only payable upon receipt of cash flows from the cardholder receivables. Changes in the fair value of these instruments are recognized in other income, net. Finance fee income related to cardholder receivables is reflected in payment solutions revenues, and finance fee expense on due to healthcare providers is reflected in payment solutions expenses separate from changes in fair value recognized in earnings.
Equity offering costs Equity offering costs
The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs will be recorded in stockholders’ equity as a reduction of additional paid-in capital generated as a result of the offering, to the extent there are sufficient proceeds. Should the equity financing no longer be considered probable of being consummated, all deferred offering costs would be charged to operating expenses in the accompanying consolidated statements of operations.
Foreign currency Foreign currencyThe functional currency of the Company’s subsidiaries and branch in the U.S. and Canada is the U.S. Dollar. The functional currency of the Company’s subsidiary in India is the Indian Rupee. For subsidiaries with functional currencies other than the U.S. Dollar, the Company translates the functional currency financial statements into U.S. Dollars using the exchange rates at the balance sheet date for assets and liabilities, the period average exchange rates for revenues and expenses, and the historical exchange rates for equity transactions. The effects of foreign currency translation adjustments are recorded as accumulated other comprehensive loss within stockholders’ equity in the Company’s consolidated balance sheets. Foreign currency transaction gains and losses to re-measure monetary assets and liabilities into each entity’s functional currency are included in Other income (expense), net in the Company’s consolidated statements of operations.
Other income (expense), net Other income, netOther income, net consists primarily of miscellaneous other income and expense items that are not attributable to the Company’s normal ongoing operations, changes in the fair value of financial instruments accounted for under the fair value option, and foreign currency-related gains and losses.
Legal and loss contingencies Legal and loss contingencies
The Company periodically evaluates the development in litigation, claims and other legal matters. The Company records liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources when it is probable that a liability has been incurred and the amount can be reasonably estimated. The Company discloses legal proceedings when it is reasonably possible that a loss has been incurred. Legal costs incurred in connection with loss contingencies are expensed as incurred.
Earnings (loss) per share Earnings (loss) per share
The Company calculates basic net income (loss) per share attributable to common stockholders using the weighted-average number of outstanding shares of common stock during the period. Diluted net income (loss) per share attributable to common stockholders is computed using the weighted-average number of outstanding shares of common stock and the effect of potentially dilutive securities outstanding during the period. Potentially dilutive securities include RSUs, PSUs, stock options, liability awards and ESPP shares. If dilutive, such potentially dilutive securities are reflected in net income (loss) per share attributable to common stockholders using the treasury stock method.
In the Company’s earnings (loss) per share footnote, antidilutive securities outstanding at the end of each period are stated on the basis of the number of anti-dilutive securities outstanding as of the end of each applicable reporting period. In the Company’s earnings (loss) per share footnote, the calculation of anti-dilutive securities outstanding at the end of each period are not reduced for shares assumed repurchased using the treasury stock method.
In computing year-to-date diluted earnings per share, periods with a net loss were assumed to have net income for purposes of determining the weighted-average number of potentially dilutive common shares outstanding.
Derivative financial instruments and hedging activities Derivative financial instruments and hedging activities
The Company conducts business in Canada and India, subjecting the Company to foreign exchange risk. The Company uses derivative financial instruments to manage foreign currency exchange risk. Derivative instruments are measured at fair value and recorded as either an asset or liability on the consolidated balance sheets. Gains and losses resulting from changes in fair value are accounted for depending on the use of the derivative and whether it is designated and qualifies for hedge accounting.
For derivative instruments designated as foreign currency cash flow hedges, which the Company uses to hedge the functional currency equivalent cash flows attributable to Canadian Dollar denominated payroll payments, the Company records the gains or losses resulting from changes in fair value of the derivative within accumulated other comprehensive income (loss) on the consolidated balance sheets and subsequently reclassified to the same line item as the hedged transaction on the consolidated statements of operations in the same period that the hedged transaction affects earnings. The Company includes cash flows related to foreign currency cash flow hedges within operating activities in its consolidated statements of cash flows as cash flows related to the hedged transaction are included in operating activities and as the Company’s derivative instruments do not contain a significant financing component.
For derivative instruments not designated as foreign currency cash flow hedges, which the Company uses as economic hedges of Canadian Dollar denominated payroll payments not hedged by derivative instruments designated as hedges, the Company records gains and losses resulting from changes in the fair value of the derivative within other income (expense) in its consolidated statements of operations, and the Company classifies cash flows within operating activities in its consolidated statements of cash flows.
The foreign currency forward contract is classified within Level 2 of the fair value hierarchy because the valuation inputs are based on quoted prices and market observable data of similar instruments in active markets, such as currency spot and forward rates.
Deferred purchase price receivables Deferred purchase price receivables
The Company receives a deferred purchase price as partial consideration for transferring cardholder receivables to a third-party financial institution. The Company initially records the deferred purchase price receivable at fair value. In addition, the Company has elected the fair value option for the subsequent measurement of its deferred purchase price receivable. The Company records changes in the fair value of its deferred purchase price receivable within other income, net. The Company reflects finance fee income on deferred purchase price receivables within payment solutions revenues.
Cardholder receivables Cardholder receivables
The Company’s cardholder receivables consist of self-pay patient accounts originated by the Company. The Company has elected the fair value option with respect to its cardholder receivables. As a result, cardholder receivables are initially and subsequently reported at fair value in the Company’s consolidated balance sheets. The Company records changes in the fair value of its cardholder receivables within other income, net. Patient repayment terms require monthly payments based on revolving credit schedules. Cardholder receivables have an estimated
average contractual maturity of 15 months. The Company is responsible for billing, collecting, and remitting the amount equal to the principal payment, less a service fee, to the healthcare provider.
The Company has full recourse against the healthcare providers for unpaid principal. If, at any point in time, the patient fails to make three consecutive minimum monthly payments, the unpaid balance is returned to the healthcare provider in exchange for extinguishment of the related due to provider liability.
Due to health care providers Due to healthcare providers
Due to healthcare providers represent a liability for cardholder receivable accounts which have been originated by the Company. The Company has elected the fair value option with respect to its due to healthcare providers liability. As a result, amounts due to healthcare providers are initially and subsequently reported at fair value in the Company’s consolidated balance sheets. The Company records changes in the fair value of its due to healthcare providers liability within other income, net. The due to healthcare providers liability is payable upon receipt of cash flows from the cardholder receivables. The due to healthcare provider liability is paid using cash flows from the cardholder receivables or is extinguished when the related cardholder receivables are returned to the healthcare provider.
Debt facilities Debt facilities
The Company accounts for debt instruments in accordance with applicable U.S. GAAP. Debt obligations are classified as current or long-term based on their contractual maturity dates and the Company’s intent and ability to refinance on a long-term basis. Amounts contractually due within one year of the balance sheet date are classified as current liabilities unless the Company has both the intent and the ability to refinance the obligation on a long-term basis under an existing financing arrangement as of the balance sheet date.
The initial carrying value of debt is recorded at the principal amount borrowed, net of unamortized discounts, premiums, issuance costs, and other deferred financing fees. The Company determines the expected term of debt based on contractual maturity, adjusted for any substantive call, put, prepayment, or extension features that are reasonably certain to be exercised. Interest expense is recognized using the effective interest method, which requires the Company to estimate the effective interest rate that exactly discounts the expected future cash payments over the expected term of the instrument to the net carrying amount at issuance. This assessment requires judgment, particularly when debt includes variable interest rates, payment-in-kind features, or other nonstandard terms.
The Company evaluates debt agreements for embedded features, including conversion options, put or call features, contingent interest provisions, and other terms that may require bifurcation as embedded derivatives. Embedded features are assessed to determine whether they are clearly and closely related to the host instrument or meet the definition of a derivative requiring separate accounting. When required, bifurcated embedded derivatives are recorded at fair value with changes in fair value recognized in earnings. The Company also evaluates whether debt instruments should be accounted for under specialized guidance, including convertible instrument or modification and extinguishment accounting, when applicable.
The Company classifies short-term debt as long-term if it is refinanced onto long-term debt prior to the issuance of the financial statements.
New accounting pronouncements New accounting pronouncements
Impact of recently adopted accounting pronouncements
On February 1, 2025, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, on a prospective basis, upon which the Company has provided greater disaggregation of information in the rate reconciliation, by both amounts and percentages, among prescribed categories, such as state and local income taxes, foreign tax effects, changes in valuation allowances and nontaxable or nondeductible items, among others. The Company also provided disaggregation of income taxes paid by U.S. federal and state income taxes and foreign income taxes. See Note 12 - Income taxes.
During the year ended January 31, 2026, the Company did not adopt any other accounting pronouncements that materially impacted the Company's financial statements.
Recent accounting pronouncements not yet adopted
In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. In January 2025, the FASB issued ASU 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, Clarifying the Effective Date. The new standards require companies to disclose disaggregated information about certain income statement expense line items. The provisions of ASU 2024-03, as amended by ASU 2025-01, are effective for annual periods beginning after December 15, 2026, and interim reporting periods in fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company plans to adopt ASU 2024-03 and ASU 2025-01 for annual periods beginning in the fiscal year ending January 31, 2028 and for interim periods beginning in the fiscal year ending January 31, 2029. The Company is currently evaluating the impact that ASU 2024-03 and ASU 2025-01 will have on its financial statements and related disclosures. The Company does not expect the disclosure changes that result from the adoption of ASU 2024-03 and ASU 2025-01 to materially impact its consolidated financial statements.
In July 2025, the FASB issued ASU 2025‑05, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, which amends ASC 326‑20 to introduce a practical expedient available to all entities that permits entities to assume that current economic conditions as of the balance‑sheet date do not change over the remaining life of current accounts receivable and current contract assets arising from transactions within the scope of ASC 606. The amendments are effective for annual periods beginning after December 15, 2025, and interim periods within those years, with early adoption permitted. The Company is currently evaluating the impact that ASU 2025-05 will have on its consolidated financial statements and related disclosures.
In September 2025, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other-Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. The ASU amends the existing standard to remove all references to prescriptive and sequential software development project stages. Under this guidance, eligible software development costs will begin capitalization when management has authorized and committed to funding the software project, and it is probable that the project will be completed and the software will be used to perform the function intended. In evaluating whether it is probable the project will be completed; management is required to consider whether there is significant uncertainty associated with the development activities of the software. This guidance is effective for all annual periods beginning after December 15, 2027, and for interim periods within those annual reporting periods, with early adoption permitted. The guidance may be applied on a prospective basis, a modified basis for in-process projects, or a retrospective basis. The Company is currently evaluating the impact of this ASU to determine the impact on the consolidated financial statements and related disclosures.
There are no other recently issued accounting pronouncements the Company has not yet adopted that will materially impact the Company's consolidated financial statements.
v3.26.1
Summary of significant accounting policies (Tables)
 12 Months Ended
Jan. 31, 2026
Accounting Policies [Abstract]  
Schedule of Property and Equipment
The Company depreciates property and equipment over the following estimated useful lives:
Useful life
(years)
PhreesiaPads and Arrivals Kiosks3
Computer equipment
3
Computer software
3 to 5
Hardware development
3
Property and equipment at January 31, 2026 and 2025 are as follows:
January 31,
20262025
PhreesiaPads and Arrivals Kiosks$16,523 $15,763 
Computer equipment
84,380 77,704 
Computer software
12,887 14,114 
Hardware development
577 575 
Furniture and fixtures
4 — 
Leasehold improvements154 — 
Total property and equipment$114,525 $108,156 
Less: accumulated depreciation(94,193)(84,505)
Property and equipment — net$20,332 $23,651 
v3.26.1
Composition of certain financial statement captions (Tables)
 12 Months Ended
Jan. 31, 2026
Composition Of Certain Financial Statement [Abstract]  
Schedule of Accrued Expenses
Accrued expenses at January 31, 2026 and 2025 are as follows:
January 31,
20262025
Payroll-related expenses and taxes$12,535 $12,016 
Stock-based compensation liability7,652 6,135 
Payment processing fees liability7,056 6,578 
Acquisition-related liabilities119 844 
Income and other tax liabilities2,674 2,503 
Information technology5,546 4,562 
Other5,675 4,822 
Total accrued expenses
$41,257 $37,460 
Schedule of Property and Equipment
The Company depreciates property and equipment over the following estimated useful lives:
Useful life
(years)
PhreesiaPads and Arrivals Kiosks3
Computer equipment
3
Computer software
3 to 5
Hardware development
3
Property and equipment at January 31, 2026 and 2025 are as follows:
January 31,
20262025
PhreesiaPads and Arrivals Kiosks$16,523 $15,763 
Computer equipment
84,380 77,704 
Computer software
12,887 14,114 
Hardware development
577 575 
Furniture and fixtures
4 — 
Leasehold improvements154 — 
Total property and equipment$114,525 $108,156 
Less: accumulated depreciation(94,193)(84,505)
Property and equipment — net$20,332 $23,651 
Schedule of Intangible Assets
The following presents the details of intangible assets as of January 31, 2026 and 2025.
Useful LifeJanuary 31,
(years)
2026
2025
Acquired technology
5 to 7
$22,910 $9,310 
Customer relationship
7 to 15
53,940 17,940 
License156,200 6,200 
Trademarks
12 to 15
10,200 3,100 
Total intangible assets, gross carrying value$93,250 $36,550 
Less: accumulated amortization(13,489)(8,407)
Net carrying value$79,761 $28,143 
Schedule of Estimated Amortization Expense for Intangible Assets
The estimated amortization expense for intangible assets for the next five years and thereafter is as follows as of January 31, 2026:
January 31, 2026
2027
$10,516 
2028
10,516 
2029
10,415 
2030
10,215 
2031
9,761 
Thereafter28,338 
Total$79,761 
Schedule of Goodwill
The following table presents a roll-forward of goodwill for the years ended January 31, 2026 and 2025:
Balance, January 31, 2024$75,845 
Balance, January 31, 2025
$75,845 
Goodwill acquired during the year ended January 31, 2026
94,219 
Balance, January 31, 2026
$170,064 
Schedule of Accounts Receivable
Accounts Receivable as of January 31, 2026 and 2025 are as follows:
January 31,
20262025
Billed$93,296 $70,342 
Unbilled5,680 4,743 
Total accounts receivable, gross$98,976 $75,085 
Less: accounts receivable allowances(1,523)(1,468)
Total accounts receivable$97,453 $73,617 
Schedule of Allowance for Doubtful Accounts
Activity in the Company's allowance for doubtful accounts was as follows for the years ended January 31, 2026 and 2025:
Balance, January 31, 2024
$1,392 
Bad debt expense1,054 
Write-offs and adjustments(978)
Balance, January 31, 2025
$1,468 
Bad debt expense1,021 
Write-offs and adjustments(966)
Balance, January 31, 2026
$1,523 
Schedule of Prepaid and Other Current Assets
Prepaid and other current assets as of January 31, 2026 and 2025 are as follows:
January 31,
20262025
Prepaid software and business systems$7,246 $6,849 
Prepaid data center expenses4,661 3,558 
Prepaid insurance1,721 912 
Other prepaid expenses and other current assets4,350 4,552 
Total prepaid and other current assets$17,978 $15,871 
v3.26.1
Revenue and contract costs (Tables)
 12 Months Ended
Jan. 31, 2026
Revenue from Contract with Customer [Abstract]  
Schedule of Sources of Revenue
The following table represents a summary of sources of revenue:
January 31,
20262025
2024
Revenue from contracts with customers
$467,819 $410,484 $345,992 
Revenue from other sources12,772 9,329 10,307 
Total revenues
$480,591 $419,813 $356,299 
Schedule of RollForward of Contract Assets and Contract Liabilities
The following table represents a roll-forward of contract assets:
January 31,
20262025
Beginning balance$4,743 $3,375 
Amount transferred to receivables from beginning balance of contract assets(4,706)(3,375)
Contract asset additions, net of reclassification to receivables5,643 4,743 
Ending balance$5,680 $4,743 
The following table represents a roll-forward of deferred revenue:
 January 31,
20262025
Beginning balance$32,877 $24,210 
Revenue recognized that was included in deferred revenue at the beginning of the period(31,719)(23,335)
Deferred revenue added from acquisitions8,475 — 
Other current year activity in deferred revenue40,133 32,002 
Ending balance$49,766 $32,877 
Schedule of Deferred Contract Acquisition Costs
The following table represents a roll-forward of deferred contract acquisition costs:
January 31,
20262025
Beginning balance$984 $1,754 
Additions to deferred contract acquisition costs334 1,045 
Amortization of deferred contract acquisition costs(570)(1,815)
Ending balance$748 $984 
Deferred contract acquisition costs, current (to be amortized in next 12 months)$410 $401 
Deferred contract acquisition costs, non-current338 583 
Total deferred contract acquisition costs$748 $984 
v3.26.1
Debt and finance leases (Tables)
 12 Months Ended
Jan. 31, 2026
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Instruments
As of January 31, 2026 and 2025, the Company had the following outstanding debt and finance lease liabilities:
January 31,
20262025
Bridge loan
$90,000 $— 
Finance leases7,431 14,256 
Accrued interest and payments2,062 24 
Financing arrangements595 1,913 
Total debt and finance lease liabilities
$100,088 $16,193 
Less: current portion of debt and finance lease liabilities
(7,971)(8,043)
Long-term debt and finance lease liabilities
$92,117 $8,150 
Schedule of Long-term Debt and Finance Lease Maturities
Maturities of debt and finance leases in each of the next five years and thereafter are as follows:
 Total
Bridge Loan
Finance LeasesOther Debt
Fiscal year ending January 31,
2027(1)
$97,971 $90,000 $5,314 $2,657 
2028
2,117 — 2,117 — 
2029
— — — — 
2030
— — — — 
2031
— — — — 
Thereafter
— — — — 
Total maturities of debt and finance leases
$100,088 $90,000 $7,431 $2,657 
(1) As of January 31, 2026, the Company had a Bridge Loan outstanding. Subsequent to year-end and prior to the issuance of the financial statements, the Company refinanced this obligation with long-term debt. Accordingly, the bridge loan has been classified as long-term on the balance sheet.
v3.26.1
Stockholders' equity (Tables)
 12 Months Ended
Jan. 31, 2026
Equity [Abstract]  
Schedule of Accumulated Other Comprehensive Loss
Activity in accumulated other comprehensive loss was as follows for the fiscal year ended January 31, 2026:
 
Unrealized gain on cash flow hedges
Foreign currency translation adjustment
Accumulated other comprehensive loss
Balance as of January 31, 2024$— $— $— 
Other comprehensive loss— (51)(51)
Balance as of January 31, 2025
$— $(51)$(51)
Balance, January 31, 2025$— $(51)$(51)
Other comprehensive income (loss) before reclassifications
182 (198)(16)
Amounts reclassified from accumulated other comprehensive loss(315)— (315)
Net current period other comprehensive loss$(133)$(198)$(331)
Balance, January 31, 2026
$(133)$(249)$(382)
v3.26.1
Equity-based compensation (Tables)
 12 Months Ended
Jan. 31, 2026
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock Based Compensation by Type of Award
The following table sets forth stock-based compensation by type of award:
For the fiscal years ended
January 31,
 202620252024
RSUs$37,814 $44,696 $53,474 
PSUs17,608 13,174 9,206 
Liability awards12,242 9,316 9,047 
ESPP833 1,149 1,256 
Stock options (1)
241 2 45 
Total stock-based compensation$68,738 $68,337 $73,028 
(1) Payments to stockholders of AccessOne in connection with AccessOne stock options accelerated in connection with the AccessOne acquisition.
Schedule of Stock Based Compensation in Financial Statements
The following table sets forth the presentation of stock-based compensation in the Company's consolidated financial statements:
For the fiscal years ended
January 31,
 202620252024
Stock-based compensation expense recorded to additional paid-in capital$56,255 $59,021 $63,981 
Stock-based compensation expense recorded to accrued expenses12,242 9,316 9,047 
Stock-based compensation expense paid in cash (1)
241 — — 
Total stock-based compensation$68,738 $68,337 $73,028 
Less: stock-based compensation expense capitalized as internal-use software(1,286)(1,362)(1,415)
Stock-based compensation expense per consolidated statements of operations$67,452 $66,975 $71,613 
(1) Payments to stockholders of AccessOne in connection with stock issued for stock options accelerated in connection with the AccessOne acquisition.
Schedule of Restricted Stock Unit Activity
Restricted stock units
Unvested, January 31, 2023
3,917,753 
Granted during year (1)
2,419,679 
Vested(1,912,432)
Forfeited and expired(624,790)
Unvested, January 31, 2024
3,800,210 
Granted during year
2,135,391 
Vested(1,897,716)
Forfeited and expired(439,937)
Unvested, January 31, 2025
3,597,948 
Granted during year
1,883,490 
Vested(1,578,301)
Forfeited and expired (410,175)
Unvested, January 31, 2026
3,492,962 
(1) Includes 24,125 awards granted pursuant to the 2023 Inducement Award Plan.
Schedule of Stock Option Activity
Stock option activity for the fiscal years ended January 31, 2026, 2025 and 2024 is as follows:
Number of
options		Weighted-
average
exercise price		Weighted-
average
remaining
contractual life
(in years)		Aggregate intrinsic
value
Outstanding — January 31, 20231,385,193 $6.26 
Granted during the year— $— 
Exercised(249,247)$3.42 
Forfeited and expired(12,508)$5.87 
Outstanding and expected to vest — January 31, 2024
1,123,438 $6.89 4.54$20,884 
Outstanding — January 31, 20241,123,438 $6.89 
Granted during the year— $— 
Exercised(220,523)$4.64 
Forfeited and expired(3,534)$20.67 
Outstanding and expected to vest — January 31, 2025
899,381 $7.39 3.66$18,952 
Outstanding — January 31, 2025899,381 $7.39 
Granted during the year— $— 
Exercised(237,516)$6.12 
Forfeited and expired(1,649)$10.60 
Outstanding and expected to vest — January 31, 2026
660,216 $7.84 2.83$3,767 
Exercisable — January 31, 2026
660,216 $7.84 2.83$3,767 
Amount vested during year ended January 31, 2026
— $— 
Schedule of Measurement Inputs and Valuation Techniques
The fair value of the PSUs granted during the fiscal years ended January 31, 2026, 2025 and 2024, respectively, was estimated using the following assumptions:
Fiscal years ended January 31,
 202620252024
Correlation coefficient0.4490 0.5305 0.5238 
Valuation date stock price$20.29 $25.19 $22.94 
Simulation term3.0 years3.0 years3.0 years
Volatility54.31 %64.18 %64.58 %
Risk-free rate3.56 %4.24 %4.05 %
Dividend yield— %— %— %
Weighted-average fair value of grants$29.22 $42.86 $36.42 
Schedule of Market-Based Performance Stock Unit Activity
Market-based PSU activity for the years ended January 31, 2026, 2025 and 2024 are as follows:
Performance
stock units
Outstanding, February 1, 2023
648,233 
Granted during the year ended January 31, 2024
576,680 
Vested(67,251)
Forfeited and expired(117,443)
Outstanding, February 1, 2024
1,040,219 
Granted during the year ended January 31, 2025
434,269 
Vested(255,269)
Forfeited(14,248)
Outstanding, February 1, 2025
1,204,971 
Granted during the year ended January 31, 2026
358,000 
Vested(214,702)
Forfeited— 
Outstanding, January 31, 2026
1,348,269 
Schedule of ESPP Valuation Assumptions
The fair value of shares granted under the ESPP during the year ended January 31, 2026 was estimated using a Black-Scholes pricing model with the following assumptions:
Year ended
January 31, 2026
Year ended
January 31, 2025
Year ended
January 31, 2024
Risk-free interest rate
3.83 %4.74 %5.30 %
Expected dividends
nonenonenone
Expected term (in years)
0.49 years0.49 years0.49 years
Volatility
51.31 %52.96 %62.41 %
v3.26.1
Fair value measurements (Tables)
 12 Months Ended
Jan. 31, 2026
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
The following table presents information about the Company's assets and liabilities that are measured at fair value on a recurring basis as of January 31, 2026 and indicates the classification of each item within the fair value hierarchy:
 Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant Other Observable Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Balance as of January 31, 2026
Assets
Money market mutual funds$44,945 $— $— $44,945 
Cardholder receivables(1)
— — 86,053 86,053 
Deferred purchase price receivable— — 23,425 23,425 
Total assets$44,945 $— $109,478 $154,423 
Liabilities
Foreign currency forward contracts
$— $148 $— $148 
Due to healthcare providers(2)
— — 83,385 83,385 
Total liabilities$— $148 $83,385 $83,533 
(1) The aggregate unpaid principal balance of cardholder receivables was $147,471 as of January 31, 2026. The difference between the aggregate fair value and the aggregate unpaid principal balance of cardholder receivables primarily reflects market‑participant assumptions for credit losses (defaults and recoveries), timing of collections, and liquidity/required returns embedded in the discounted cash flow valuation approach.
(2) The aggregate unpaid principal balance of due to healthcare providers was $144,802 as of January 31, 2026. The difference between the aggregate fair value and the aggregate unpaid principal balance of amounts due to healthcare providers primarily reflects market‑participant assumptions, timing of collections, and liquidity/required returns embedded in the discounted cash flow valuation approach similar to the related cardholder receivables.
The following table presents information about the Company's assets and liabilities that are measured at fair value on a recurring basis as of January 31, 2025 and indicates the classification of each item within the fair value hierarchy:
 Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant Other Observable Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Balance as of January 31, 2025
Assets
Money market mutual funds$66,588 $— $— $66,588 
Total assets$66,588 $— $— $66,588 
Schedule of Reconciliation of Changes in Level 3 Instruments Measured on a Recurring Basis, Asset
The following table summarizes the activity related to the aggregate fair value of the Company’s cardholder receivables:
 
January 31, 2026
Beginning balance
$— 
Acquisitions(1)
93,191 
Originations17,585 
Sales and settlements
(14,577)
Cash collections
(12,709)
Gains (losses) recognized in earnings2,563 
Ending balance
$86,053 
(1) Represents the Closing Date fair value of cardholder receivables. See Note 18 - Acquisitions.
The following table summarizes the activity related to the aggregate fair value of the Company’s deferred purchase price receivable:
 January 31, 2026
Beginning balance$— 
Acquisitions(1)
24,519 
Deferred purchase price received for sale of receivables886 
Cash Collections(3,000)
Gains (losses) recognized in earnings1,020 
Ending balance$23,425 
(1) Represents the Closing Date fair value of deferred purchase price receivable. See Note 18 - Acquisitions.
The following sensitivity analysis shows the potential decrease of the fair value of the Company’s deferred purchase price receivable based on hypothetical changes in key assumptions including the discount rate and repayment rate as of January 31, 2026:
Discount RateRepayment Rate
10% adverse change$(257)$(1,261)
20% adverse change$(373)$(1,987)
The following tables present the range and weighted‑average of the significant unobservable inputs used in Level 3 fair value measurements:
Cardholder receivables
January 31, 2026
Unobservable Input
Minimum
Maximum
Weighted- Average(1)
Discount rate
14.21%15.21%14.71%
Default rate
27.00%33.00%30.00%
(1) Weighted-average shown as a representative midpoint within the disclosed range.
Deferred purchase price receivable
January 31, 2026
Unobservable Input
Minimum
Maximum
Weighted- Average(1)
Discount rate
7.25%10.75%9.00%
Funded monthly repayment rate4.50%5.50%5.00%
(1) Weighted-average shown as a representative midpoint within the disclosed range.
Schedule of Reconciliation of Changes in Level 3 Instruments Measured on a Recurring Basis, Liability
The following table summarizes the activity related to the aggregate fair value of amounts due to healthcare providers:
 January 31, 2026
Beginning balance$— 
Acquisitions(1)
90,454 
Additions(2)
17,585 
Cash remittances to healthcare providers(27,217)
Gains (losses) recognized in earnings2,563 
Ending balance$83,385 
(1) Represents the Closing Date fair value of due to healthcare providers. See Note 18 - Acquisitions.
(2) Represents new obligations arising from patient payments or receivable activity before remittance.
Due to healthcare providers
January 31, 2026
Unobservable Input
Minimum
Maximum
Weighted- Average(1)
Discount rate
14.21%15.21%14.71%
Default rate
27.00%33.00%30.00%
(1) Weighted-average shown as a representative midpoint within the disclosed range.
v3.26.1
Leases (Tables)
 12 Months Ended
Jan. 31, 2026
Leases [Abstract]  
Schedule of Operating and Finance Leases
Supplemental balance sheet information related to operating and finance leases as of January 31, 2026 and 2025 was as follows:
January 31,
20262025
Operating leases:
Lease right-of-use assets$2,002 $1,477 
Lease liabilities, current$1,254 $964 
Lease liabilities, non-current1,107 646 
Total operating lease liabilities$2,361 $1,610 
Finance leases:
Property and equipment, at cost$49,009 $49,009 
Accumulated depreciation(42,060)(34,815)
Property and equipment, net$6,949 $14,194 
Lease liabilities, current (included in Current portion of debt and finance lease liabilities)
$5,314 $6,825 
Lease liabilities, non-current (included in Long-term debt and finance lease liabilities)
2,117 7,431 
Total finance lease liabilities$7,431 $14,256 
Schedule of Lease Expense and Cash Flow Information
The components of lease expense for the years ended January 31, 2026, 2025 and 2024 were as follows:
Fiscal years ended
January 31,
202620252024
Operating leases:
Operating lease cost$954 $983 $740 
Variable lease cost— — 47 
Total operating lease cost$954 $983 $787 
Finance leases:
Amortization of right-of-use assets$7,245 $7,416 $6,742 
Interest on lease liabilities879 980 580 
Total finance lease cost$8,124 $8,396 $7,322 
Other supplemental cash flow information for the years ended January 31, 2026, 2025 and 2024 was as follows:
Fiscal years ended
January 31,
202620252024
Supplemental cash flow information
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash used for operating leases$1,147 $1,023 $1,238 
Operating cash used for finance leases$879 $980 $535 
Financing cash used for finance leases$6,825 $7,811 $6,779 
Schedule of Maturing Lease Commitments of Operating Leases
The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2026:
January 31, 2026
OperatingFinance
Maturity of lease liabilities
Fiscal year ending January 31,
2027
$1,318 $5,688 
2028
793 2,169 
2029
292 — 
Total future minimum lease payments$2,403 $7,857 
Less: interest(42)(426)
Present value of lease liabilities$2,361 $7,431 
Schedule of Maturing Lease Commitments of Finance Leases
The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2026:
January 31, 2026
OperatingFinance
Maturity of lease liabilities
Fiscal year ending January 31,
2027
$1,318 $5,688 
2028
793 2,169 
2029
292 — 
Total future minimum lease payments$2,403 $7,857 
Less: interest(42)(426)
Present value of lease liabilities$2,361 $7,431 
v3.26.1
Commitments and contingencies (Tables)
 12 Months Ended
Jan. 31, 2026
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Minimum Payments Under Purchase Commitments
Other contractual commitments consist primarily of non-cancelable purchase commitments to support the Company’s technology infrastructure as well as commitments related to its acquisition.
Future minimum payments under the Company’s non-cancelable contractual commitments as of January 31, 2026 are presented in the table below.
Purchase obligations
Fiscal year ending January 31,
2027
$11,621 
2028
4,705 
2029
742 
Total$17,068 
v3.26.1
Income taxes (Tables)
 12 Months Ended
Jan. 31, 2026
Income Tax Disclosure [Abstract]  
Schedule of Income (Loss) before Income Tax, Domestic and Foreign
The following table sets forth the Company’s income (loss) before income taxes disaggregated between domestic and foreign for fiscal 2026, 2025 and 2024:
Fiscal years ended January 31,
202620252024
Domestic $(13,505)$(63,782)$(138,629)
Foreign4,565 7,971 3,287 
Total loss before income taxes$(8,940)$(55,811)$(135,342)
Schedule of Income Tax (Benefit)
The Company's income tax provision consisted of the following for fiscal 2026, 2025 and 2024:
Fiscal years ended January 31,
202620252024
Current tax
Federal$— $— $— 
State356 102 76 
Foreign1,669 2,400 1,239 
Deferred tax
Federal(12,581)214 38 
State903 — — 
Foreign(1,593)— 190 
Total provision for income taxes$(11,246)$2,716 $1,543 
Schedule of Income Taxes Paid
The following table sets forth the Company’s income taxes paid by major jurisdiction for fiscal 2026 (in thousands):
Fiscal years ended January 31, 2026
Federal
$— 
State and local
Texas
7 
Total state and local7 
Foreign
India
516 
Canada
1,374 
Total foreign1,890 
Total income taxes paid$1,897 
Schedule of Effective Tax Rate Reconciliation A reconciliation of the statutory U.S. federal rate and effective rate for the year ended January 31, 2026, after the adoption of ASU 2023-09, is as follows:
Fiscal years ended January 31, 2026
Amount%
Federal income tax benefit at statutory rate$(1,877)21 %
State and local tax, net of federal benefit994 (11)%
Foreign tax effects
India 68 (1)%
Canada(275)3 %
Federal tax credits(1,034)12 %
Changes in valuation allowances on federal deferred tax assets(18,857)211 %
Effect of nontaxable or non-deductible items on federal income taxes
Stock based compensation5,056 (57)%
Transaction Cost1,730 (19)%
Capitalized Internal-Use Software2,049 (23)%
Section 162(m)656 (8)%
Other125 (1)%
Changes in unrecognized tax benefits119 (1)%
Benefit for income taxes$(11,246)126 %
A reconciliation of the statutory U.S. federal income tax rate to the Company's effective tax rate for fiscal 2025 and 2024 prior to the adoption of ASU 2023-09 is as follows:
Fiscal years ended January 31,
20252024
Federal income tax benefit at statutory rate21 %21 %
State and local tax, net of federal benefit4 %3 %
Permanent differences1 %— %
Equity compensation(6)%— %
Foreign taxes(3)%(1)%
Other— %— %
Change in valuation allowance(22)%(24)%
Effective income tax rate(5)%(1)%
Schedule of Deferred Tax Assets and Liabilities
The significant components of the Company's deferred tax assets and liabilities as of January 31, 2026 and 2025 are as follows:
January 31,
Deferred tax assets:20262025
Net operating loss carryforwards$170,985 $160,998 
Stock based compensation12,125 9,495 
Accruals, reserves, and other expenses(1)
3,809 3,129 
Disallowed interest expense— 969 
Depreciation and amortization— 1,412 
Capitalized R&D Expense(1)
23,835 23,897 
Cardholder Receivable15,779 — 
Other109 — 
Total deferred tax assets$226,642 $199,900 
Less: valuation allowance(176,652)(188,712)
Net deferred tax assets$49,990 $11,188 
Deferred tax liabilities:
Depreciation and amortization$(7,741)$— 
Intangible assets(12,818)(340)
Capitalized internal-use-software(1)
(14,623)(11,074)
Due to Healthcare Provider(15,660)— 
Other(1)
(2,053)(258)
Total deferred tax liabilities$(52,895)$(11,672)
Net deferred tax liabilities$(2,905)$(484)
(1) Prior year amounts have been reclassified to conform to the current year presentation.
Schedule of Unrecognized Tax Benefits
The following is a roll-forward of the Company's total gross unrecognized tax benefits for fiscal 2026:
Balance, January 31, 2023$— 
Increases for income tax positions related to prior years844 
Increases for income tax positions related to current years396 
Balance, January 31, 2024
$1,240 
Increases for income tax positions related to prior years— 
Increases for income tax positions related to current years365 
Balance, January 31, 2025
$1,605 
Increases for income tax positions related to prior years— 
Increases for income tax positions related to current years305 
Balance, January 31, 2026
$1,910 
v3.26.1
Net income (loss) per share attributable to common stockholders (Tables)
 12 Months Ended
Jan. 31, 2026
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
Basic and diluted net income (loss) per share attributable to common stockholders was calculated as follows:
Fiscal years ended January 31,
202620252024
Basic net income (loss) per share
Numerator:
Net income (loss)
$2,306 $(58,527)$(136,885)
Denominator:
Weighted-average shares of common stock outstanding, basic
59,737,915 57,589,687 54,561,449 
Basic net income (loss) per share attributable to common stockholders:
$0.04 $(1.02)$(2.51)
Diluted net income (loss) per share
Numerator:
Net income (loss)
$2,306 $(58,527)$(136,885)
Denominator:
Number of shares used for basic net income (loss) per computation59,737,915 57,589,687 54,561,449 
RSUs
698,122 — — 
PSUs
555,972 — — 
Stock options
335,357 — — 
Liability awards
148,271 — — 
ESPP
19,241 — — 
Weighted-average shares of common stock outstanding, diluted
61,494,878 57,589,687 54,561,449 
Diluted net income (loss) per share attributable to common stockholders:
$0.04 $(1.02)$(2.51)
Schedule of Shares Excluded from Computation of Diluted Net Loss Per Share The following potential shares of common stock, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net income (loss) per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
Fiscal years ended January 31,
202620252024
Stock options to purchase common stock, restricted stock units and performance stock awards1,580,596 6,577,715 7,273,621 
Employee stock purchase plan109,152 71,848 91,452 
Total1,689,748 6,649,563 7,365,073 
v3.26.1
Segments and geographic information (Tables)
 12 Months Ended
Jan. 31, 2026
Segment Reporting [Abstract]  
Schedule of Information About Segment Revenue, Segment Profit or Loss, Significant Segment Expenses and Other Quantitative Segment Disclosures
The following table presents the Company’s segment revenue, segment profit (loss), significant segment expenses, and other segment items, as well as a reconciliation from segment profit (loss) to consolidated net income (loss).
Fiscal years ended January 31,
202620252024
Revenue
$480,591 $419,813 $356,299 
Labor costs (1)
193,362224,792238,533
Payment solutions expense
82,75868,70762,986
Third-party non-labor operating expenses
102,95589,55090,159
Stock-based compensation
67,45266,97571,613
Other segment items
31,75828,31629,893
Segment net income (loss)
$2,306 $(58,527)$(136,885)
Reconciliation of profit or loss
Adjustments and reconciling items
$— $— $— 
Consolidated net income (loss)
$2,306 $(58,527)$(136,885)
(1) Excludes stock-based compensation expense which is presented separately
The following table presents other quantitative segment disclosures for the fiscal years ended January 31, 2026, 2025 and 2024, respectively.
Fiscal years ended January 31,
202620252024
Depreciation and amortization
$31,453 $27,886 $29,487 
Interest expense
$(6,953)$(2,347)$(1,854)
Interest income
$2,173 $2,677 $4,065 
Loss on extinguishment of debt$(501)$— $(1,118)
Gain on settlement (included in other income, net)
$— $2,345 $— 
Income tax benefit (expense)
$11,246 $(2,716)$(1,543)
Expenditures for long-lived assets
$176,246 $25,940 $96,474 
v3.26.1
Derivative instruments and hedging activities (Tables)
 12 Months Ended
Jan. 31, 2026
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Fair Values Of Outstanding Derivative Foreign Currency Forward Contract
The fair values of outstanding derivative foreign currency forward contract was as follows:
January 31,
Consolidated balance sheet location
2026
2025
Foreign currency cash flow hedges
Accrued expenses
$133 $— 
Non-designated hedges
Accrued expenses
14 — 
Schedule of Derivative Instruments, Gain (Loss)
The effect of derivative instruments on the Company’s consolidated statements of operations were as follows:
Consolidated statements of operations location
Fiscal years ended January 31,
2026
2025
2024
Foreign currency cash flow hedges
Expenses$(315)$— $— 
Foreign currency cash flow hedges
Income tax benefit (expense)
— — — 
Non-designated hedges
Other income, net
217 — — 
Pre-tax gains (losses) associated with cash flow hedges were as follows:
Consolidated statements of operations and Statements of comprehensive income (loss) locations
Fiscal years ended January 31,
 
2026
2025
2024
Gains recognized in accumulated other comprehensive income (included in assessment of effectiveness)
Unrealized gain on cash flow hedge
$182 $— $— 
Gains reclassified from accumulated other comprehensive income into income (effective portion)Expenses(315)— — 
Tax effect reclassified from accumulated other comprehensive income into income (effective portion)
Income tax benefit (expense)
— — — 
v3.26.1
Acquisitions (Tables)
 12 Months Ended
Jan. 31, 2026
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Schedule of Consideration Transferred for Acquisition
The following table summarizes the calculation of cash paid for the AccessOne Acquisition, net of cash acquired per the Company's consolidated statements of cash flows for the year ended January 31, 2026.
Cash consideration paid to sellers$163,666 
Less: cash and restricted cash acquired
(10,474)
Cash paid for acquisitions, net of cash and restricted cash acquired per statements of cash flows
$153,192 
The following table summarizes the estimated acquisition-date fair value of consideration transferred for each acquisition:
MediFindAccessConnectOnCallTotal
Cash consideration paid to sellers$4,195 $6,766 $3,946 $14,907 
Equity consideration paid to sellers4,676 30,645 — 35,321 
Liabilities incurred to sellers— — 10,000 10,000 
Total fair value of acquisition consideration$8,871 $37,411 $13,946 $60,228 
The following table summarizes the calculation of cash paid for each acquisition, net of cash acquired per the Company's consolidated statements of cash flows for the fiscal year ended January 31, 2024.

MediFindAccessConnectOnCallTotal
Cash consideration paid to sellers$4,195 $6,766 $3,946 $14,907 
Less: cash acquired(231)(80)(23)(334)
Cash paid for acquisitions, net of cash acquired per statements of cash flows$3,964 $6,686 $3,923 $14,573 
Schedule of Allocation of Purchase Price of Assets Acquired and Liabilities Assumed
The following table summarizes the preliminary purchase price allocation of the fair values of the assets acquired and liabilities assumed at the Closing Date:
Amounts Recognized as of the Closing Date
(Preliminary)
Cash and restricted cash$10,474 
Accounts receivable708 
Cardholder receivables42,537 
Deferred purchase price receivable19,615 
Accrued interest and fees receivable394 
Other current assets376 
Property and equipment255 
Operating lease right-of-use assets1,439 
Identified intangible assets acquired56,700 
Goodwill94,219 
Long-term cardholder receivables50,654 
Long-term deferred purchase price receivable4,904 
Other assets208 
Total assets acquired282,483 
Current portion of operating lease liabilities(685)
Accounts payable(651)
Accrued liabilities(1,434)
Current portion of due to healthcare providers(40,669)
Deferred revenue(8,522)
Other current liabilities(166)
Long-term deferred revenue(39)
Operating lease liabilities, non-current(1,174)
Long-term deferred tax liabilities(15,692)
Long-term due to healthcare providers(49,785)
Total purchase price$163,666 
Schedule of Estimate of Contractual Cash Flows not Expected to be Collected for Cardholder Receivables The following table presents the fair value, gross contractual amounts receivable, and the Company’s best estimate of contractual cash flows not expected to be collected for cardholder receivables as of the Closing Date:
Cardholder Receivables
(Preliminary)
Fair value$93,191 
Gross contractual amounts receivable$157,208 
Best estimate of contractual cash flows not expected to be collected$58,735 
Schedule of Intangible Assets Acquired
The following table sets forth the preliminary amounts, allocated to the intangible assets identified and their estimated useful lives as of the Closing Date:
Estimated Useful Life
(in Years)		Fair Value
Trademark12$7,100 
Technology613,600 
Customer relationships836,000 
Total identifiable intangible assets acquired$56,700 
Schedule of Business Combination Pro Forma Information
Accordingly, the following unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operations of the combined company would have been if the AccessOne Acquisition had occurred at the beginning of fiscal year 2025, nor are they indicative of future results of operations:
Year ended January 31,
20262025
Revenue
$516,438 $469,030 
Net income (loss)$2,168 $(61,929)
v3.26.1
Background and liquidity (Details) - USD ($)
$ in Thousands
Mar. 13, 2026
Jan. 28, 2026
Nov. 12, 2025
Jan. 31, 2026
Debt Instrument [Line Items]        
Long-term debt       $ 2,657
Bridge Loan        
Debt Instrument [Line Items]        
Debt instrument, term (in months/years)     364 days  
Debt instrument, face amount     $ 110,000 $ 90,000
Debt instrument, repaid, principal   $ 20,000    
Second Capital One Credit Facility | Subsequent Event        
Debt Instrument [Line Items]        
Debt instrument, term (in months/years) 5 years      
Long-term debt $ 275,000      
Number of months with sufficient funds to operate (in months) 12 months      
v3.26.1
Summary of significant accounting policies - Narrative (Details)
 12 Months Ended
Jan. 31, 2026
USD ($)
processor
Jan. 31, 2025
USD ($)
Jan. 31, 2024
USD ($)
Accounting Policies [Line Items]      
Number of third party payment processors | processor 2    
Advertising expense $ 1,754,000 $ 1,675,000 $ 1,900,000
Allowance for doubtful accounts 1,523,000 1,468,000 1,392,000
Asset impairment charges $ 0 0 $ 0
Cardholder receivables average contractual maturity (in months) 15 months    
Securitization Program      
Accounting Policies [Line Items]      
Restricted cash $ 1,691,000 0  
ESPP      
Accounting Policies [Line Items]      
Employee purchase price of common stock (as a percent) 85.00%    
Credit and Securitization Agreements | Securitization Program      
Accounting Policies [Line Items]      
Debt instrument, covenant, minimum liquidity   $ 3,500,000  
Revenue Benchmark | Customer Concentration Risk | One Customer      
Accounting Policies [Line Items]      
Concentration risk, percentage 10.00% 10.00%  
Minimum      
Accounting Policies [Line Items]      
Customer payment period (in days) 30 days    
Settlement period (in days) 1 day    
Minimum | Computer software      
Accounting Policies [Line Items]      
Finite-lived intangible asset, useful life (in years) 3 years    
Maximum      
Accounting Policies [Line Items]      
Customer payment period (in days) 60 days    
Settlement period (in days) 2 days    
Maximum | Computer software      
Accounting Policies [Line Items]      
Finite-lived intangible asset, useful life (in years) 5 years    
v3.26.1
Summary of significant accounting policies - Schedule of Property and Equipment (Details)
Jan. 31, 2026
PhreesiaPads and Arrivals Kiosks  
Property, Plant and Equipment [Line Items]  
Useful life (years) 3 years
Computer equipment  
Property, Plant and Equipment [Line Items]  
Useful life (years) 3 years
Computer software | Maximum  
Property, Plant and Equipment [Line Items]  
Useful life (years) 5 years
Computer software | Minimum  
Property, Plant and Equipment [Line Items]  
Useful life (years) 3 years
Hardware development  
Property, Plant and Equipment [Line Items]  
Useful life (years) 3 years
v3.26.1
Composition of certain financial statement captions - Schedule of Accrued Expenses (Details) - USD ($)
$ in Thousands
Jan. 31, 2026
Jan. 31, 2025
Composition Of Certain Financial Statement [Abstract]    
Payroll-related expenses and taxes $ 12,535 $ 12,016
Stock-based compensation liability 7,652 6,135
Payment processing fees liability 7,056 6,578
Acquisition-related liabilities 119 844
Income and other tax liabilities 2,674 2,503
Information technology 5,546 4,562
Other 5,675 4,822
Total accrued expenses $ 41,257 $ 37,460
v3.26.1
Composition of certain financial statement captions - Schedule of Property and Equipment (Details) - USD ($)
$ in Thousands
Jan. 31, 2026
Jan. 31, 2025
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 114,525 $ 108,156
Less: accumulated depreciation (94,193) (84,505)
Property and equipment — net 20,332 23,651
PhreesiaPads and Arrivals Kiosks    
Property, Plant and Equipment [Line Items]    
Total property and equipment 16,523 15,763
Computer equipment    
Property, Plant and Equipment [Line Items]    
Total property and equipment 84,380 77,704
Computer software    
Property, Plant and Equipment [Line Items]    
Total property and equipment 12,887 14,114
Hardware development    
Property, Plant and Equipment [Line Items]    
Total property and equipment 577 575
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Total property and equipment 4 0
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 154 $ 0
v3.26.1
Composition of certain financial statement captions - Narrative (Details) - USD ($)
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Finite-Lived Intangible Assets [Line Items]      
Depreciation $ 12,972,000 $ 14,183,000 $ 17,584,000
Property and equipment, at cost 49,009,000 49,009,000  
Accumulated depreciation (42,060,000) (34,815,000)  
Capitalized cost of computer software 14,907,000 16,846,000 19,521,000
Capitalized computed software amortization 13,399,000 10,222,000 9,527,000
Amortization of intangible assets $ 5,082,000 3,481,000 2,376,000
Market capitalization exceeded carrying value of equity percentage 100.00%    
Impairment of goodwill $ 0 0 0
Accounts receivable, allowance for credit loss, write-off 0 0 0
Capitalized implementation costs 1,532,000 1,532,000  
Capitalized implementation costs, accumulated amortization (1,532,000) (1,432,000)  
Other income, net 2,953,000 1,956,000 44,000
Contingent consideration, settlement gain $ 0 2,345,000 $ 0
ConnectOnCall      
Finite-Lived Intangible Assets [Line Items]      
Contingent consideration, settlement gain   $ 2,345,000  
Acquired technology      
Finite-Lived Intangible Assets [Line Items]      
Finite-lived intangible assets, remaining amortization period (in years) 5 years 4 months 24 days 5 years 1 month 6 days  
Customer relationship      
Finite-Lived Intangible Assets [Line Items]      
Finite-lived intangible assets, remaining amortization period (in years) 8 years 7 months 6 days 11 years 7 months 6 days  
License      
Finite-Lived Intangible Assets [Line Items]      
Finite-lived intangible assets, remaining amortization period (in years) 10 years 9 months 18 days 11 years 9 months 18 days  
Trademarks      
Finite-Lived Intangible Assets [Line Items]      
Finite-lived intangible assets, remaining amortization period (in years) 12 years 13 years 6 months  
Computer equipment      
Finite-Lived Intangible Assets [Line Items]      
Property and equipment, at cost $ 49,009,000 $ 49,009,000  
Accumulated depreciation $ (42,060,000) $ (34,815,000)  
v3.26.1
Composition of certain financial statement captions - Schedule of Intangible Assets (Details) - USD ($)
$ in Thousands
Jan. 31, 2026
Jan. 31, 2025
Finite-Lived Intangible Assets [Line Items]    
Total intangible assets, gross carrying value $ 93,250 $ 36,550
Less: accumulated amortization (13,489) (8,407)
Net carrying value 79,761 28,143
Acquired technology    
Finite-Lived Intangible Assets [Line Items]    
Total intangible assets, gross carrying value $ 22,910 9,310
Acquired technology | Minimum    
Finite-Lived Intangible Assets [Line Items]    
Useful life (in years) 5 years  
Acquired technology | Maximum    
Finite-Lived Intangible Assets [Line Items]    
Useful life (in years) 7 years  
Customer relationship    
Finite-Lived Intangible Assets [Line Items]    
Total intangible assets, gross carrying value $ 53,940 17,940
Customer relationship | Minimum    
Finite-Lived Intangible Assets [Line Items]    
Useful life (in years) 7 years  
Customer relationship | Maximum    
Finite-Lived Intangible Assets [Line Items]    
Useful life (in years) 15 years  
License    
Finite-Lived Intangible Assets [Line Items]    
Useful life (in years) 15 years  
Total intangible assets, gross carrying value $ 6,200 6,200
Trademarks    
Finite-Lived Intangible Assets [Line Items]    
Total intangible assets, gross carrying value $ 10,200 $ 3,100
Trademarks | Minimum    
Finite-Lived Intangible Assets [Line Items]    
Useful life (in years) 12 years  
Trademarks | Maximum    
Finite-Lived Intangible Assets [Line Items]    
Useful life (in years) 15 years  
v3.26.1
Composition of certain financial statement captions - Schedule of Estimated Amortization Expense for Intangible Assets (Details) - USD ($)
$ in Thousands
Jan. 31, 2026
Jan. 31, 2025
Composition Of Certain Financial Statement [Abstract]    
2027 $ 10,516  
2028 10,516  
2029 10,415  
2030 10,215  
2031 9,761  
Thereafter 28,338  
Net carrying value $ 79,761 $ 28,143
v3.26.1
Composition of certain financial statement captions - Schedule of Goodwill (Details)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
USD ($)
Goodwill [Roll Forward]  
Goodwill balance at beginning of period $ 75,845
Goodwill acquired during the year 94,219
Goodwill balance at end of period $ 170,064
v3.26.1
Composition of certain financial statement captions - Schedule of Accounts Receivable (Details) - USD ($)
$ in Thousands
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Composition Of Certain Financial Statement [Abstract]      
Billed $ 93,296 $ 70,342  
Unbilled 5,680 4,743  
Total accounts receivable, gross 98,976 75,085  
Less: accounts receivable allowances (1,523) (1,468) $ (1,392)
Total accounts receivable $ 97,453 $ 73,617  
v3.26.1
Composition of certain financial statement captions - Schedule of Allowance for Doubtful Accounts (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Accounts Receivable, Allowance for Credit Loss [Roll Forward]    
Allowance for doubtful accounts at beginning of period $ 1,468 $ 1,392
Bad debt expense 1,021 1,054
Write-offs and adjustments (966) (978)
Allowance for doubtful accounts at end of period $ 1,523 $ 1,468
v3.26.1
Composition of certain financial statement captions - Schedule of Prepaid and Other Current Assets (Details) - USD ($)
$ in Thousands
Jan. 31, 2026
Jan. 31, 2025
Composition Of Certain Financial Statement [Abstract]    
Prepaid software and business systems $ 7,246 $ 6,849
Prepaid data center expenses 4,661 3,558
Prepaid insurance 1,721 912
Other prepaid expenses and other current assets 4,350 4,552
Total prepaid and other current assets $ 17,978 $ 15,871
v3.26.1
Revenue and contract costs - Schedule of Sources of Revenue (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Revenue from Contract with Customer [Abstract]      
Revenue from contracts with customers $ 467,819 $ 410,484 $ 345,992
Revenue from other sources 12,772 9,329 10,307
Total revenues $ 480,591 $ 419,813 $ 356,299
v3.26.1
Revenue and contract costs - Schedule of RollForward of Contract Assets and Contract Liabilities (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Contract With Customer Asset [Roll Forward]    
Beginning balance $ 4,743 $ 3,375
Amount transferred to receivables from beginning balance of contract assets (4,706) (3,375)
Contract asset additions, net of reclassification to receivables 5,643 4,743
Ending balance 5,680 4,743
Contract With Customer Liability [Roll Forward]    
Beginning balance 32,877 24,210
Revenue recognized that was included in deferred revenue at the beginning of the period (31,719) (23,335)
Deferred revenue added from acquisitions 8,475 0
Other current year activity in deferred revenue 40,133 32,002
Ending balance $ 49,766 $ 32,877
v3.26.1
Revenue and contract costs - Narrative (Details) - USD ($)
 3 Months Ended 12 Months Ended
Jan. 31, 2026
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Jan. 30, 2025
Revenue from External Customer [Line Items]          
Capitalized contract cost, amortization   $ 570,000 $ 1,815,000 $ 1,056,000  
Deferred contract acquisition costs, amortization period (in years)     3 years   5 years
Capitalized contract cost, additional amortization $ 1,198,000        
Capitalized contract cost, impairment loss   $ 0 $ 0 $ 0  
Minimum          
Revenue from External Customer [Line Items]          
Capitalized contract cost, amortization period (in years) 3 years 3 years      
Maximum          
Revenue from External Customer [Line Items]          
Capitalized contract cost, amortization period (in years) 5 years 5 years      
v3.26.1
Revenue and contract costs - Schedule of Deferred Contract Acquisition Costs (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Capitalized Contract Cost [Roll Forward]      
Capitalized contract costs at beginning of period $ 984 $ 1,754  
Additions to deferred contract acquisition costs 334 1,045  
Amortization of deferred contract acquisition costs (570) (1,815) $ (1,056)
Capitalized contract costs at end of period 748 984 1,754
Deferred contract acquisition costs, current (to be amortized in next 12 months) 410 401  
Deferred contract acquisition costs, non-current 338 583  
Total deferred contract acquisition costs $ 748 $ 984 $ 1,754
v3.26.1
Debt and finance leases - Schedule of Outstanding Loan Balances (Details) - USD ($)
$ in Thousands
Jan. 31, 2026
Jan. 31, 2025
Debt Instrument [Line Items]    
Bridge loan $ 90,000 $ 0
Finance leases 7,431 14,256
Long-term debt 2,657  
Total debt and finance lease liabilities 100,088 16,193
Less: current portion of debt and finance lease liabilities (7,971) (8,043)
Long-term debt and finance lease liabilities 92,117 8,150
Accrued interest and payments    
Debt Instrument [Line Items]    
Long-term debt 2,062 24
Financing arrangements    
Debt Instrument [Line Items]    
Long-term debt $ 595 $ 1,913
v3.26.1
Debt and finance leases - Narrative (Details) - USD ($)
 1 Months Ended 12 Months Ended
Jan. 31, 2026
Jan. 28, 2026
Nov. 12, 2025
Dec. 31, 2023
Jun. 30, 2023
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Debt Instrument [Line Items]                
Loss on extinguishment of debt           $ 501,000 $ 0 $ 1,118,000
Long-term debt $ 2,657,000         2,657,000    
Financing arrangements                
Debt Instrument [Line Items]                
Debt instrument, term (in months/years)         36 months      
Long-term debt 595,000         595,000 $ 1,913,000  
Installment payment, amount         $ 123,000      
Effective interest rate percentage         10.50%      
Bridge Loan                
Debt Instrument [Line Items]                
Debt instrument, repaid, principal   $ 20,000,000            
Debt instrument, term (in months/years)     364 days          
Third SVB Facility | Revolving Credit Facility                
Debt Instrument [Line Items]                
Loss on extinguishment of debt       $ 1,118,000        
Line of Credit | Bridge Credit Agreement | Bridge Loan                
Debt Instrument [Line Items]                
Line of credit facility, expiration period (in days)     364 days          
Line of credit borrowing capacity     $ 110,000          
Debt instrument, basis spread on variable rate (as percent)     4.00%          
Debt instrument, interest rate, increase (decrease) (as percent)     0.50%          
Line of credit facility, outstanding amount 90,000              
Debt instrument, unamortized discount (premium) and debt issuance costs, net $ 3,122,000         $ 3,122,000    
Revolving Credit Facility | Senior Secured Asset-based Revolving Credit Facility | Line of Credit                
Debt Instrument [Line Items]                
Line of credit borrowing capacity       $ 50,000        
Debt instrument, term (in months/years)       5 years        
Interest rate (as a percent)           6.70%    
Quarterly fee (as a percent)       0.25%        
Debt issuance costs       $ 778,000        
Bridge Loan | Senior Secured Asset-based Revolving Credit Facility | Line of Credit                
Debt Instrument [Line Items]                
Line of credit borrowing capacity       5,000        
Letter of Credit | Senior Secured Asset-based Revolving Credit Facility | Line of Credit                
Debt Instrument [Line Items]                
Line of credit borrowing capacity       $ 5,000        
v3.26.1
Debt and finance leases - Schedule of Long-term Debt and Finance Lease Maturities (Details) - USD ($)
$ in Thousands
Jan. 31, 2026
Jan. 31, 2025
Total    
2027 $ 97,971  
2028 2,117  
2029 0  
2030 0  
2031 0  
Thereafter 0  
Total maturities of debt and finance leases 100,088  
Bridge Loan    
2027 90,000  
2028 0  
2029 0  
2030 0  
2031 0  
Thereafter 0  
Bridge Loan 90,000 $ 0
Finance Leases    
2027 5,314  
2028 2,117  
2029 0  
2030 0  
2031 0  
Thereafter 0  
Total finance lease liabilities 7,431 $ 14,256
Other Debt    
2027 2,657  
2028 0  
2029 0  
2030 0  
2031 0  
Thereafter 0  
Total maturities of debt and finance leases $ 2,657  
v3.26.1
Stockholders' equity - Narrative (Details) - USD ($)
 12 Months Ended
Aug. 11, 2023
Jun. 30, 2023
Jan. 31, 2026
Mar. 31, 2025
Jan. 31, 2025
Jan. 31, 2024
Jan. 30, 2024
Jan. 31, 2023
Jul. 22, 2019
Class of Stock [Line Items]                  
Common stock, authorized (in shares)     500,000,000   500,000,000       500,000,000
Common stock, par value per share (in dollars per share)     $ 0.01   $ 0.01       $ 0.01
Shares withheld for tax withholding obligation     0            
Equity attributable to parent     $ 337,207,000   $ 264,808,000 $ 251,449,000   $ 287,819,000  
Stock Repurchase Program                  
Class of Stock [Line Items]                  
Repurchase of outstanding common stock (in shares)       2,500,000          
Common stock                  
Class of Stock [Line Items]                  
Equity attributable to parent     620,000   601,000 577,000   542,000  
Common stock | Acquisition of MediFind                  
Class of Stock [Line Items]                  
Business acquisition, shares (in shares)   150,786              
Common stock | Acquisition of Access                  
Class of Stock [Line Items]                  
Business acquisition, shares (in shares) 1,096,436                
Accumulated other comprehensive loss                  
Class of Stock [Line Items]                  
Equity attributable to parent     $ (382,000)   $ (51,000) $ 0 $ 0 $ 0  
v3.26.1
Stockholders' equity - Schedule of Accumulated Other Comprehensive Loss (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance $ 264,808 $ 251,449 $ 287,819
Other comprehensive loss (331) (51) 0
Other comprehensive income (loss) before reclassifications (16)    
Amounts reclassified from accumulated other comprehensive loss (315)    
Ending balance 337,207 264,808 251,449
Unrealized gain on cash flow hedges      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance 0 0  
Other comprehensive loss (133) 0  
Other comprehensive income (loss) before reclassifications 182    
Amounts reclassified from accumulated other comprehensive loss (315)    
Ending balance (133) 0 0
Foreign currency translation adjustment      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance (51) 0  
Other comprehensive loss (198) (51)  
Other comprehensive income (loss) before reclassifications (198)    
Amounts reclassified from accumulated other comprehensive loss 0    
Ending balance (249) (51) 0
Accumulated other comprehensive loss      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance (51) 0 0
Ending balance $ (382) $ (51) $ 0
v3.26.1
Equity-based compensation - Narrative (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
Jan. 01, 2021
Dec. 31, 2020
Jun. 30, 2019
shares
Jan. 31, 2026
USD ($)
offering_period
$ / shares
shares
Jan. 31, 2025
USD ($)
$ / shares
shares
Jan. 31, 2024
USD ($)
$ / shares
shares
Dec. 31, 2022
Jul. 31, 2023
shares
Jan. 31, 2018
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Stock-based compensation expense per consolidated statements of operations       $ 67,452 $ 66,975 $ 71,613      
Reduced stock compensation expense       $ 431 $ 1,333        
Weighted average fair market value of grants (in dollars per share) | $ / shares       $ 24.03 $ 21.93 $ 29.08      
Intrinsic value       $ 4,671 $ 4,210 $ 6,059      
Minimum shares earned, minimum target percentage       55.00% 55.00% 60.00%      
Maximum shares earned, minimum target percentage       90.00%          
Issuance of common stock for employee stock purchase plan       $ 2,225 $ 2,821 $ 3,235      
Issuance of stock for share-settled bonus awards       10,499 9,071 9,041      
Benefit for income taxes       (11,246) 2,716 $ 1,543      
Income tax benefit (expense)                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Stock-based compensation expense per consolidated statements of operations       $ 1,593 $ 0        
Common stock                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Purchase of ESPP settlement (in shares) | shares       124,869 158,262 141,121      
Issuance of common stock for employee stock purchase plan       $ 1 $ 2 $ 1      
Issuance of stock for share-settled bonus awards       $ 4 $ 4 $ 4      
Issuance of stock for share-settled bonus awards (in shares) | shares       425,182 406,427 354,817      
Additional paid-in capital                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Issuance of common stock for employee stock purchase plan       $ 2,224 $ 2,819 $ 3,234      
Issuance of stock for share-settled bonus awards       $ 10,495 $ 9,067 $ 9,037      
ESPP                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
ESPP, employee common stock purchase discount (as a percent)       15.00%          
Unrecognized compensation costs       $ 390          
Weighted average term for recognition (in months/years)       5 months          
Employee purchase price of common stock (as a percent)       85.00%          
RSUs                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Vesting term (in years)   7 years              
Unrecognized compensation costs       $ 67,299          
Weighted average term for recognition (in months/years)       2 years 9 months 18 days          
Bonus settlement in shares (as a percent)       115.00%          
RSUs | Share-based Payment Arrangement, Year 1                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Vesting term (in years)   1 year              
Percentage of vest option (as a percent)   10.00%              
RSUs | Share-based Payment Arrangement, Year 2                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Vesting term (in years)   2 years              
Percentage of vest option (as a percent)   20.00%              
RSUs | Share-based Payment Arrangement, Year 3                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Vesting term (in years)   3 years              
Percentage of vest option (as a percent)   30.00%              
RSUs | Share-based Payment Arrangement, Year 4                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Vesting term (in years)   4 years              
Percentage of vest option (as a percent)   40.00%              
RSUs | Employees Other than NEOs                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Vesting term (in years) 4 years                
Quarterly vesting rate (as a percent) 6.25%                
RSUs | NEOs and Other Members of Executive Management                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Vesting term (in years)           4 years 4 years    
Quarterly vesting rate (as a percent)           25.00% 6.25%    
Employee Stock Option                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Vesting term (in years)       4 years          
Expiration period / maximum term (in years)       10 years          
Unrecognized compensation cost       $ 0          
PSUs                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Vesting term (in years)       3 years          
Percentage of vest option (as a percent)       100.00%          
Unrecognized compensation costs       $ 27,359          
Weighted average term for recognition (in months/years)       2 years 1 month 6 days          
Weighted average fair market value of grants (in dollars per share) | $ / shares       $ 29.22 $ 42.86 $ 36.42      
PSUs | Minimum                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Percentage of vest option (as a percent)       0.00%          
PSUs | Maximum                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Percentage of vest option (as a percent)       220.00% 220.00% 220.00%      
2018 Stock Option Plan                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Number of shares available for issuance (in shares) | shares                 3,048,490
2019 Stock Option And Incentive Plan                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Common stock reserve for future issuance (in shares) | shares     2,139,683            
Percentage increase in number of shares reserved (as a percent)     5.00%            
2019 Stock Option And Incentive Plan | ESPP                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Number of shares available for grant (in shares) | shares     855,873 6,583,030          
Additional shares authorized (in shares) | shares       131,404          
ESPP, number of offering periods per year | offering_period       2          
ESPP offering period (in months)       6 months          
2019 Stock Option And Incentive Plan | Employee Stock Option | Share-based Payment Arrangement, Year 1                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Vesting term (in years)       1 year          
Percentage of vest option (as a percent)       25.00%          
2019 Stock Option And Incentive Plan | Employee Stock Option | Share-based Payment Arrangement, Year 2                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Vesting term (in years)       1 year          
Percentage of vest option (as a percent)       25.00%          
2019 Stock Option And Incentive Plan | Employee Stock Option | Share-based Payment Arrangement, Year 3                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Vesting term (in years)       1 year          
Percentage of vest option (as a percent)       25.00%          
2019 Stock Option And Incentive Plan | Employee Stock Option | Share-based Payment Arrangement, Year 4                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Vesting term (in years)       1 year          
Percentage of vest option (as a percent)       25.00%          
2023 Inducement Award Plan                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Common stock reserve for future issuance (in shares) | shares               500,000  
2023 Inducement Award Plan | RSUs                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Number of shares available for grant (in shares) | shares       485,217          
Equity instruments, outstanding, number (in shares) | shares       5,896          
v3.26.1
Equity-based compensation - Schedule of Stock Based Compensation by Type of Award (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock based compensation $ 68,738 $ 68,337 $ 73,028
RSUs      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock based compensation 37,814 44,696 53,474
PSUs      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock based compensation 17,608 13,174 9,206
Liability awards      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock based compensation 12,242 9,316 9,047
ESPP      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock based compensation 833 1,149 1,256
Stock options      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock based compensation $ 241 $ 2 $ 45
v3.26.1
Equity-based compensation - Schedule of Stock Based Compensation in Financial Statements (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Share-Based Payment Arrangement [Abstract]      
Stock-based compensation expense recorded to additional paid-in capital $ 56,255 $ 59,021 $ 63,981
Stock-based compensation expense recorded to accrued expenses 12,242 9,316 9,047
Stock-based compensation expense paid in cash 241 0 0
Total stock-based compensation 68,738 68,337 73,028
Less: stock-based compensation expense capitalized as internal-use software (1,286) (1,362) (1,415)
Stock-based compensation expense per consolidated statements of operations $ 67,452 $ 66,975 $ 71,613
v3.26.1
Equity-based compensation - Schedule of Restricted Stock Unit Activity (Details) - shares
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
RSUs      
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]      
Beginning balance (in shares) 3,597,948 3,800,210 3,917,753
Granted during year (in shares) 1,883,490 2,135,391 2,419,679
Vested (in shares) (1,578,301) (1,897,716) (1,912,432)
Forfeited and expired (in shares) (410,175) (439,937) (624,790)
Ending balance (in shares) 3,492,962 3,597,948 3,800,210
RSUs | 2023 Inducement Award Plan      
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]      
Granted during year (in shares)   24,125  
PSUs      
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]      
Beginning balance (in shares) 1,204,971 1,040,219 648,233
Granted during year (in shares) 358,000 434,269 576,680
Vested (in shares) (214,702) (255,269) (67,251)
Forfeited and expired (in shares) 0 (14,248) (117,443)
Ending balance (in shares) 1,348,269 1,204,971 1,040,219
v3.26.1
Equity-based compensation - Schedule of Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Number of options      
Number of options outstanding at beginning of period (in shares) 899,381 1,123,438 1,385,193
Granted during the year (in shares) 0 0 0
Exercised (in shares) (237,516) (220,523) (249,247)
Forfeited and expired (in shares) (1,649) (3,534) (12,508)
Number of options outstanding at end of period (in shares) 660,216 899,381 1,123,438
Exercisable (in shares) 660,216    
Amount vested at the end of the period (in shares) 0    
Weighted- average exercise price      
Weighted- average exercise price outstanding at beginning of period (in dollars per share) $ 7.39 $ 6.89 $ 6.26
Granted during the year (in dollars per share) 0 0 0
Exercised (in dollars per share) 6.12 4.64 3.42
Forfeited and expired (in dollars per share) 10.60 20.67 5.87
Weighted- average exercise price outstanding at end of period (in dollars per share) 7.84 $ 7.39 $ 6.89
Exercisable (in dollars per share) 7.84    
Amount vested at the end of the period (in dollars per share) $ 0    
Weighted-average remaining contractual life of options outstanding and expected to vest (in years) 2 years 9 months 29 days 3 years 7 months 28 days 4 years 6 months 14 days
Weighted-average remaining contractual life of options exercisable (in years) 2 years 9 months 29 days    
Aggregate intrinsic value outstanding and expected to vest $ 3,767 $ 18,952 $ 20,884
Aggregate intrinsic value exercisable $ 3,767    
v3.26.1
Equity-based compensation - Schedule of Valuation Allowance of Performance-Based Restricted Stock Units (Details)
 12 Months Ended
Jan. 31, 2026
$ / shares
Jan. 31, 2025
$ / shares
Jan. 31, 2024
$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Weighted average fair market value of grants (in dollars per share) $ 24.03 $ 21.93 $ 29.08
PSUs      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Correlation coefficient 0.4490 0.5305 0.5238
Valuation date stock price (in dollars per share) $ 20.29 $ 25.19 $ 22.94
Simulation term (in years) 3 years 3 years 3 years
Volatility (as a percent) 54.31% 64.18% 64.58%
Risk-free rate (as a percent) 3.56% 4.24% 4.05%
Dividend yield (as a percent) 0.00% 0.00% 0.00%
Weighted average fair market value of grants (in dollars per share) $ 29.22 $ 42.86 $ 36.42
v3.26.1
Equity-based compensation - Weighted Average Assumptions (Details) - ESPP
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Risk-free interest rate (as a percent) 3.83% 4.74% 5.30%
Expected dividends (as a percent) 0.00% 0.00% 0.00%
Expected term (in years) 5 months 26 days 5 months 26 days 5 months 26 days
Volatility (as a percent) 51.31% 52.96% 62.41%
v3.26.1
Fair value measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Money market mutual funds $ 44,945 $ 66,588
Cardholder receivables 86,053  
Deferred purchase price receivable 23,425  
Total assets $ 154,423 66,588
Derivative Liability Statement of Financial Position Extensible Enumeration Not Disclosed Flag Foreign currency forward contracts  
Foreign currency forward contracts $ 148  
Due to healthcare providers 83,385  
Total liabilities 83,533  
Unpaid principal balance of cardholder receivables 147,471  
Unpaid principal balance due to healthcare providers 144,802  
Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Money market mutual funds 44,945 66,588
Cardholder receivables 0  
Deferred purchase price receivable 0  
Total assets 44,945 66,588
Foreign currency forward contracts 0  
Due to healthcare providers 0  
Total liabilities 0  
Significant Other Observable Inputs (Level 2)    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Money market mutual funds 0 0
Cardholder receivables 0  
Deferred purchase price receivable 0  
Total assets 0 0
Foreign currency forward contracts 148  
Due to healthcare providers 0  
Total liabilities 148  
Significant Unobservable Inputs (Level 3)    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Money market mutual funds 0 0
Cardholder receivables 86,053  
Deferred purchase price receivable 23,425  
Total assets 109,478 $ 0
Foreign currency forward contracts 0  
Due to healthcare providers 83,385  
Total liabilities $ 83,385  
v3.26.1
Fair value measurements - Schedule of Reconciliation of Changes in Level 3 Instruments Measured on a Recurring Basis (Details) - USD ($)
$ in Thousands
 12 Months Ended
Nov. 12, 2025
Jan. 31, 2026
Cardholder Receivables    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning balance   $ 0
Fair value $ 93,191  
Originations   17,585
Sales and settlements   (14,577)
Cash collections   (12,709)
Gains (losses) recognized in earnings   2,563
Ending balance   86,053
Deferred Purchase Price Receivable    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning balance   0
Fair value   24,519
Sales and settlements   886
Cash collections   (3,000)
Gains (losses) recognized in earnings   1,020
Ending balance   $ 23,425
v3.26.1
Fair value measurements - Schedule of Potential Decrease of Fair Value of Company’s Deferred Purchase Price Receivable Based on Hypothetical Changes in Key Assumptions (Details)
$ in Thousands
Jan. 31, 2026
USD ($)
Ten Percent  
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Deferred purchase price receivable, Unobservable input, Discount rate, amount $ (257)
Deferred purchase price receivable, Unobservable input, Repayment rate, amount (1,261)
Twenty Percent  
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Deferred purchase price receivable, Unobservable input, Discount rate, amount (373)
Deferred purchase price receivable, Unobservable input, Repayment rate, amount $ (1,987)
v3.26.1
Fair value measurements - Schedule of Activity Related to Aggregate Fair Value of Amounts Due to Health Care Providers (Details) - Due to Health Care Providers
$ in Thousands
 12 Months Ended
Jan. 31, 2026
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Beginning balance $ 0
Acquisitions 90,454
Additions 17,585
Cash remittances to healthcare providers (27,217)
Gains (losses) recognized in earnings 2,563
Ending balance $ 83,385
v3.26.1
Fair value measurements - Schedule of Range and Weighted‑Average of Significant Unobservable Inputs Used in Level 3 Fair Value Measurements by Asset (Details)
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Minimum      
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Cardholder receivables, Unobservable Input, Discount rate (as a percent) 14.21%    
Cardholder receivables, Unobservable Input, Default rate (as a percent) 27.00%    
Deferred purchase price receivable, Unobservable Input, Discount rate (as a percent) 7.25%    
Deferred purchase price receivable, Unobservable Input, Funded monthly repayment rate (as a percent) 4.50%    
Maximum      
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Cardholder receivables, Unobservable Input, Discount rate (as a percent) 15.21%    
Cardholder receivables, Unobservable Input, Default rate (as a percent) 33.00%    
Deferred purchase price receivable, Unobservable Input, Discount rate (as a percent)   10.75%  
Deferred purchase price receivable, Unobservable Input, Funded monthly repayment rate (as a percent)   5.50%  
Weighted Average      
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Cardholder receivables, Unobservable Input, Discount rate (as a percent) 14.71%    
Cardholder receivables, Unobservable Input, Default rate (as a percent) 30.00%    
Deferred purchase price receivable, Unobservable Input, Discount rate (as a percent)     9.00%
Deferred purchase price receivable, Unobservable Input, Funded monthly repayment rate (as a percent)   5.00%  
v3.26.1
Fair value measurements - Schedule of Range and Weighted‑Average of Significant Unobservable Inputs Used in Level 3 Fair Value Measurements by Liability (Details)
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Minimum      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Due to health care providers, Unobservable Input, Discount rate (as a percent) 14.21%    
Due to health care providers, Unobservable Input, Default rate (as a percent) 27.00%    
Maximum      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Due to health care providers, Unobservable Input, Discount rate (as a percent)   15.21%  
Due to health care providers, Unobservable Input, Default rate (as a percent)   33.00%  
Weighted Average      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Due to health care providers, Unobservable Input, Discount rate (as a percent)     14.71%
Due to health care providers, Unobservable Input, Default rate (as a percent)   30.00%  
v3.26.1
Leases - Narrative (Details)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
USD ($)
extension_option
Jan. 31, 2025
USD ($)
Jan. 31, 2024
USD ($)
Lessee, Lease, Description [Line Items]      
Operating lease, weighted average remaining lease term (in years) 2 years    
Operating lease, weighted average discount rate (as a percent) 7.50%    
Finance lease, weighted average remaining lease term (in years) 1 year 4 months 24 days    
Finance lease, weighted average discount rate (as a percent) 7.80%    
Number of options to extend | extension_option 0    
Subscription and Related Services      
Lessee, Lease, Description [Line Items]      
Lease income | $ $ 9,102 $ 9,329 $ 10,307
Computer equipment | Minimum      
Lessee, Lease, Description [Line Items]      
Finance lease, term of contract (in years) 3 years    
v3.26.1
Leases - Schedule of Operating and Finance Leases (Details) - USD ($)
$ in Thousands
Jan. 31, 2026
Jan. 31, 2025
Operating leases:    
Lease right-of-use assets $ 2,002 $ 1,477
Lease liabilities, current 1,254 964
Lease liabilities, non-current 1,107 646
Total operating lease liabilities 2,361 1,610
Finance leases:    
Property and equipment, at cost 49,009 49,009
Accumulated depreciation (42,060) (34,815)
Property and equipment, net 6,949 14,194
Lease liabilities, current (included in Current portion of debt and finance lease liabilities) 5,314 6,825
Lease liabilities, non-current (included in Long-term debt and finance lease liabilities) 2,117 7,431
Total finance lease liabilities $ 7,431 $ 14,256
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Property and equipment, net of accumulated depreciation and amortization of $94,193 and $84,505 as of January 31, 2026 and 2025, respectively Property and equipment, net of accumulated depreciation and amortization of $94,193 and $84,505 as of January 31, 2026 and 2025, respectively
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] Long-Term Debt and Lease Obligation, Current Long-Term Debt and Lease Obligation, Current
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Long-term debt and finance lease liabilities Long-term debt and finance lease liabilities
v3.26.1
Leases - Schedule of Lease Expenses (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Operating leases:      
Operating lease cost $ 954 $ 983 $ 740
Variable lease cost 0 0 47
Total operating lease cost 954 983 787
Finance leases:      
Amortization of right-of-use assets 7,245 7,416 6,742
Interest on lease liabilities 879 980 580
Total finance lease cost $ 8,124 $ 8,396 $ 7,322
v3.26.1
Leases - Schedule of Maturing Lease Payments (Details) - USD ($)
$ in Thousands
Jan. 31, 2026
Jan. 31, 2025
Operating    
2027 $ 1,318  
2028 793  
2029 292  
Total future minimum lease payments 2,403  
Less: interest (42)  
Total operating lease liabilities 2,361 $ 1,610
Finance    
2027 5,688  
2028 2,169  
2029 0  
Total future minimum lease payments 7,857  
Less: interest (426)  
Finance leases $ 7,431 $ 14,256
v3.26.1
Leases - Schedule of Supplemental Cash flow Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Cash paid for amounts included in the measurement of lease liabilities:      
Operating cash used for operating leases $ 1,147 $ 1,023 $ 1,238
Operating cash used for finance leases 879 980 535
Financing cash used for finance leases $ 6,825 $ 7,811 $ 6,779
v3.26.1
Commitments and contingencies (Details)
$ in Thousands
Jan. 31, 2026
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2027 $ 11,621
2028 4,705
2029 742
Total $ 17,068
v3.26.1
Income taxes - Narrative (Details) - USD ($)
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Jan. 31, 2023
Operating Loss Carryforwards [Line Items]        
Benefit for income taxes $ (11,246,000) $ 2,716,000 $ 1,543,000  
Effective tax rate (as a percent) (125.80%) 4.90% 1.10%  
Deferred tax assets $ 1,593,000 $ 0    
Long-term deferred tax liabilities 4,498,000 484,000    
Valuation allowance (176,652,000) (188,712,000)    
Increase in valuation allowance (12,060,000) 13,069,000    
Operating loss carryforwards with expiration from 2005 and 2006 316,000      
Unrecognized tax benefits 1,910,000 1,605,000 $ 1,240,000 $ 0
Tax examination, penalties and interest accrued 0      
Tax Year 2024        
Operating Loss Carryforwards [Line Items]        
Net operating loss carryforward 12,388,000      
Tax Year 2023        
Operating Loss Carryforwards [Line Items]        
Net operating loss carryforward $ 136,020,000      
Research Tax Credit Carryforward        
Operating Loss Carryforwards [Line Items]        
Tax credit carryforward, expiration period (in years) 20 years      
Domestic Tax Jurisdiction        
Operating Loss Carryforwards [Line Items]        
Net operating loss carryforward $ 587,240,000 $ 596,509,000    
Foreign tax effects        
Operating Loss Carryforwards [Line Items]        
Net operating loss carryforward $ 0      
v3.26.1
Income taxes - Schedule of Income (Loss) before Income Tax, Domestic and Foreign (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Income Tax Disclosure [Abstract]      
Domestic $ (13,505) $ (63,782) $ (138,629)
Foreign 4,565 7,971 3,287
Loss before income tax expense $ (8,940) $ (55,811) $ (135,342)
v3.26.1
Income taxes - Schedule of Components of Tax (Benefit) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Current tax      
Federal $ 0 $ 0 $ 0
State 356 102 76
Foreign 1,669 2,400 1,239
Deferred tax      
Federal (12,581) 214 38
State 903 0 0
Foreign (1,593) 0 190
Total provision for income taxes $ (11,246) $ 2,716 $ 1,543
v3.26.1
Income taxes - Schedule of Reconciliation of Statutory U.S. Federal Rate and Effective Rate (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Amount      
Federal income tax benefit at statutory rate $ (1,877)    
State and local tax, net of federal benefit 994    
Federal tax credits (1,034)    
Changes in valuation allowances on federal deferred tax assets (18,857)    
Stock based compensation 5,056    
Transaction Cost 1,730    
Capitalized Internal-Use Software 2,049    
Section 162(m) 656    
Other 125    
Changes in unrecognized tax benefits 119    
Total provision for income taxes $ (11,246) $ 2,716 $ 1,543
Percent      
Federal income tax benefit at statutory rate 21.00% 21.00% 21.00%
State and local tax, net of federal benefit (11.00%) 4.00% 3.00%
Foreign tax effects   (3.00%) (1.00%)
Federal tax credits 12.00%    
Changes in valuation allowances on federal deferred tax assets 211.00% (22.00%) (24.00%)
Stock based compensation (57.00%) (6.00%) 0.00%
Transaction Cost (19.00%)    
Capitalized Internal-Use Software (23.00%)    
Section 162(m) (8.00%)    
Other (1.00%)    
Changes in unrecognized tax benefits (1.00%)    
Effective income tax rate 125.80% (4.90%) (1.10%)
India      
Amount      
Foreign tax effects $ 68    
Percent      
Foreign tax effects (1.00%)    
Canada      
Amount      
Foreign tax effects $ (275)    
Percent      
Foreign tax effects 3.00%    
v3.26.1
Income taxes - Schedule of Income Taxes Paid (Details)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
USD ($)
Income Tax Paid, by Individual Jurisdiction [Line Items]  
Federal $ 0
State and local 7
Total foreign 1,890
Total income taxes paid 1,897
Texas  
Income Tax Paid, by Individual Jurisdiction [Line Items]  
State and local 7
India  
Income Tax Paid, by Individual Jurisdiction [Line Items]  
Total foreign 516
Canada  
Income Tax Paid, by Individual Jurisdiction [Line Items]  
Total foreign $ 1,374
v3.26.1
Income taxes - Schedule of Effective Tax Rate Reconciliation (Details)
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Income Tax Disclosure [Abstract]      
Federal income tax benefit at statutory rate 21.00% 21.00% 21.00%
State and local tax, net of federal benefit (11.00%) 4.00% 3.00%
Permanent differences   1.00% 0.00%
Equity compensation (57.00%) (6.00%) 0.00%
Foreign taxes   (3.00%) (1.00%)
Other   0.00% 0.00%
Change in valuation allowance 211.00% (22.00%) (24.00%)
Effective income tax rate 125.80% (4.90%) (1.10%)
v3.26.1
Income taxes - Schedule of Company's Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Jan. 31, 2026
Jan. 31, 2025
Deferred tax assets:    
Net operating loss carryforwards $ 170,985 $ 160,998
Stock based compensation 12,125 9,495
Accruals, reserves, and other expenses 3,809 3,129
Disallowed interest expense 0 969
Depreciation and amortization 0 1,412
Capitalized R&D Expense 23,835 23,897
Cardholder Receivable 15,779 0
Other 109 0
Total deferred tax assets 226,642 199,900
Less: valuation allowance (176,652) (188,712)
Net deferred tax assets 49,990 11,188
Deferred tax liabilities:    
Depreciation and amortization (7,741) 0
Intangible assets (12,818) (340)
Capitalized internal-use-software (14,623) (11,074)
Due to Healthcare Provider (15,660) 0
Other (2,053) (258)
Total deferred tax liabilities (52,895) (11,672)
Net deferred tax liabilities $ (2,905) $ (484)
v3.26.1
Income taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Unrecognized Tax Benefits [Roll Forward]      
Balance, January 31, 2024 $ 1,605 $ 1,240 $ 0
Increases for income tax positions related to prior years 0 0 844
Increases for income tax positions related to current years 305 365 396
Balance, January 31, 2026 $ 1,910 $ 1,605 $ 1,240
v3.26.1
Net income (loss) per share attributable to common stockholders - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Numerator:      
Net income (loss) $ 2,306 $ (58,527) $ (136,885)
Denominator:      
Weighted-average shares of common stock outstanding, basic (in shares) 59,737,915 57,589,687 54,561,449
Basic net income (loss) per share attributable to common stockholders - basic (in usd per share) $ 0.04 $ (1.02) $ (2.51)
Numerator:      
Net income (loss) $ 2,306 $ (58,527) $ (136,885)
Denominator:      
Number of shares used for basic net income (loss) per computation (in shares) 59,737,915 57,589,687 54,561,449
Weighted-average shares of common stock outstanding, diluted (in shares) 61,494,878 57,589,687 54,561,449
Diluted net income (loss) per share attributable to common stockholders - diluted (in usd per share) $ 0.04 $ (1.02) $ (2.51)
RSUs      
Denominator:      
Incremental common shares attributable to dilutive effect of share-based payment arrangements (in shares) 698,122 0 0
PSUs      
Denominator:      
Incremental common shares attributable to dilutive effect of share-based payment arrangements (in shares) 555,972 0 0
Stock options      
Denominator:      
Incremental common shares attributable to dilutive effect of share-based payment arrangements (in shares) 335,357 0 0
Liability awards      
Denominator:      
Incremental common shares attributable to dilutive effect of share-based payment arrangements (in shares) 148,271 0 0
ESPP      
Denominator:      
Incremental common shares attributable to dilutive effect of share-based payment arrangements (in shares) 19,241 0 0
v3.26.1
Net income (loss) per share attributable to common stockholders - Schedule of Antidilutive Securities (Details) - shares
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive securities excluded from computation of earnings per share (in shares) 1,689,748 6,649,563 7,365,073
Stock options to purchase common stock, restricted stock units and performance stock awards      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive securities excluded from computation of earnings per share (in shares) 1,580,596 6,577,715 7,273,621
Employee stock purchase plan      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive securities excluded from computation of earnings per share (in shares) 109,152 71,848 91,452
v3.26.1
Retirement savings plan (Details) - USD ($)
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Retirement Benefits [Abstract]      
Company contributions $ 0 $ 0 $ 0
v3.26.1
Related party transactions (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Related Party Transaction [Line Items]      
Revenue $ 480,591 $ 419,813 $ 356,299
Accounts receivable 97,453 73,617  
General and administrative 79,903 76,597 $ 79,926
Related Party      
Related Party Transaction [Line Items]      
Revenue 1,124 1,343  
Accounts receivable $ 450 116  
General and administrative   $ 118  
v3.26.1
Segments and geographic information - Narrative (Details)
 12 Months Ended
Jan. 31, 2026
segment
Segment Reporting [Abstract]  
Number of reportable segments 1
Number of operating segment 1
v3.26.1
Segments and geographic information - Schedule of Expenditures on Long-Lived Assets (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Segment Reporting Information [Line Items]      
Revenue $ 480,591 $ 419,813 $ 356,299
Payment solutions expense [1] 82,758 68,707 62,986
Stock-based compensation 67,452 66,975 71,613
Net income (loss) 2,306 (58,527) (136,885)
Technology Solutions Segment      
Segment Reporting Information [Line Items]      
Net income (loss) 2,306 (58,527) (136,885)
Technology Solutions Segment | Operating Segments      
Segment Reporting Information [Line Items]      
Revenue 480,591 419,813 356,299
Labor costs 193,362 224,792 238,533
Payment solutions expense 82,758 68,707 62,986
Third-party non-labor operating expenses 102,955 89,550 90,159
Stock-based compensation 67,452 66,975 71,613
Other segment items 31,758 28,316 29,893
Net income (loss) 2,306 (58,527) (136,885)
Technology Solutions Segment | Eliminations and Reconciling Items      
Segment Reporting Information [Line Items]      
Net income (loss) $ 0 $ 0 $ 0
[1]
(1) The revenue line previously labeled “Payment processing fees” has been relabeled “Payment solutions” to reflect the expanded scope of our payments offerings following the AccessOne Acquisition, which closed on November 12, 2025. Additionally, “Payment processing expense” has been relabeled “Payment solutions expense.” Prior period amounts have not been reclassified, as the Company did not own the acquired operations in prior periods and the change in presentation did not affect any previously reported amounts. See Note 2 - Basis of presentation.
v3.26.1
Segments and geographic information - Schedule of Other Quantitative Segment Disclosures (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Segment Reporting Information [Line Items]      
Interest expense $ 6,953 $ 2,347 $ 1,854
Interest income 2,173 2,677 4,065
Loss on extinguishment of debt (501) 0 (1,118)
Income tax benefit (expense) 11,246 (2,716) (1,543)
Technology Solutions Segment      
Segment Reporting Information [Line Items]      
Depreciation and amortization 31,453 27,886 29,487
Interest expense (6,953) (2,347) (1,854)
Interest income 2,173 2,677 4,065
Loss on extinguishment of debt (501) 0 (1,118)
Gain on settlement (included in other income, net) 0 2,345 0
Income tax benefit (expense) 11,246 (2,716) (1,543)
Expenditures for long-lived assets $ 176,246 $ 25,940 $ 96,474
v3.26.1
Derivative instruments and hedging activities - Narrative (Details) - Foreign currency cash flow hedges
$ in Thousands, $ in Thousands
Jan. 31, 2026
CAD ($)
Jan. 31, 2026
USD ($)
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Derivative, notional amount $ 16,100  
Derivative, remaining maturity (in months) 3 months 3 months
Foreign currency cash flow hedge gain (loss) to be reclassified during next 12 months   $ (133)
Designated as Hedging Instrument    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Derivative, notional amount $ 14,490  
Non-designated hedges    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Derivative, notional amount $ 1,610  
v3.26.1
Derivative instruments and hedging activities - Schedule of Fair Values Of Outstanding Derivative Foreign Currency Forward Contract (Details) - Foreign currency cash flow hedges - USD ($)
$ in Thousands
Jan. 31, 2026
Jan. 31, 2025
Designated as Hedging Instrument    
Derivatives, Fair Value [Line Items]    
Derivative asset $ 133 $ 0
Non-designated hedges    
Derivatives, Fair Value [Line Items]    
Derivative asset $ 14 $ 0
v3.26.1
Derivative instruments and hedging activities - Schedule of Effect of Derivative Instruments on the Company’s Consolidated Statements of Operations (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Non-designated hedges      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Derivative, gain (loss) on derivative, net $ 217 $ 0 $ 0
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Other income, net Other income, net  
Foreign currency cash flow hedges | Designated as Hedging Instrument | Expenses      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Derivative, gain (loss) on derivative, net $ (315) $ 0 0
Foreign currency cash flow hedges | Designated as Hedging Instrument | Income tax benefit (expense)      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Derivative, gain (loss) on derivative, net $ 0 $ 0 $ 0
v3.26.1
Derivative instruments and hedging activities - Schedule of Pre-tax Gains (Losses) Associated with Cash Flow Hedges (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]      
Gains recognized in accumulated other comprehensive income (included in assessment of effectiveness) $ 182 $ 0 $ 0
Gains reclassified from accumulated other comprehensive income into income (effective portion) (315) 0 0
Tax effect reclassified from accumulated other comprehensive income into income (effective portion) $ 0 $ 0 $ 0
v3.26.1
Acquisitions - Narrative (Details)
$ in Thousands
 3 Months Ended 12 Months Ended
Nov. 12, 2025
USD ($)
Oct. 03, 2023
USD ($)
installment
Aug. 11, 2023
USD ($)
shares
Jun. 30, 2023
USD ($)
shares
Jan. 31, 2026
USD ($)
Jan. 31, 2026
USD ($)
Jan. 31, 2025
USD ($)
Jan. 31, 2024
USD ($)
Business Combination [Line Items]                
Cash consideration paid to sellers               $ 14,907
Business combination, acquiree's revenue since acquisition date, actual         $ 9,679      
Business combination, acquiree's earnings (loss) since acquisition date, actual         251      
Business combination, acquisition related costs           $ 9,200    
Total consideration transferred               60,228
Access One                
Business Combination [Line Items]                
Percentage of equity acquired (as a percent) 100.00%              
Cash consideration paid to sellers $ 163,666         163,666    
Business combination base purchase price $ 160,000              
Business combination, cost of professional and advisory services         $ 9,223      
Weighted average amortization period (in years) 8 years              
Total consideration transferred           $ 153,192    
Acquisition of MediFind                
Business Combination [Line Items]                
Percentage of equity acquired (as a percent)       100.00%        
Cash consideration paid to sellers       $ 4,195       4,195
Total consideration transferred       $ 8,871        
Acquisition of MediFind | Common stock                
Business Combination [Line Items]                
Business acquisition, shares (in shares) | shares       150,786        
Acquisition of Access                
Business Combination [Line Items]                
Percentage of equity acquired (as a percent)     100.00%          
Cash consideration paid to sellers     $ 6,766         6,766
Total consideration transferred     $ 37,411          
Acquisition of Access | Common stock                
Business Combination [Line Items]                
Business acquisition, shares (in shares) | shares     1,096,436          
ConnectOnCall                
Business Combination [Line Items]                
Percentage of equity acquired (as a percent)   100.00%            
Cash consideration paid to sellers   $ 3,946           3,946
Total consideration transferred   $ 13,946            
Number of quarterly installments | installment   7            
Appropriate credit-adjusted discount rate (as a percent)           9.30%    
Interest accrual per annum (as a percent)           9.30%    
Interest expense           $ 732 $ 294  
MediFind, Access, and ConnectOnCall                
Business Combination [Line Items]                
Acquisition related costs incurred               $ 3,106
v3.26.1
Acquisitions - Schedule of AccessOne Purchase Price Consideration (Details) - USD ($)
$ in Thousands
 12 Months Ended
Nov. 12, 2025
Jan. 31, 2026
Jan. 31, 2024
Business Combination [Line Items]      
Cash consideration paid to sellers     $ 14,907
Less: cash and restricted cash acquired     (10,000)
Cash paid for acquisitions, net of cash and restricted cash acquired per statements of cash flows     $ 60,228
Access One      
Business Combination [Line Items]      
Cash consideration paid to sellers $ 163,666 $ 163,666  
Less: cash and restricted cash acquired   (10,474)  
Cash paid for acquisitions, net of cash and restricted cash acquired per statements of cash flows   $ 153,192  
v3.26.1
Acquisitions - Schedule of Final Allocation of AccessOne Purchase Price (Details) - USD ($)
$ in Thousands
Jan. 31, 2026
Nov. 12, 2025
Jan. 31, 2025
Jan. 31, 2024
Business Combination [Line Items]        
Goodwill $ 170,064   $ 75,845 $ 75,845
Access One        
Business Combination [Line Items]        
Cash and restricted cash   $ 10,474    
Accounts receivable   708    
Cardholder receivables   42,537    
Deferred purchase price receivable   19,615    
Accrued interest and fees receivable   394    
Other current assets   376    
Property and equipment   255    
Operating lease right-of-use assets   1,439    
Identified intangible assets acquired $ 56,700 56,700    
Goodwill   94,219    
Long-term cardholder receivables   50,654    
Long-term deferred purchase price receivable   4,904    
Other assets   208    
Total assets acquired   282,483    
Current portion of operating lease liabilities   (685)    
Accounts payable   (651)    
Accrued liabilities   (1,434)    
Current portion of due to healthcare providers   (40,669)    
Deferred revenue   (8,522)    
Other current liabilities   (166)    
Long-term deferred revenue   39    
Operating lease liabilities, non-current   (1,174)    
Long-term deferred tax liabilities   (15,692)    
Long-term due to healthcare providers   (49,785)    
Total purchase price   $ 163,666    
v3.26.1
Acquisitions - Schedule of Fair Value of Gross Contractual Amounts Receivable (Details) - Cardholder Receivables - USD ($)
$ in Thousands
Nov. 12, 2025
Jan. 31, 2026
Business Combination [Line Items]    
Fair value $ 93,191  
Gross contractual amounts receivable   $ 157,208
Financing Receivable, Allowance for Credit Loss   $ 58,735
v3.26.1
Acquisitions - Schedule of Intangible Asset Acquired Related to AccessOne Acquisition (Details) - Access One - USD ($)
$ in Thousands
Jan. 31, 2026
Nov. 12, 2025
Intangible Asset, Acquired, Finite-Lived [Line Items]    
Identified intangible assets acquired $ 56,700 $ 56,700
Trademark    
Intangible Asset, Acquired, Finite-Lived [Line Items]    
Finite-lived intangible asset, useful life (in years)   12 years
Identified intangible assets acquired $ 7,100  
Technology    
Intangible Asset, Acquired, Finite-Lived [Line Items]    
Finite-lived intangible asset, useful life (in years) 6 years  
Identified intangible assets acquired $ 13,600  
Customer relationships    
Intangible Asset, Acquired, Finite-Lived [Line Items]    
Finite-lived intangible asset, useful life (in years) 8 years  
Identified intangible assets acquired $ 36,000  
v3.26.1
Acquisitions - Schedule of Business Combination Pro Forma Information (Details) - Access One - USD ($)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Business Combination [Line Items]    
Revenue $ 516,438 $ 469,030
Net income (loss) $ 2,168 $ (61,929)
v3.26.1
Acquisitions - Schedule of Consideration of Each Acquisition (Details) - USD ($)
$ in Thousands
 12 Months Ended
Oct. 03, 2023
Aug. 11, 2023
Jun. 30, 2023
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Business Combination [Line Items]            
Cash consideration paid to sellers           $ 14,907
Equity consideration paid to sellers       $ 0 $ 0 35,321
Liabilities incurred to sellers           10,000
Cash paid for acquisitions, net of cash and restricted cash acquired per statements of cash flows           60,228
Acquisition of MediFind            
Business Combination [Line Items]            
Cash consideration paid to sellers     $ 4,195     4,195
Equity consideration paid to sellers     4,676      
Liabilities incurred to sellers     0      
Cash paid for acquisitions, net of cash and restricted cash acquired per statements of cash flows     $ 8,871      
Acquisition of Access            
Business Combination [Line Items]            
Cash consideration paid to sellers   $ 6,766       6,766
Equity consideration paid to sellers   30,645        
Liabilities incurred to sellers   0        
Cash paid for acquisitions, net of cash and restricted cash acquired per statements of cash flows   $ 37,411        
ConnectOnCall            
Business Combination [Line Items]            
Cash consideration paid to sellers $ 3,946         $ 3,946
Equity consideration paid to sellers 0          
Liabilities incurred to sellers 10,000          
Cash paid for acquisitions, net of cash and restricted cash acquired per statements of cash flows $ 13,946          
v3.26.1
Acquisitions - Schedule of Consideration Paid (Details) - USD ($)
$ in Thousands
 12 Months Ended
Oct. 03, 2023
Aug. 11, 2023
Jun. 30, 2023
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Business Combination [Line Items]            
Cash consideration paid to sellers           $ 14,907
Less: cash acquired           (334)
Cash paid for acquisitions, net of cash acquired per statements of cash flows       $ 153,191 $ 0 14,573
Acquisition of MediFind            
Business Combination [Line Items]            
Cash consideration paid to sellers     $ 4,195     4,195
Less: cash acquired           (231)
Cash paid for acquisitions, net of cash acquired per statements of cash flows           3,964
Acquisition of Access            
Business Combination [Line Items]            
Cash consideration paid to sellers   $ 6,766       6,766
Less: cash acquired           (80)
Cash paid for acquisitions, net of cash acquired per statements of cash flows           6,686
ConnectOnCall            
Business Combination [Line Items]            
Cash consideration paid to sellers $ 3,946         3,946
Less: cash acquired           (23)
Cash paid for acquisitions, net of cash acquired per statements of cash flows           $ 3,923
v3.26.1
Securitization program and variable interest entities (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Securitization or Asset-Backed Financing Arrangement, Financial Asset for which Transfer is Accounted as Sale [Line Items]    
Transfer of financial assets accounted for sales, cash proceeds received $ 13,691  
Cardholder receivables 166,745  
Cardholder receivables derecognized 143,320  
Cardholder receivables recognized 23,425  
Cardholder receivables, unpaid 166,745  
Fee income 4,861  
Deferred Purchase Price Receivable    
Securitization or Asset-Backed Financing Arrangement, Financial Asset for which Transfer is Accounted as Sale [Line Items]    
Maximum exposure to loss from transferred financial assets 23,425 $ 0
Cardholder Receivables    
Securitization or Asset-Backed Financing Arrangement, Financial Asset for which Transfer is Accounted as Sale [Line Items]    
Maximum exposure to loss from transferred financial assets $ 86,053 0
Securitization Program    
Securitization or Asset-Backed Financing Arrangement, Financial Asset for which Transfer is Accounted as Sale [Line Items]    
Financing receivable, percent past due 92.70%  
Reserve cash account, percentage 1.00%  
Restricted cash $ 1,691 0
Securitization related costs 3,052  
Securitization Program | Credit and Securitization Agreements    
Securitization or Asset-Backed Financing Arrangement, Financial Asset for which Transfer is Accounted as Sale [Line Items]    
Debt instrument, covenant, minimum liquidity   $ 3,500
Securitization Program | Deferred Purchase Price Receivable    
Securitization or Asset-Backed Financing Arrangement, Financial Asset for which Transfer is Accounted as Sale [Line Items]    
Maximum exposure to loss from transferred financial assets 23,425  
Transfers accounted for secured borrowings, assets, carrying amount $ 23,425  
Securitization Program | Cardholder Receivables    
Securitization or Asset-Backed Financing Arrangement, Financial Asset for which Transfer is Accounted as Sale [Line Items]    
Financing receivable, percent past due 90.50%  
Securitization Program | Financial Asset, 1 to 29 Days Past Due    
Securitization or Asset-Backed Financing Arrangement, Financial Asset for which Transfer is Accounted as Sale [Line Items]    
Financing receivable, percent past due 4.70%  
Threshold period past due, receivables, current (in days) 30 days  
Securitization Program | Financial Asset, 30 to 89 Days Past Due    
Securitization or Asset-Backed Financing Arrangement, Financial Asset for which Transfer is Accounted as Sale [Line Items]    
Financing receivable, percent past due 1.60%  
Securitization Program | Financial Asset, 30 to 89 Days Past Due | Minimum    
Securitization or Asset-Backed Financing Arrangement, Financial Asset for which Transfer is Accounted as Sale [Line Items]    
Threshold period past due, receivables, current (in days) 30 days  
Securitization Program | Financial Asset, 30 to 89 Days Past Due | Maximum    
Securitization or Asset-Backed Financing Arrangement, Financial Asset for which Transfer is Accounted as Sale [Line Items]    
Threshold period past due, receivables, current (in days) 89 days  
Securitization Program | Financial Asset, 90 to 119 Days Past Due    
Securitization or Asset-Backed Financing Arrangement, Financial Asset for which Transfer is Accounted as Sale [Line Items]    
Financing receivable, percent past due 1.00%  
Securitization Program | Financial Asset, 90 to 119 Days Past Due | Minimum    
Securitization or Asset-Backed Financing Arrangement, Financial Asset for which Transfer is Accounted as Sale [Line Items]    
Threshold period past due, receivables, current (in days) 90 days  
Securitization Program | Financial Asset, 90 to 119 Days Past Due | Maximum    
Securitization or Asset-Backed Financing Arrangement, Financial Asset for which Transfer is Accounted as Sale [Line Items]    
Threshold period past due, receivables, current (in days) 120 days  
Securitization Program | Financial Asset, Equal to or Greater than 120 Days Past Due    
Securitization or Asset-Backed Financing Arrangement, Financial Asset for which Transfer is Accounted as Sale [Line Items]    
Financing receivable, percent past due 0.00%  
Threshold period past due, receivables, current (in days) 120 days  
Securitization Program | Financial Asset, 30 to 59 Days Past Due | Cardholder Receivables    
Securitization or Asset-Backed Financing Arrangement, Financial Asset for which Transfer is Accounted as Sale [Line Items]    
Financing receivable, percent past due 5.10%  
Securitization Program | Financial Asset, 30 to 59 Days Past Due | Minimum | Cardholder Receivables    
Securitization or Asset-Backed Financing Arrangement, Financial Asset for which Transfer is Accounted as Sale [Line Items]    
Threshold period past due, receivables, current (in days) 30 days  
Securitization Program | Financial Asset, 30 to 59 Days Past Due | Maximum | Cardholder Receivables    
Securitization or Asset-Backed Financing Arrangement, Financial Asset for which Transfer is Accounted as Sale [Line Items]    
Threshold period past due, receivables, current (in days) 59 days  
Securitization Program | Financial Asset, 60 to 89 Days Past Due | Cardholder Receivables    
Securitization or Asset-Backed Financing Arrangement, Financial Asset for which Transfer is Accounted as Sale [Line Items]    
Financing receivable, percent past due 2.40%  
Securitization Program | Financial Asset, 60 to 89 Days Past Due | Minimum | Cardholder Receivables    
Securitization or Asset-Backed Financing Arrangement, Financial Asset for which Transfer is Accounted as Sale [Line Items]    
Threshold period past due, receivables, current (in days) 60 days  
Securitization Program | Financial Asset, 60 to 89 Days Past Due | Maximum | Cardholder Receivables    
Securitization or Asset-Backed Financing Arrangement, Financial Asset for which Transfer is Accounted as Sale [Line Items]    
Threshold period past due, receivables, current (in days) 89 days  
Securitization Program | Financial Asset, Equal to or Greater than 90 Days Past Due | Cardholder Receivables    
Securitization or Asset-Backed Financing Arrangement, Financial Asset for which Transfer is Accounted as Sale [Line Items]    
Financing receivable, percent past due 2.00%  
Threshold period past due, receivables, current (in days) 90 days  
v3.26.1
Subsequent Events (Details) - New Capital One Credit Facility and Refinancing of Bridge Loan - Line of Credit - Subsequent Event
$ in Thousands
Mar. 13, 2026
USD ($)
Revolving Credit Facility  
Subsequent Event [Line Items]  
Line of credit borrowing capacity $ 275,000
Line of credit facility, current borrowing capacity $ 92
Revolving Credit Facility | Minimum  
Subsequent Event [Line Items]  
Line of credit facility, commitment fee percentage 0.25%
Revolving Credit Facility | Maximum  
Subsequent Event [Line Items]  
Line of credit facility, commitment fee percentage 0.40%
Bridge Loan  
Subsequent Event [Line Items]  
Line of credit facility, swingline sublimit $ 20
Letter of Credit  
Subsequent Event [Line Items]  
Line of credit facility, letter of credit sublimit $ 10